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In science we have to be particularly
cautious about ’why’ questions.
When we ask, ’Why?’ we usually
mean ’How?’ If we can answer the
latter, that generally suffices for our
purposes.
Lawrence M. Krauss
A Universe from Nothing
The origin of modern science dates back to 16th century Europe, when Nicolaus Copernicus
dared to defy the anthropocentristic view imposed by the Catholic church. His lifework, ’De
revolutionibus orbium coelestium’, shook the foundations of religious orthodoxy that had held
society in its grasp throughout the Dark Ages. Despite the ferocious attempts of the Roman
Inquisition to nip this new movement in the bud, the power of inductive reasoning proved to be
an unstoppably force. Gaining more and more momentum via the sequential, mind-blowing - but
at that time utterly controversial - insights of Giordano Bruno, Galileo Galilei, Johannes Kepler
and Isaac Newton, humanity had finally broken out of the clerical yoke and launched itself into a
new era fueled by freethinking rational minds. In the following 5 centuries scientific discoveries
were translated into practical application and infiltrated every aspect of our daily lives.
Since then, every scientific breakthrough started out as a simple question regarding why - or more
accurately how - some natural process happens the way it does. Scientists have the irresistible
need to completely dismantle every natural phenomenon into all its individual compartments.
During this process, the emergence of more and more detailed knowledge inevitably raises nu-
merous side questions, all of which have to be answered. Ultimately, after years of copious
experiments, the final detail reveals itself. The scientists take a step back and marvel how all the
pieces fall into place.
The story of Gelsolin amyloidosis - the main scope of this manuscript - is not different. In the
decennia after this disease was first described in a patient, a troop of scientists have meticulously
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Gelsolin amyloidosis (AGel), formerly known as familial amyloidosis Finnish type (FAF), is a
debilitating, autosomal, dominantly heritable, incurable disease caused by a point mutation -
most commonly G654A/T - in the GSN gene. As a result, gelsolin’s second domain loses part of
its intrinsic stability and can adopt an intermediate state during Ca2+ activation. This aberrant
conformation exposes an otherwise buried furin cleavage site. During secretion, mutant plasma
gelsolin encounters furin in the trans-Golgi network. Proteolysis produces a C-terminal, 68 kDa
fragment - C68 - which, upon secretion in the extracellular matrix, gets cleaved by MT1-MMP-
like proteases. With this, 8 and 5 kDa amyloidogenic fragments are produces which, in time,
start to polymerize into amyloid fibrils and which eventually form amyloid plaques. Patients,
of whom the majority is found in Finland, experience a triad of ophthalmological, neurological
and dermatological symptoms. At the moment, treatment is purely symptomatic; eye drops,
corneal transplantation and plastic surgery. Therapies involving the inhibition of furin and/or
MT1-MMP have been suggested. However, tampering with these key proteases will almost
surely result in severe unwanted side effects. In our lab we therefore redirected our attention
towards mutant plasma gelsolin. Nanobodies were developed against both gelsolin and the 8 kDa
amyloidogenic fragment. Upon in vitro screening a chaperone for mutant plasma gelsolin - Nb11
- and chaperones for C68 - FAF Nb1, 2 and 3 - (partly) protected their antigen against furin
and MT1-MMP respectively. Intraperitoneal injection with FAF Nb2 and in vivo expression of
Nb11 in the AGel mouse model both resulted in a reduced deposition of the amyloidogenic 8 kDa
fragment. In this thesis we further explored the potential of these nanobodies in regard to AGel
therapeutics.
In a first study the imaging potential of the FAF nanobodies was explored. The rationale for this
was that, up until now, the efficacy of AGel therapeutics under development could only be mea-
sured via end-stage animal trials. With the already characterized FAF Nbs - raised against the 8
kDa amyloidogenic gelsolin fragment - we set out to shed light on this black box hurdle. Coupled
to 99mTc, all three nanobodies rendered clear, low background, SPECT/CT images of the gelsolin
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amyloid buildup in AGel mice. Based on its superior signal-to-noise ratio and signal specificity,
FAF Nb1 was chosen as the most promising candidate. A follow-up study involving AGel mice
expressing the therapeutically active Nb11 demonstrated that, besides rendering qualitative im-
ages, FAF Nb1 can also provide quantitative data. Indeed, comparison of quantified SPECT/CT
images, biodistribution analysis and immunofluorescent histology revealed similar patterns in sig-
nal increase. Furthermore, a correlation plot showed a positive relationship between 99mTc-FAF
Nb1 uptake and in vivo gelsolin amyloid buildup.
In a second study the two types of therapeutic chaperone nanobodies - Nb11 shields mutant
plasma gelsolin form furin and FAF Nb1, 2 and 3 shield C68 from MT1-MMP - were combined
into a single bispecific format. The FAF Nbs were linked head-to-tail to Nb11 via a MT1-MMP
sensitive linker. We hypothesized that during secretion, the bispecific Nb would encounter mutant
plasma gelsolin in the trans-Golgi network and (partly) shield it from furin degradation. Upon
secretion in the extracellular matrix, the MT1-MMP sensitive linker would serve as a decoy and,
at the same time, release the FAF Nb moiety, which would then shield (the lower amount of)
C68 from MT1-MMP degradation. Overall this double hit strategy would result in a significant
decrease in amyloidogenic 8 kDa peptide production. In vitro, a combination of Nb11 and
FAF Nb1 proved to be the most potent. As this approach requires intracellular delivery of the
protective bispecific nanobody, adeno-associated virus serotype 9 (AAV9) gene therapy seemed
an appropriate and clinically relevant method of administration during an intervention study in
AGel mice. FAF Nb1 based SPECT/CT imaging, and immunohistochemistry evinced a significant




Gelsoline amyloïdose is een slopende, autosomaal, dominant overerfbare, ongeneeselijke ziekte die
veroorzaakt wordt door een punt mutatie - hoofdzakelijk G654A/T - in het GSN gen. Vanwege
deze mutatie verliest het tweede domein van gelsoline een deel van zijn intrinsieke stabiliteit en
neemt een intermediaire conformatie aan tijdens Ca2+ activatie. In deze abberante conformatie
komt een anderzijds begraven furine knipplaats aan het oppervlakte te liggen. Tijdens secretie
colocaliseert mutant plasma gelsoline met furine in het trans-Golgi netwerk. Proteolyse resulteert
in de vorming van een C-terminaal, 68 kDa fragment - C68 - dat op zijn beurt, bij secretie in
de extra cellulaire matrix, verknipt wordt door MT1-MMP like proteasen. Hierbij worden 8 en 5
kDa amyloïdogene fragmenten vrijgesteld die, op termijn, polymerizeren in amyloïd fibrillen die
finaal samenklitten in amyloïd plaques. Patiënten, waarvan de meerderheid terug te vinden is in
Finland, ervaren een triade van oftalmologische, neurologische en dermatologische symptomen.
Momenteel wordt enkel symptomatisch behandeld; oogdruppels, cornea transplantatie en plas-
tische chirurgie. Therapeutica gebaseerd op de inhibitie van furine of MT1-MMP werden reeds
naar voor geschoven. Echter, inhibitie van deze proteasen zal nagenoeg zeker resulteren in ern-
stige, ongewenste neveneffecten. Op basis hiervan richtten we onze aandacht op mutant plasma
gelsoline. Nanobodies werden ontwikkeld tegen zowel gelsoline en het 8 kDa amyloïdogene frag-
ment. In vitro screening identificeerde één chaperone nanobody voor mutant plasma gelsoline -
Nb11 - en drie voor C68 - FAF Nb1, 2 en 3 - die hun antigen (gedeeltelijk) beschermen tegen
respectievelijk furine en MT1-MMP. Intraperitonale injectie met FAF Nb2 en in vivo expressie
van Nb11 in het AGel muis model resulteerde in beide gevallen in een verminderde afzetting van
het amyloïdogeen 8 kDa fragment. In dit proefschrift werden deze nanobodies verder getest op
hun potentiëel binnen de AGel diagnostiek en therapie.
In een eerste studie werd het potentieel van de FAF nanobodies binnen de amyloïd beeldvorming
verkend. De motivering hiervoor was dat, tot nu toe, de werkzaamheid van potentiële AGel thera-
peutica enkel kon worden nagegaan via end-stage dierenproeven. Met de reeds gekarakteriseerde
FAF Nbs - opgewekt tegen het 8 kDa amyloïdogene gelsoline fragment - op zak namen we het op
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ons om dit obstakel weg te werken. Gekoppeld aan 99mTc produceerden alle drie de nanobodies
scherpe, SPECT/CT beelden van de gelsoline amyloïd afzettingen in AGel muizen. Op basis van
zijn superieure signal-to-noise ratio en signaalspecificiteit werd FAF Nb1 gekozen als het meest
veelbelovende nanobody. In een follow-up study met AGel muizen die Nb11 expresseren, werd
duidelijk dat FAF Nb1 eveneens bruikbaar is voor kwantitatieve beeldvorming. Inderdaad, een
vergelijking van SPECT/CT kwantificatie, biodistributie data en immunofluorescente histologie
resulteerde in gelijkaardige patronen van signaal toename. Daarenboven, correlatieplots toonden
een positief verband aan tussen 99mTc-FAF Nb1 opname en in vivo gelsoline amyloïd afzetting.
In een tweede studie werden de twee types therapeutische chaperone nanobodies - Nb11 die
mutant plasma gelsoline afschermt van furine en FAF Nb1, 2 en 3 die C68 afschermen van
MT1-MMP - samengevoegd in één bispecifiek nanobody. De FAF Nbs werden kop-staart ver-
bonden met Nb11 met behulp van een MT1-MMP gevoelige linker sequentie. De hypothese was
dat, tijdens secretie, het bispecifieke nanobody mutant plasma gelsoline zou binden in het trans-
Golgi netwerk en (gedeeltelijk) behoeden voor furine degradatie. Vervolgens zou, bij secretie
in de extracellulaire matrix, de MT1-MMP gevoelige linker optreden als afleiding en simultaan
instaan voor de vrijstelling van het FAF Nb fragment. Dit laatste zou dan op zijn beurt instaan
voor de afscherming van (de reeds lagere hoeveelheid) C68 tegen MT1-MMP proteolyse. Deze
double hit strategie zou resulteren in een significante reductie van de geproduceerde hoeveel-
heid 8 kDa peptide. In vitro, gaf een combinatie van Nb11 en FAF Nb1 het beste resultaat.
Gezien deze strategie een intracellulair actieve component bevat, leek adeno-geassocieerd virus
serotype 9 (AAV9) gentherapie een toepasselijke en klinisch relevante toedieningsmethode tijdens
een interventie studie in AGel muizen. FAF Nb1 gebaseerde SPECT/CT beeldvorming en im-
munohistochemie toonden een significante reductie in de gelsoline amyloïd afzetting aan. Deze






Introduction to the actin skeleton and
gelsolin
1.1 The Cytoskeleton
One of the most striking features of living organisms is their ability to move; bacteria follow
chemical gradients, plants have parts that respond to touch, moisture and/or light and the
majority of animals have the ability to roam freely, at least during one stage of their life cycle.
On the cellular level this movement is the result of an immense array of interactions with the
cytoskeleton. Every organism is a specific combination of the basic building block of life: the cell.
Although they come in more than 200 different forms and sizes (bionumbers ID 103626) - ranging
from the tadpole shaped sperm cell being only 60 µm to neurons of almost one meter (bionumbers
ID 104901) - their basic design is identical. In essence a cell is a bubble of viscous, protein-rich
liquid, the cytoplasm, contained in a lipid bilayer called the plasma membrane. Internally, more
lipid bilayers define separate compartments in which the key functions for survival are performed.
(i) The nucleus holds the DNA, the molecule which encodes all the information necessary to
build a complete organism. When needed, pieces of this information get translated into RNA, a
messenger molecule able to leave the nucleus. (ii) The protein production center is formed by
the ribosomes, the endoplasmic reticulum (ER), Golgi apparatus and all the associated transport
vesicles. Ribosomes translate the information - coded in the DNA/RNA - into proteins which are
released into the cytoplasm or further mature in the ER and Golgi apparatus and get distributed to
their final location. Proteins can hold many functions, from simple building blocks for structures
such as hair or skin to miniature copy machines which duplicate DNA when a cell is about to
divide. (iii) The mitochondria are the power stations of the cell. The fact that these essential
structures still hold their own DNA is a remnant of their bacterial origin. In these structures,
sugars react with oxygen forming carbon dioxide, water and energy. The latter is stored under
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the form of adenosine triphosphate (ATP), the number one energy transfer molecule1.
In order for this system of data copying in the nucleus, translation by the ribosomes and distri-
bution by the Golgi apparatus - all fueled by the energy generated in the mitochondria - to run
smoothly, evolution has employed a cellular framework called the cytoskeleton. This vast network
of fibrous structures serves several important functions. (i) The cytoskeleton defines the overall
shape of cells which stands in a close relationship to its function. (ii) Being a dynamic structure,
breakdown at one side of a cell and buildup on the opposite site enables certain cell types to
move in a specific direction. (iii) Subsets of these fibrous structures serve different functions. The
microtubules can be used as roadways for transport proteins such as kinesin and dynein whereas
intermediate filaments and microfilaments grant tensile strength and pressure resistance to cells.
1.1.1 Actin
Microfilaments are also called actin filaments as they are primarily composed of polymerized actin,
combined with a whole array of interacting proteins. In any eukaryotic cell, actin is the most
abundant protein - ranging from 25% in muscle cells to about 1-5% in liver cells [2, 3] - and can
be visualized with specific fluorescent dyes such as phalloidin (Figure 1.1).
Figure 1.1: Phalloidin staining of the cytoskeleton. Phalloidin selectively binds to fila-
mentous actin and prevents depolymerization. Using fluorescently labeled derivatives of phalloidin
microscopic images can be taken of the actin cytoskeleton, as depected here in blue [4].
1I would like to emphasize that this description is an oversimplification of all the intricate structures and
processes contained within a cell. For more details I kindly refer to the book Molecular Biology of the Cell
from Alberts et al., 2002 [1] and other similar outstanding literature.
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The amino acid (AA) sequence of actin is heavily conserved in the eukarya - the domain of life
including all life forms comprised of (a) nucleated cell(s) (Figure 1.2) - and differs no more
than 20% between any two species. It is however an oversimplification to talk about actin as
a specific protein. It is better to consider it as a family of actin proteins since in mammals 6
and in some plants even 60 isoforms are expressed [1, 5]. The six isoforms can be subdivided in
two groups, (i) αskeletal-actin, αcardiac-actin, αsmooth-actin and γsmooth-actin are primarily expressed
in cardiac, skeletal and smooth muscle cells whereas (ii) βcyto-actin and γcyto-actin are ubiqui-
tously expressed. Compared to one another these different isoforms share at least 93% identity [6].
Figure 1.2: The classification of life in three domains - bacteria, archaea and eukarya -
was introduced by Carl Woese in 1977. It underlines the fundamental difference between the two
prokaryotic groups, with the archaea being closer related to the eukary than the bacteria. Figure
adapted from Lehninger Principles of Biochemistry, Sixth Edition [7].
The actin cytoskeleton is not a rigid, defined structure. There is a constant dynamic balance
between assembly and disassembly. If one would isolate a single actin filament, called F-actin,
it would appear to move forward in a specific direction2. This optical illusion is due to the fact
that actin is not an equilibrium polymer. Indeed, as G-actin starts to polymerize, the on- and
off-rates differ between both ends of the filament. In order to compensate for this thermodynamic
2Indeed, as the more critical reader may point out, this is an oversimplification. In order to observe
this phenomenon, the F-actin filaments need to be placed in a solution containing 0.1 µM G-actin - the
critical concentration for treadmilling - otherwise the filament would also increase (higher concentrations)
or decrease (lower concentrations) in size.
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imbalance, actin utilizes its ATPase activity [8]. Actin monomers have the capacity to bind ATP.
After being assembled at the barbed end, G-ATP-actin will slowly hydrolyze to form F-ADP-actin
thereby releasing a phosphate group and energy. At the pointed end, the opposite takes place.
F-actin disassembles, thereby releasing G-ADP-actin. With the help of profilin this G-ADP-actin
can exchange its ADP for ATP and the process starts over. This unceasing flux of actin from the
pointed end to the barbed end, called treadmilling, is the driving force behind actin-based cell
motility (Figure 1.3) [9]. Besides energy in the form of ATP, this actin polymerization process
also requires Mg2+. This divalent cation serves as a cofactor - a non-protein compound required
by a protein to perform its biological function - for actin’s ATPase activity.
This actin polymerization process is carefully controlled and guided towards the desired end
structures by a broad range of actin binding proteins (ABPs). More than 160 identified ABPs
are involved in actin (de)polymerization, bundling, stability, fragmentation and crosslinking [3].
According to their specific functions, the ABPs have been divided into seven groups (Table 1.1).
Figure 1.3: Actin treadmilling. The dynamic equilibrium of actin filaments results in a constant
turnover of actin monomers. At the pointed end, G-ADP-actin is released and recycled back
into ATP-actin via phosphorylation. At the barbed end this ATP-actin polymerizes into F-actin,
thereby elongating the actin-filament. This process results in a directional force enabling the cell -
or individual organelles - to move into a specific direction. Over time the incorporated ATP-actin
monomers will be hydrolyzed back into ADP-actin and the cycle can repeat itself. Depolymerization
at the pointed end is accelerated by cofilin while the branching towards the barbed-ends is facilitated
by Arp2/3, which is activated via an Arp2/3 activator and Small GTPases [10].
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Table 1.1: Actin binding protein groups
Group type Function Examples
Monomer-binding proteins
Sequestration of G-actin
and prevention of its
polymerization
Thymosin β4, DNase I
Filament depolymerizing
proteins
Induction of the conversion




Capping of the actin
filament ends, thereby






















length of filaments by
binding to the side of
F-actin and cutting it into
two pieces
Gelsolin
Adapted from dos Remedios et al., 2003 [11].
A key member of the filament severing group, gelsolin, has several mutants which cause a disease
known as gelsolin amyloidosis. This affliction is essentially the main topic of this PhD and will
be rigorously discussed in Chapter 3. But first the native function of gelsolin and a phenomenon
known as amyloidosis will be discussed.
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1.1.2 Gelsolin
Gelsolin was first described in 1979 by Yin and Stossel as a protein able to liquefy solid actin gels:
the gel-sol reaction, hence the name [12]. It is the founding member of the gelsolin superfamily; a
group of Ca2+-regulated actin binding proteins with the ability to sever, cap and/or nucleate actin.
These proteins are highly conserved in the animal kingdom and contain three or more prototypical
‘gelsolin-like’ domains. The basic architecture of such a globular ‘gelsolin-like’ domain consists of
a central, five or six-stranded β-sheet packed between a long, roughly parallel and a short, roughly
perpendicular α-helix (Figure 1.4) [13, 14]. Gelsolin is composed of six such domains (G1-6) -
each domain is about 120-130 amino acids long - which, in a Ca2+-free environment, are closely
packed together. Given the great homology between domain 1-2-3 and domain 4-5-6 respectively,
gelsolin seems to have evolved through a gene triplication followed by a gene duplication. The
single, 70 kb gelsolin gene (GSN), located on chromosome 9q34 contains 14 exons and gives rise
to three gelsolin isoforms via multiple transcription initiation sites and alternative splicing [15].
The two main isoforms; plasma gelsolin (PG, 84 kDa) and cytoplasmic gelsolin (CG, 82 kDa) are
ubiquitously expressed and differ from one another at two points. (i) PG contains an N-terminal
extension of which 24 amino acids remain present after cleavage of the ER signal peptide3. (ii)
Of the five cysteine residues, two of them form a disulfide bond in PG - Cys188 with Cys201 -
whereas in CG they are all in the free thiol form [16]. The third isoform, gelsolin-3 (82 kDa), has
until now only been detected in brain oligodendrocytes, lungs and testis tissue. Just like PG it
contains an N-terminal extension, albeit only 11 residues long [17].
Figure 1.4: Schematic representation of a gelsolin domain. A gelsolin domain consist of
a five or six-stranded β-sheet (yellow, five stranded) sandwiched between a long, roughly parallel
(red, right helix) and a short, roughly perpendicular α-helix (red, left helix). Unpublished figure
from Van Overbeke et al., 2015 [18].
3An ER signal peptide is a short peptide sequence - usually between 5 and 30 amino acids - used to tag
proteins which are destined for the secretory pathway which begins in the ER.
1.1 THE CYTOSKELETON 17
To our current knowledge the overall structure and activity regulation of the isoforms is essentially
identical. As we proceed with the disquisition of the structure and activity regulation, I will
therefore simply refer to both isoforms as ‘gelsolin’.
Ca2+ activation
Given the catalytic nature of gelsolin, its function is tightly regulated by both Ca2+, pH levels,
phosphatidylinositol 4,5-biphosphate and lysophosphatidic acid. All six gelsolin domains contain a
type-2 Ca-2+ binding site, each having a different affinity (Figure 1.6). Upon sequential binding
of Ca2+ to each one of these domains, gelsolin will unfold its globular inactive state, thereby
bringing its actin binding regions to the surface. This process involves the unfolding/relocation
of three latches (Figure 1.5A) - (i) the tail latch formed by the C-terminus and G2 domain, (ii)
the G1-G3 latch and (iii) the G4-G6 latch - and can be divided in several stages based on the
required concentration of Ca2+. (i) 0.2 µM Ca2+: G6 binds Ca2+ thereby straightening its major
helix and destabilizing the G4-G6 latch. The tail latch is weakened [19]. (ii) 2 µM Ca2+: G4 binds
Ca2+, G4 and G5 shift and the G4-G6 latch further weakens. The tail latch is now fully released
[19]. (iii) 100 µM Ca2+: G5 binds Ca2+, by that stabilizing its interface with G4 and locking the
G4-G6 latch in an open state. Simultaneously, G3 binds Ca2+ thereby straightening its long helix
and opening the G1-G3 latch. The latter reveals the cryptic, high affinity Ca2+-binding site on
G2 [20]. This site cooperatively binds Ca2+ and pushes G2-G3 towards its active conformation.
Once activated, G2 releases its Ca2+ ion. (iv) From 0.6 mM Ca2+ onwards: G1 binds Ca2+ and
gets locked into position via the G1-G2 linker. Gelsolin is ready to strike and sever F-actin. Upon
interaction with actin, two more Ca2+ binding sites come into play. These so called type-1 Ca2+-
binding sites are sandwiched between the actin:G1 and actin:G4 interfaces. In other words, these
Ca2+-binding sites are a conjunction between gelsolin and actin residues and most likely have an
influence on the affinity between the two during F-actin severing [21]. This process happens in
three stages (Figure 1.5B). (i) The activated G2-G3 - step (iii) of the activation process - binds
to F-actin via G2. (ii) Binding of G2 induces G6, the G1-G2 and G3-G4 linker to wrap around the
filament, enabling G1 and G4 to move towards the cleavage site. (iii) G1 and G4 cleave F-actin.
Gelsolin remains bound thereby preventing polymerization at the newly formed barbed end. This
action is called capping4.
4Although I have described this entire process of gelsolin activation and F-actin severing/capping in a
discrete number of individual steps, it is important to realize that this is a model derived from in vitro
observations using carefully controlled amounts of Ca2+. In reality, in vivo, this is a continuous process
which takes place in a fraction of a second. The cell does not contain individual compartments with all the
specific concentrations mentioned in the text.
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Figure 1.5: Schematic representation of gelsolin activation (panel A) and its actin
severing activity (panel B). Ca2+-free gelsolin domains are represented as hexagons. Ca2+-
activated domains are represented as ovals. Actin subunits are represented as light blue U-shapes.
For each step which requires Ca2+, the needed ion concentrations are indicated. Given the high
Ca2+ concentration in the blood compared to the cytoplasm’s carefully controlled Ca2+ concentra-
tion, this stepwise representation of gelsolin’s activation is more representative for the cytoplasmic
isoform than it is for the plasma variant. Figure adapted from Burtnick et al., 2004 [22].
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Figure 1.6: Schematic representation of gelsolin. Black boxes represent the six gelsolin
domains. Ca2+-binding sites (grey and black dots), actin-binding sites (red), PIP2-binding sites
(yellow) and caspase-3 sensitive linker (blue arrow) are indicated [23].
In distinction to the two destructive functions described above, gelsolin has, at least in vitro,
a constructive capacity; nucleation [24]. Gelsolin has the ability to bind two actin monomers,
thereby bringing them in close proximity. Onto this complex, actin polymerization can be per-
formed, forming a new F-actin filament. It is highly unlikely that this process also takes places in
vivo. In eukaryote cells G-actin is bound to either thymosin-b4 or profilin, rendering it unfit for
pointed end growth from a gelsolin-actin nucleus [25]. Rather, in vivo actin nucleation is ascribed
to the Arp2/3 complex and formins [26].
Physiological Ca2+
The tight regulation of gelsolin’s activity by Ca2+ is not a peculiarity. In fact, Ca2+ is one of the
most important intracellular messenger ions in a plethora of cellular processes. Its intracellular
distribution is therefore meticulously regulated.
Blood plasma contains 2.5 mM Ca2+ of which 1.2 mM is free, unbound. Intracellular free Ca2+
is used to regulate all sorts of intracellular processes via numerous proteins with the ability to
buffer Ca2+. They reside in the different organelles and differ in their buffering capacity and
response to Ca2+ [27]. Hence, each organelle is characterized by a specific Ca2+ concentration
and Ca2+-response. One thing all these Ca2+-buffering proteins do have in common is the fact
that they aren’t merely Ca2+-buffers. These multifunctional proteins are of major importance in
processes such as apoptosis, gene transcription, mitochondrial metabolism and protein folding
[28]. The latter can be directly linked to the activation of CG (discussed above) and protein
folding which will be discussed in Chapter 2.
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Zooming in on PG, two organelles are of major importance; the endoplasmic reticulum and
Golgi apparatus. As will be explained in more detail in subsection 2.1.1 Protein synthesis, PG
travels through the ER and Golgi apparatus during its synthesis. Simultaneously it will adopt its
correct folding and eventually gets secreted into the bloodstream where it can achieve its active
conformation.
The ER represents the largest intracellular Ca2+-buffer; 1 mM Ca2+ of which 200 µM is unbound
[28]. The majority of the ER Ca2+-binding proteins serve as folding chaperones for proteins like
PG. Calreticulin, which binds 50% of the ER Ca2+, and BiP are two examples of such chaperones
and will be discussed in more detail in subsection 2.1.1 Protein synthesis.
The Golgi apparatus has also been identifies as a Ca2+-buffer; 2 to 300 µM Ca2+. Calnuc, also
known as nucleobinding, is the primary Ca2+-binding protein in the Golgi apparatus and shows
some homology to Calreticulin [29]. It has been postulated that this protein may serve both as
a Ca2+-buffer, Ca2+-sensor and interacts with a large number of other proteins [30].
PIP2 and LPA regulation
The Ca2+ activation of gelsolin is meticulously counterbalanced by the inhibitory actions of
phosphatidylinositol 4,5-biphosphate (PIP2) and lysophosphatidic acid (LPA). The phospholipid
PIP2 is a minor component of cell membranes, enriched in certain areas, where it serves a key
role in a number of signaling pathways and is considered one of the fundamental regulators of
the subcortical actin network in eukaryotes [31]. In gelsolin, two amino acid stretches - G1:
AA 135-149 and G2: AA 150-169 - have been identified as PIP2-binding motifs (Figure 1.6)
[32, 33]. Corresponding regions have also been detected in all other members of the gelsolin
superfamily. As PIP2 is incorporated in the plasma membrane, binding to gelsolin sequesters
the latter, making it unavailable for Ca2+ activation, thereby inhibiting actin-severing. When
bound to PIP2, gelsolin - and a number of other ABPs - readily undergo phosphorylation by
pp60c-src and PYK2 which further decreases its affinity for actin5 [34, 35]. In addition, PIP2
is able to disrupt gelsolin’s capping function, by that actively promoting actin polymerization
[36]. Hydrolysis of PIP2 releases gelsolin from the plasma membrane, allowing Ca2+ mediated
reactivation of gelsolin’s actin severing and capping functions.
LPA, a phospholipid which contains the same uncommon phosphomonoester as PIP2 in its head-
group, has similar effects on gelsolin regulation as PIP2. Additionally, LPA directly influences
a number of intracellular components with a pivotal role in signal transduction; n-chimaerin,
G-proteins, protein kinase C, etc. [37–39]. Interestingly, the same peculiar phosphomonoester
group can also be found in lipopolysaccharides (LPS) - large molecules consistent of a lipid and
a polysaccharide present in Gram-negative bacteria. In fact, gelsolin has a higher affinity for LPS
5Phosphorylation is a common post-translational modification in which a phosphate group is transferred
from ATP to one (or several) of the amino acids in a protein. This charged group induces conformational
changes which may (de)activate a protein or modify its function.
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than for PIP2 or LPA [40]. Gelsolin-LPS binding impedes LPS-mediated thrombin inhibition,
LPS-induced actin remodeling and collagen-induced platelet activation pathways independent of
toll-like receptors (TLR) [40]. Despite the fact that gelsolin itself does not affect bacterial growth,
this evidence does suggest that interaction with LPS inhibits the inflammatory and coagulatory
effect of the latter.
Regulation by pH
The earlier discussed activation of gelsolin by Ca2+ can, at least in vitro, be overruled. The pH
value - a negative log10 scale of the proton concentration specifying the acidity of a solution
(acidic < 7 < basic) - of our extracellular fluids fluctuates around a value of 7.4. In such an
environment gelsolin requires at least 10 µM of Ca2+ for activation. In vitro, lowering the value
to pH 6.5 reduces this to 3 µM Ca2+. At pH values below 6.0, gelsolin severing activity has even
been observed in solutions containing EGTA6. Dynamic light scattering experiments suggest that
the increased proton concentrations induce conformational changes in gelsolin similar to the ones
induced by Ca2+-binding [41]. Furthermore, slightly acidic pH levels boost PIP2 binding affinity
[42]. These findings suggest that gelsolin integrates Ca2+, PIP2/LPA and pH signals in order to
fine-tune its activity status.
Functions of gelsolin
Cell motility & invasion: During different stages of development, several types of eukaryotic
cells are able to move freely throughout the body. Cells migrate to their final location during
embryogenesis, immune cells search and destroy pathogens and cancers cells may one day leave
their tissue of origin ready to colonize the rest of the patient’s body. Their movement resembles
the crawling motion of amoebas and is fueled by the polarized polymerization/depolymerization
of the actin skeleton (Figure 1.3 and 1.7). CG is a key regulator of these actin remodeling
processes and it plays a substantial role in cellular movement. This was first demonstrated in
NIH 3T3 fibroblast; overexpression7 of CG resulted in an increased motility [43]. More elaborate
evidence came from gelsolin null mice (GSN-/-) in which osteoclasts are unable to form podosomes
- cell adhesion structures involved in cell motility and invasion - resulting in a defect basal and
osteopontin-induced motility [44]. Also, during neuronal growth, cone formation and retraction
is delayed [45] and fibroblasts show defective chemotaxis resulting in delayed wound healing
[46]. Thus, even though GSN-/- mice are viable - at least in a mixed strain background - and
phenotypically healthy, they display several cellular defects which prove lethal at perinatal and
early postnatal stages [47].
6EGTA is a chelating agent capable of binding all the Ca2 ions present in the solution, making them
unavailable for other processes.
7During overexpression, cells are stimulated to abundantly express an artificial gene.
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Apoptosis: The bodies of full-grown, multicellular organism are not static. Every cell will even-
tually be replaced via a mechanism of programmed cell death called apoptosis. This process
involves a cascade of breakdown processes whereby no lysis products are released onto the sur-
rounding cells, as is the case in necrosis. Instead the cell will disintegrate in a large amount
of apoptotic bodies - small vesicles containing (partly) degraded cell matter - which are then
engulfed by macrophages and recycled. Apoptosis is strictly regulated by caspases; a family of
cysteine-aspartases. One member, caspase-3, is able to cleave gelsolin in half (Asp352-Gly353).
The N-terminal half (G1-G3) hereby no longer requires Ca2+ for activation and, in the case of
CG, will induce uncontrolled actin cytoskeleton breakdown, one of the first steps of apoptosis.
Intriguingly, full length CG has been shown to inhibit apoptosis in murine hearts, Jurkat T cells
and in studies with the GSN-/- mice [48–52].
Figure 1.7: Cell motility by actin polymerization. The constant directional turnover of
actin filaments allows cells to migrate into a specific direction [53].
Cancer: The duality of gelsolins’ pro- and anti-apoptotic properties, discussed in the previous
paragraph, sow controversy regarding its role in tumor formation. During the initial stages of
tumor development, cancerous cells play it safe and downregulate gelsolin expression [54], as was
observed in breast, pancreas, stomach, bladder, colon, kidney, ovarium and colon cancer. Low
levels of CG enable a rapid expansion without the risk of gelsolin-related apoptosis or growth
inhibition. Indeed CG has the ability to induce cell cycle arrest at the G2 phase [55, 56]. In
later stages - during the transition to a malignant and/or metastatic cancer - cancer cells change
strategy and start to overexpress gelsolin. Most probably this is due to the increased need for
cell motility [54].
Signal transduction: In 1987 it came to light that cofilin plays a role in the intranuclear actin
modulation [57]. Since then profilin, supervillin, CapG and plastins have been added to the list
of nuclear actin binding proteins (nABPs). These proteins normally reside in the cytoplasm but
during stress- or hormone-induced cellular differentiation they can migrate into the nucleus. The
way in which this is achieved is still under investigation. The same capacity has been observed for
CG in differentiated endothelial cells [58] and serum-starved NR6 fibroblasts [59]. CG also has a
role in several signal transduction pathways. For example, it interacts with the testosterone-bound
androgen receptor, facilitates its nuclear translocation and enhances its transcriptional activity
[60]. Furthermore, an interaction between hypoxia-inducible factor 1 (HIF-1) - a transcription
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factor and key regulator of cell metabolism under hypoxic conditions - and CG has been reported
[61]. Additionally, gelsolin involvement has been reported in EGF-mediated motility [62, 63], the
Ras-PI3K signaling pathway [64, 65], PI3K modulated osteoclast function [66] and many more.
Extracellular actin scavenging: During inflammation or injury vast amounts of actin are released
into the bloodstream, an environment which promotes the polymerization into F-actin. This pro-
cess would drastically increase the blood viscosity if left unchecked. This is where, hypothetically,
the secreted plasma isoform of gelsolin comes into play. Its primary function is the removal of
this excess actin via its actin scavenging and severing activity. This hypothesis is backed by the
observed lower levels of free PG during hepatic failure, malaria, acute lung injuries, myonecrosis
and cardiac injury [67–70]. Moreover, patient injuries accompanied by a prolonged reduction in
PG-levels correlate with a poor outcome or even death [71]. This may be explained by the fact
that PG binds to inflammatory messenger molecules such as lysophosphatidic acid and platelet
activating factor (PAF), thereby keeping the inflammation contained. As PG gets depleted dur-
ing injury, these molecules are no longer sequestered, opening the doors for uncontrolled immune
reactions throughout the body [72].
2
Introduction to amyloid disease
2.1 Amyloidosis
Having dissected gelsolin, the first part of this PhD thesis’ major topic, let’s move on to the
second; amyloidosis. This therm is best known in regard to Alzheimer’s disease. As our life
expectancy rose, so did the prevalence of this debilitating and eventually lethal neurodegenerative
disease. In this Chapter I will show that this is just one member of a large group of amyloid
diseases and provide detailed insight into the nature of the common causative agent; amyloid.
In Chapter 3 both concepts will come together in the disquisition of a disease called gelsolin
amyloidosis.
2.1.1 Protein synthesis
Before we are able to talk about amyloid, we have to go back to the central dogma of molecular
biology which states that information flows from DNA to RNA to protein1. DNA or deoxyri-
bonucleic acid is a double stranded, linear molecule composed of four nucleobases; cytosine (C),
adenine (A), guanine (G) and thymine (T). In the same way digital data is essentially stored in
large arrays of zeros and ones, so is all the information that defines a person stored in large arrays
of C’s, A’s, G’s and T’s2. DNA molecules are safely locked away in the nucleus. Whenever a
fragment of this DNA information is needed a RNA polymerase copies it into RNA or ribonucleic
acid. This process is called transcription. Just as DNA, RNA is composed of four nucleobases,
1This flow of information, formulated by Francis Crick in 1958 is not completely correct. In 1970 it was
adjusted as by then it had became clear that information can also flow from RNA to DNA or from RNA to
RNA.
2In recent years it has become clear that DNA contains extra layers of information in the form of methyl
groups places both on the cytosines and histone proteins. This new scientific field is called epigenetics and
has significantly enhanced our understanding of how genotypes relate to phenotypes [73].
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however instead of thymine, uracil (U) is used. Moreover, RNA is single stranded and, contrary
to DNA, able to leave the nucleus. In the cytosol, protein-coding RNA molecules will associate
with ribosomes - ribonucleoproteins able to translate RNA coded information into an amino acid
sequence - and translation will commence. Every triplet of RNA bases - called codons - codes for
one of the 20 canonical amino acids used in eukaryotes3. This process heralds an important shift
in information. The information, linearly stored in DNA and RNA gets translated into an amino
acid chain which, when fully matured, will adopt a specific 3D structure directly correlated to the
protein’s function (Figure 2.1)4. In every organism, proteins perform a vast array of functions,
including, but not limited to, the formation of rigid structures - e.g. keratin in hair and nails -
transportation of molecules and other particles - e.g. hemoglobin ships oxygen from the lungs
throughout the body - and catalyzing chemical reactions. Proteins serving this latter function
are called enzymes.
Figure 2.1: The central dogma in biology; information generally flows from DNA to
RNA to protein. In preparation to cell division, the double stranded DNA gets duplicated in a
process called replication. Information coded by the DNA can only leave the nucleus after it has
been copied into a single stranded RNA molecule; transcription. Every RNA coding for a protein
will be translated. Each RNA-nucleobasetriplet codes for a single amino acid. The resulting peptide
will adopt its native 3D conformation resulting in a functional protein [76].
In the early days of molecular biology, it was common belief that the primary structure of a protein
- the linear sequence of amino acids joined by covalent bonds - contained all the information
necessary to migrate towards the final 3D structure [77, 78]. To a certain degree this is true.
The presence of hydrophilic/hydrophobic and negatively/positively charged side chains is sufficient
to induce the local formation of α-helices and β-strands/sheets. These secondary structures can
self-assemble into a denser tertiary state. Larger proteins which consist of multiple subunits will
fit their individual parts together forming a quaternary structure. However, this entire process is
3Selenocysteine, although present in 25 human proteins is not directly coded by DNA [74].
4As always there are exceptions. Secondary structures in DNA and RNA molecules serve specific func-
tions and micropeptides, although lacking significant secondary structures, have been shown to be biologically
active [75].
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stochastic. Starting from its initial primary structure, the proteins sample several conformations
in search for a thermodynamically favorable outcome. As they migrate through the folding
landscape, there is a risk of getting stuck in local energy minima representing partly folded
states, or worse, drifting off course towards non-functional oligomers, amorphous aggregates or
amyloid fibrils (Figure 2.2). By now we know that a great deal of proteins rely on chaperones;
proteins which assist them during the folding process, guiding them towards their native state.
Figure 2.2: The protein folding landscape. The folding process of newly synthesized polypep-
tides is a thermodynamically driven process during which several conformations in the folding land-
scape are sampled in a search towards the native state. The presence of local thermodynamical
minima entail the risk of getting trapped in a partially folded state. Chaperones serve to prevent
or overcome such bottlenecks. However, if, for whatever reason, the folding mechanism fails, evi-
dence suggests that each protein could adopt aggregated and amyloidogenic conformations as these
represent thermodynamically stable configurations [79].
Secretory protein synthesis
The synthesis of secretory proteins is essentially the same as for any other protein. The only dif-
ference lies in the fact that secretory proteins contain a hydrophobic N-terminal signal sequence
that directs them toward the endoplasmic reticulum (ER) (Figure 2.3). Upon translation, the
signal sequence is recognized by a signal recognition particle (SRP). Translation is put on hold
and the entire complex is guided towards the ER. As the SRP interacts with the SRP receptor
(SR), the emerging polypeptide can enter the ER. The SRP/SR complex dissociates from the
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signal sequence and translation resumes. The folding process starts in concert with translation
and, just as for cytosolic proteins, may require the assistance of chaperone proteins.
Figure 2.3: Cotranslational uptake in the ER. During translation of RNA coding for secretory
proteins, the first translated stretch of amino acids contains a signal sequence which is recognized
by the SRP. Binding of the SRP halts translation and targets the entire complex (ribosome bound
to RNA and the nascent polypeptide chain) towards the translocon; a protein-conducting channel
(represented as a purple cylinder) via docking with the SRP receptor. Upon release of the SRP,
translation continues. The nascent polypeptide is cotranslationally guided through the translocon
into the ER lumen where protein folding takes place [80].
2.1.2 Protein quality control
At any given time, a single human cell contains several billion proteins. Each of which, on
average, required 3000 ATP molecules to make. Maintaining a proteome of this magnitude
requires a constant translation by about 3 million ribosomes at a rate of six amino acids per
second [81]. This machinery consumes up to 75% of the cell’s energy [82, 83]. Thus, it is
in the cell’s best interest to optimize every step. Remarkably the translation process itself is
extremely efficient. By contrast, folding proteins into their functional, native state frequently
fails. Moreover, the more than 300 different types of posttranslational modification, 35 types of
oxidative damage and more than 10 types of carbonylation make protein maintenance a heavy
burden [5]. During the course of evolution several mechanism have been developed to enhance
folding efficiently and dispose of proteins lost beyond repair.
Quality control at the ribosomes
Translational errors can have devastating effects on protein stability. A single mutation changes
the free energy with about 0.5-5 kcal/mol [84]. Therefore ribosomes are assisted by a cohort
of nearly 300 proteins which restrict the misincorporation to about 1/10.000 amino acids. A
second effective way in which translational errors can be minimized is optimization of the mRNA
codon use. The hypothesis that ‘the use of codons that slow translation increases proper folding’
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has been demonstrated by incorporating wobble codons in the luciferase gene5 [85]. A slower
translation broadens the timeframe during which chaperones can bind to aggregation-prone amino
acid stretches. Also, during times of stress, cells will actively slow down or pause translation.
On the other hand, a rapid translation may prevent the formation of intermediate folding states,
thereby increasing the fraction of proteins reaching their native fold. The take home message is
that the rate of translation itself may significantly affect the folding efficiency.
Cotranslational folding is another means to avoid incorrect folding. As single proteins can be
as large as 3.7 MDa [86], sequential translation and folding would leave hydrophobic stretches
exposed for a prolonged period of time, increasing the risk for aberrant folding intermediates. In
eukaryotes chaperones like heat shock protein 40 and 70 (Hsp40, Hsp70) will bind to nascent
polypeptides and chaperone the cotranslational folding process.
Despite the high translational efficiency, up to 15% of nascent proteins are cotranslationally
tagged for degradation. The majority of these are associated with truncated mRNAs or difficult
to translate sequences leading to ribosome stalling. How such ribosomes are detected is still under
investigation. What is known is that nascent proteins in stalled ribosomes get ubiquitinated via the
ribosome-associated E3 ligase Hel3, targeting them for degradation by the ubiquitin proteasome
system (UPS).
Incorrectly folded protein and the ubiquitin proteasome system
Eventually, any protein not reaching its native conformation or losing it due to oxidative damage
will be marked by ubiquitin. This highly conserved, small - 76 amino acids - protein is first
activated by E1, a ubiquitin activating enzyme. Next it is attached to E2, a ubiquitin carrier
protein which is recognized by E3. The latter is a ubiquitin protein ligase which has the ability to
recognize misfolded proteins and tag them with ubiquitin transferred from E2 (Figure 2.4). Any
E1 can bind with several E2s, which in turn can bind hundreds of E3s. This hierarchical system
allows a tight regulation of the ubiquitin pathway [87]. Soluble, ubiquitinated proteins or protein
aggregates will be sequestered in the juxtanuclear quality control compartment (JUNQ) [88].
This non-membrane bound cellular site is associated with copious chaperones and proteasome
complexes. The local high concentration of chaperones and misfolded proteins may increase the
possibility of refolding. If the chaperone machinery does fail, degradation by the 26S proteasome
follows6. The proteasome consist of a 20S central hollow cylinder composed of 2 times 14
different polypeptides. Both ends are equipped with two 19S caps. Subunits in the central
core have trypsin-like, chymotrypsin-like and post-glutamyl activity. During the ATP-consuming
protein degradation, the ubiquitin peptides get recycled.
5The term wobble refers to abnormal base pairing between the mRNA codon and tRNA anticodon.
There are 43=64 possible mRNA codons, yet most organisms contain no more than 45 different tRNAs.
Non-Watson-Crick base pairing - guanine with uracil or hypoxanthine (a sixth nucleobase) with uracil,
adenine or cytosine - fix this discrepancy.
6Svedberg, S, is a non-SI unit for sedimentation rate. This unit correlates with the size and shape of a
particle, in this case a protein.
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Figure 2.4: Ubiquitination. Using ATP E1 binds a ubiquiting protein. This ubiquiting-
activating enzyme E1 then transfers ubiquiting to E2 which forms a complex with E3. The latter
is able to recognize proteins destined for ubiquitinylation and catalyzes the transfer of ubiquitin
from E2 to the target protein. This cycle is repeated untill the target protein is tagged by a
polyubiquiting chain [89].
Together with JUNQ a second distinct, non-membrane bound, cytoplasmic structure was discov-
ered [88]. In contrast to JUNQ it contains highly insoluble aggregates and amyloid. A single cell
can contain several of these insoluble protein deposits (IPODs). Although the association with
chaperones like Hsp104, 70 and 40 [90] indicates an effort to disaggregate the content, most
IPOD protein is highly terminal and should be degraded.
Autophagocytosis
Given the presence of insoluble protein deposits, it is clear that the ubiquitin-proteasome system
has its limits. This is in sharp contrast with autophagocytosis, a lysosomal degradation pathway
which not only targets protein aggregates but also entire organelles [91]. This disposal mechanism
allows (i) cells to dispose of defective organelles and protein aggregates, (ii) remove and recycle
superfluous structures and macromolecules during differentiation and (iii) survive times of nutrient
deprivation or environmental stress [92].
In mammalian cells, three types of autophagy are known. (i) Chaperone-mediated autophagy
which sequesters protein(aggregates) via their KFERQ-like motif using heat shock cognate 70
and other co-chaperones. (ii) Microautophagy, a process especially important during cellular
starvation. Here, cytoplasmic material is engulfed via membrane invagination. In general this
type of autophagy is non-selective. (iii) Macroautophagy which differs from the other two due to
the de novo formation of phagophores. More specifically macroautophagy relies on the formation
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of a double membrane around the target molecule or organelle which will later on fuse with the
lysosomal membrane.
All three types of autophagy rely on an array of associated proteins and lysosomal proteases to
recognize, transport, dispose and recycle the targeted substances. Therefore it should not come as
a surprise that mutations in the lysosomal pathway have been associated with neurodegenerative
diseases. For example, Gaucher disease - a deficiency of glucocerebrosidase due to a mutation
in the GBA1 gene - is considered to be a major risk factor for the development of Parkinson’s
disease [93].
Consequently, in neurodegenerative diseases heavily stocked IPODs can still be found in the cells
of infected tissues. Incapable of degrading the amyloidogenic deposits associated with these
diseases, the cells isolate them in IPODs as a last resort [88].
Endoplasmic-reticulum-associated protein degradation (ERAD) and unfolded protein re-
sponse (UPR)
During translation, proteins processed by the ER get decorated with glycans; covalently bound
carbohydrate structures of major importance in a plethora of cellular functions, one of them being
protein folding. Calnexin (CNX) and calreticulin (CRT) , two lectins - proteins able to recognize
specific carbohydrate structures - are at the center of a glycan based ER protein folding/refolding
treadmill. In the ER, newly formed proteins are equipped with Glc3Man9GlcNAc2 - a branched
polysaccharide chain consisting of 3 glucose, 9 mannose and 2 N-acetylglucosamines. Should
the protein not fold correctly, sequential glucose trimming by α-glucosidase I and II exposes
the Glc1Man9GlcNAc2 epitope recognized by calnexin and calreticulin. Via their chaperone
domain these lectins will attempt to steer the bound protein towards its native fold. Next α-
glucosidase II will remove the last glucose moiety. If the native fold was achieved, the protein can
proceed through the secretory pathway. If not, glucosyltransferase will reglycosylate and another
CNX/CRT cycle will take place (Figure 2.5). Terminally unfolded proteins will be transported
back into the cytosol, ubiquitinated and targeted to the proteasome, as described above.
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Figure 2.5: The calnexin/calreticulin cycle. The glycans of misfolded glycoproteins are
trimmed by α-glucosidase I and II, enabling these glycoproteins to enter the calnexin/calreticulin
cycle after which α-glucosidase II will remove the last glucose moiety. When interaction with these
chaperones results in a native conformational fold the glycoprotein can exit the ER. If not it will be
recognized by (UDP)-glucose:glycoprotein glucosyltransferase (UGGT), reglycosylated and enter
another CNX/CRT cycle [94].
If, for whatever reason, the CNX/CRT cycle proves insufficient, the unfolded protein response is
initiated. UPR will (i) halt protein translation, (ii) degrade misfolded proteins and (iii) increase
the expression of the molecular chaperone BiP, an ER-variant of HSP70. If however the cell is
still unable to reverse the ER protein stress, UPR will eventually initiate apoptosis.
2.1.3 Amyloidosis
A very peculiar form of protein (mis)folding is amyloid. In 1854 Rudolf Virchow examined human
brain tissue and discovered deposits with similar iodine staining as cellulose-like materials in plants
which he named corpora amylacea [95]. In the following decades comparable reaction patterns
were discovered in other diseased organs and were likewise referred to as amyloid. Although the
original cranial structures described by Virchow turned out to be polymeric carbohydrates [96],
hence the positive iodine staining and the term amyloid (meaning starch-like), the later discovered
deposits in other diseased organs were of proteinaceous nature. Nonetheless, the term amyloid
stuck.
Using X-ray diffraction patterns and electron microscopy, the underlying universal structure of
amyloid was unraveled. Individual proteins, or protein fragments, are assembled into β-sheets.
These β-sheets come together to form an amyloid protofibril in which the sheets run parallel and
the individual protein strands perpendicular to the protofibril direction (Figure 2.6). Such an
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arrangement is referred to as cross-β-sheets. Several of these ± 4 nm wide protofibrils align in
parallel and form a mature amyloid fibril containing a slight twist in the same way a rope consists
of individual fibers twisted together (Figure 2.7). Over time all these amyloid fibrils will become
tangled, forging dense networks known as amyloid plaques. Mature amyloid can be stained with
Congo red thereby displaying green birefringence under polarized light (Figure 2.8).
Figure 2.6: Cross β-sheets. Amyloido-
genic protein(fragments) form β-sheets and
align themselves perpendicular to the fibril
axes of the protofibril [97].
Figure 2.7: Amyloid fibrils. Protofibrils
allineate with a slight twist into mature amy-
loid fibrils [98].
The above described amyloid structure and staining characteristics (Figure 2.8) are common to
all known forms of amyloid, independent of the constituent protein. Variation has however been
observed at the protofibril level. Indeed, (i) individual strands may run parallel or antiparallel, (ii)
β-sheets may be stacked parallel or antiparallel and (iii) inter-sheet packing may be face-to-face
or face-to-back [99].
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Figure 2.8: Congo red stained amyloid. Congo red displays apple-green birefringence under
polarized light when bound to mature, cross-β-sheet amyloid fibrils (indicated by white arrows).
Congo red is therefore still the golden standard for amyloid detection. The gelsolin amyloidosis
mouse model (discussed later in this manuscript) displays Congo red positive amyloid buildup
starting from the age of 12 months in both muscle (left panel, scale bar = 100 µM) and skin (right
panel, scale bar = 30 µM) tissue. Unpublished figure from Van Overbeke et al., 2014 [100].
Pathological amyloid
To date, 35 diseases associated with extracellular fibril proteins have been identified. Their
nomenclature is based on the precursor protein. These afflictions can be subdivided into classes
depending on whether amyloid deposition is systemic or localized, and whether the illness is
hereditary or acquired. A subset of these amyloidosis also display intracellular protein inclusion
bodies exhibiting amyloidogenic properties [101].
The precursor proteins (Table 2.1) differ greatly in regard to their native function, structure,
length, hydrophobicity,... . Depending on the disease it may either be the WT protein, a mutant
form or an aberrant fragment which polymerizes into amyloid fibrils. Exactly how or why these
proteins bypass the complex protein quality control system is, at least for now, still quite obscure.
What we do know is that, at a certain point, defective folding of the precursor protein seems
to overload the system, thereby initiating their accumulation and subsequent aggregation into
amyloid fibrils. Once formed, these prove to be highly stable. Over time considerable amounts
of amyloid can infiltrate tissues and organs - in AL amyloidosis, livers weighing up to 15 kg have
been reported7 [102] - thereby debilitating the patient or inducing life-threatening organ failure.
Why amyloid is deposited in specific locations is still under investigation. At the moment our
best guess is the combined action of specific production sites and interaction with tissue specific
components such as heparin sulfate proteoglycans.
7A normal liver weighs about 1,2 - 1,4 kg in woman and 1,4 - 1,5 kg in men.
2.1 AMYLOIDOSIS 34
Table 2.1: Amyloid fibril proteins and their precursors in human.
Fibril protein Precursor protein Systemic and/or localized
AL Immunoglobulin light chain S, L
AH Immunoglobulin heavy chain S, L
AA (Apo) Serum amyloid A S
ATTR Transthyretin, wild type S
Transthyretin, variants S
Aβ2M β2-Microglobulin, wild type S
β2-Microglobulin, variant S
AApoAI Apolipoprotein A I, variants S
AApoAII Apolipoprotein A II, variants S
AApoAIV Apolipoprotein A IV, wild type S
AApoCII Apolipoprotein C II, variants S
AApoCIII Apolipoprotein C III, variants S
AGel Gelsolin, variants S
ALys Lysozyme, variants S
ALECT2 Leukocyte chemotactic factor-2 S
AFib Fibrinogen α, variants S
ACys Cystatin C, variants S
ABri ABriPP, variants S
ADan* ADanPP, variants L
Aβ Aβ protein precursor, wild type L
Aβ protein precursor, variant L
AαSyn α-Synuclein L
ATau Tau L
APrP Prion protein, wild type L
Prion protein variants L
Prion protein variant S
ACal (Pro)calcitonin L
AIAPP Islet amyloid polypeptide** L
AANF Atrial natriuretic factor L
APro Prolactin L
AIns Insulin L
ASPC*** Lung surfactant protein L







Fibril protein Precursor protein Systemic and/or localized
AOAAP Odontogenic ameloblast-associated protein L
ASem1 Semenogelin 1 L
AEnf Enfurvitide L
*ADan is the product of the same gene as ABri, **Also called amylin, ***Not proven by amino
acid sequence analysis. Adopted from Sipe et al., 2016 [101].
Functional amyloid
Interestingly a genome-wide analysis revealed that almost all proteins hold the capacity to form
amyloid [79]. In fact, in bacteria, fungi and yeast, the controlled production of amyloid serves
a function in, among other things, biofilm formation, modulation of water surface tension, reg-
ulation of stop-codon read-through and fungal coat formation. In insects and fish, functional
amyloid is present in eggshells and spider silk [103]. Even in human melanocytes, amyloid fibrils
of pigment cell-specific pre-melanosomal protein (PMEL) are employed as scaffolds on which
melanin is deposited. The production of PMEL fibrils is tightly regulated and compartmentalized
as any mutation results in the formation of pathogenic PMEL amyloid [104, 105]. The discov-
ery of functional amyloid, combined with its high biophysical stability fuels the development of
new nanomaterials such as bioactive matrixes, nanowires, biosensors and carbon-amyloid hybrid
materials [106–108].
3
Introduction to gelsolin amyloidosis
3.1 Gelsolin amyloidosis
Chapter 3 gelsolin amyloidosis; in this chapter the information regarding gelsolin and amyloid
given in Chapter 1 and 2 respectively, will merge.
3.1.1 Discovery
In 1969 the Finnish ophthalmologist Jouko Meretoja first described a new familial amyloidosis
syndrome characterized by corneal dystrophy, cranial neuropathies and skin affliction [109]. Over
the years this syndrome came to be known under many different names; Meretoja’s disease,
amyloid polyneuropathy type IV, gelsolin related amyloidosis, corneal lattice dystrophy type II,
familial amyloidosis of the Finnish type (FAF) and gelsolin amyloidosis (AGel). It wasn’t until
1990 that the role of gelsolin in AGel was demonstrated. Two independent research groups
had isolated and sequenced the amyloid fibrils from patient tissues [110, 111]. The fragments
appeared to be an internal part of a gelsolin variant having an aspartate to asparagine mutation
at position 187 of the primary structure of gelsolin. AGel therefore seemed to arise from an
abnormal internal degradation from this gelsolin variant.
In the following years, the role of gelsolin, the genetic cause and pathogenic pathway were further
elaborated.
3.1.2 Epidemiology & genealogy
Before the standardized nomenclature for amyloid diseases, AGel was known as familial amyloi-
dosis of the Finnish type referring to the fact that AGel patients show a prominent clustering in
Southeastern Finland. This, combined with the Mendelian segregation and genetic homogeneity
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amongst different families lead to the hypothesiss that all patients could be traced back to a
single ancestral mutation; G654A1. However, soon after the original report from Meretoja, AGel
was correctly diagnosed in several countries across Europe, the Americas and the Far East. Of
special interest are (i) Danish, Czech, Korean and Brazilian families carrying a G654T mutation
[112–115] and (ii) American families with a G588A or (iii) C633A mutation. Contrary to the clin-
ical similarity (discussed below) between the two most common mutations (G654A and G654T),
the more recently discovered mutant forms (G588A and C633A) are only associated with renal
amyloidosis [116, 117]. Furthermore no genealogical ties could be found between afflicted fami-
lies outside of Finland. Taken together it is more likely that the worldwide prevalence of gelsolin
amyloidosis is due to sporadic mutations. The founder affect observed in Finland may be the
result of a genetic bottleneck.
Estimations regarding the number of AGel patients are scarce and range from 400 patients [118]
to 1000 gene carriers [119]. Although, given the rather mild symptoms in young and middle-
aged patients, and the obscurity of AGel amongst physicians, the actual number of patients/gene
carriers is most likely significantly higher.
3.1.3 Clinical features
The majority of AGel patients is heterozygous. Their first symptom, corneal lattice dystrophy,
manifests at the age of 25-30 years [109]. In the following decades cranial neuropathy and cutis
laxa will, slowly, but surely, set in. The severity of this triad of clinical manifestations vary
significantly among patients. Patients of high age may be (i) visually impaired or completely
blind, (ii) suffer from minor facial sensory loss or severe sensory ataxia - loss of sensory input into
the control of movement - with complete loss of ambulation - the ability to freely move about
[120] - and (iii) be affected by negligible laxity of facial skin or suffer a major socio-aesthetic
handicap [121]. The exact cause behind the large interpatient symptom variability is yet to be
determined. On average, the life expectancy of AGel patients is somewhat shortened compared
to the general population [119–121] as a minor subset of patients develops life threatening renal
and cardiac amyloidotic complications between the age of 40 and 50 [119, 121, 122]. On the
other hand, in homozygous patients, symptoms can manifest as early as at age of 13 and progress
significantly faster. A fatal outcome before the age of 30 is no exception [119, 123].
Ophthalmological findings
Gelsolin related corneal lattice dystrophy (CLD type II) - the appearance of AGel fibrils in the
cornea rendering it opaque, thereby reducing the patients vision - is often the first symptom in
AGel patients [109], manifesting in the 3rd decade of life (Figure 3.1). Homozygous patients can
1The X-number-Y notation should be read as: ‘nucleotide X at position “number” was replaced by
nucleotide Y’.
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already be affected at the age of 12 [123, 124]. Typically only the peripheral cornea is affected
whereas the central cornea remains largely free from any fibril deposits. Common complaints are
eye dryness, photophobia - intolerance to strong visual light - and temporary visual impairment in
the morning [109, 118, 124–127]. Furthermore, optical nerve damage and stromal fibrosis may,
in aged individuals, lead to blindness [128, 129].
Figure 3.1: Corneal dystrophy. Fibrous amyloid deposits in the corneal result in cornealy
dystrophy. These deposits appear centrally at a young age and spread outwards over the years
[130].
Neurological findings
Around their 4th and 5th decade of life, AGel patients slowly develop a progressive cranial neuropa-
thy specifically affecting the facial nerves [109, 112, 125, 131] (Figure 3.2a). It may initially be
asymmetrical and only involve the upper branches, but will eventually progress to facial diplegia
- paralysis of both sides of the face - accompanied with facial myokymias - involuntary quiver-
ing of the facials muscles [118]. At advanced age patients may suffer from severe macroglossia
or tongue atrophy (Figure 3.2b), dysarthria - motor speech disorder -, dysphagia - difficulty in
swallowing - and drooling which significantly affects their quality of life. Furthermore involvement
of proximal nerves and posterior columns of the spinal cord can result in balance problems and
ataxia with occasionally complete loss of ambulation [118, 120, 124, 128, 131–134].
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Figure 3.2: Gelsolin amyloidosis patient. Typical clinical characteristics of gelsolin amyloi-
dosis: (a) Droopy facial expression due to affliction of the facial nerves, (b) macroglossia and (c-f)
cutis laxa affecting the scalp, fingers, back and facial skin [121].
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Dermatological findings
The most distinctive clinical feature of AGel is progressive premature facial aging [135] caused
by abnormal skin laxity or cutis laxa (Figure 3.2c-f). From their 5th decade of life onwards,
patients are burdened with a loose, thickened scalp and forehead skin [109, 118]. Later in life
lower parts of the face, back, hands, elbows and knees are also affected accompanied with dryness,
itching, increased vulnerability and abnormal scarring of the afflicted areas. The facial skin laxity
combined with the facial palsies and muscular atrophy encumbers patients with a permanent sad
facial expression. Once again, in homozygous patients this process is severely expedited.
Cardiological and renal findings
Although clinically detectable amyloid cardiomyopathy is uncommon in middle-aged patients,
cardiac arrhythmias may necessitate a pacemaker in AGel patients before the age of sixty [136,
137]. Homozygotes can already experience cardiac problems in their thirties [123].
Renal involvement is quite variable amongst patients. Carriers of the G654A/T mutations mostly
manifest only minor intermittent proteinuria - the presence of excess protein in the urine - at
advanced age [125, 138]. In contrast, as mentioned earlier, symptoms of G588A or C633A
patients seems to be almost exclusively nephrological. Their severe renal amyloidosis necessitates
dialysis and eventually kidney transplantation [116, 117]. Once more, homozygous patients draw
the short stick. Already in their teens proteinuria manifests itself. By the age of 20 this can
progress into a severe nephritic syndrome [123, 139].
3.1.4 Molecular mechanism
Production of amyloidogenic gelsolin fragments
At the moment there are four known mutations resulting in gelsolin related amyloidosis; D187N,
D187Y, G167R and the recently discovered N184K2 (Figure 3.3) [113, 116, 117]. The first two,
D187N/Y, affect the vast majority of patients. The replacement of the charged aspartic acid (D)
by the uncharged asparagine (N) or hydrophobic tyrosine (Y) results in the loss of a Ca2+ binding
site - formed by D187, E209 and D259 - in the second gelsolin domain [14]. Due to this, G2 is
able to adopt a partly folded, intermediate state between the active and inactive conformation
of gelsolin [22]. This process negatively influences the overall stability of the protein, rendering
an otherwise buried cryptic furin cleavage site - R169-V-V-R172-A173 - susceptible to aberrant
proteolysis in the trans-Golgi network [20].
2In the context of proteins the X-number-Y notation should be read as: ‘amino acid X at position
“number” was replaced by amino acid Y’.
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Figure 3.3: Gelsolin amyloidosis, involvement of the G2 domain The entire molecular
mechanism behind AGel is played out in the second gelsolin domain, depicted here as a ribbon
cartoon. Indicated in this figure are the three mutation sites (G167, N184 and D187), the furin
cleavage site (A173) and the two MT1-MMP cleavage sites (R225 and M243). Figure adapted from
Van Overbeke et al., 2015 [18].
Furin is a membrane bound member of the proprotein convertase family, active in the endosomal
and lysosomal pathway. It shuttles between the trans-Golgi network and the cell surface whilst
activating a wide range of serum proteins, hormones and receptors [140–142]. During secretion,
PG naturally encounters furin without any consequence since wild type gelsolin is already cor-
rectly folded due to high Ca2+-levels in the ER/Golgi compartments. PG* on the other hand
is susceptible to pathological furin processing due to its induced structural intermediate state.
The scissile bond between R172 and A173 is cleaved (Figure 3.3), thereby releasing a 68 kDa
C-terminal fragment [143]. During secretion, this aberrant C68 constitutes a substrate for MT1-
MMP-like proteases present in the extracellular matrix. MT1-MMP-like proteases are members
of the maxtrix-metalloprotease family [144]. They play a pivotal role in protein degradation pro-
cesses during embryonic development and tissue remodeling. Here however, 8 kDa (AA 173-243)
and 5 kDa (AA 173-225) gelsolin amyloidogenic peptides are generated (Figure 3.3 and 3.4).
Over time, the 8 and 5 kDa fragments start to aggregate in a cross-β sheet configuration, a hall-
mark of amyloid fibrils with the former being the major component of gelsolin amyloid in patients.
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Figure 3.4: Molecular characteristics of AGel: non-pathological versus pathological
PG processing. The left side depicts the non pathogenic synthesis and secretion of wild type PG
via the ER and Golgi-network. On the right, the mechanism for PG* is depicted. Furin cleaves
PG* in the trans-Golgi network, thereby releasing a C68 fragment. During secretion, C68 is cleaved
by MT1-MMP-like proteases, forming 8 and 5 kDa amyloidogenic fragments in the extracellular
matrix [23].
Although the more recently discovered G167R and N184K mutations result in the same aberrant
proteolytic cascade as described above, their causative mode of action is less clear. The latter is
associated with a triad of G2 amino acids - Q164, K166, and D187 - linked by hydrogen bonds
which strongly contribute to the stability of G2’s β-sheet [14] (Figure 3.5). The exchange of the
uncharged asparagine (N) by the positively charged lysine (K) could disrupt this stability locus.
The same may be true for the G167R gelsolin variant. Although it does not participate in the
hydrogen bonding, replacing glycine (G) - the smallest amino acid - by the positively charged
arginine (R), may displace it’s neighboring amino acid K166. As the latter is part of the hydrogen
bound quartet (Figure 3.5), this may once again, although indirectly, disrupt the stability of G2.
More in to depth structural analysis of these mutants is necessary to reveal their true mode of
action and could throw light on why G167R and N184K patients only seem to present nephrosis.
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Figure 3.5: Structure of gelsolins G2 segment. Q164, K166 and N184 are within binding dis-
tance to the amyloidosis mutation site D187. The 8 kDa amyloidogenic fragment consists of colored
red and purple. It contains the disulphide bond which may help tot stabilize the amyloidogenic
fragment. Figure adapted from Burtnick et al., 1997 [14].
Plasma gelsolin is the sole source of amyloid in AGel
As all gelsolin isoforms are transcribed from the same gene, the AGel mutations are present in
each one. Nevertheless, PG is the sole source of amyloid. Taking a second look to the aberrant
proteolytic cascade described above offers a straightforward explanation for this phenomenon.
Furin, the protease responsible for the production of C68, the first step in the AGel pathway,
shuttles between the Golgi-network and the plasma membrane. Therefore, PG, the secreted
isoform, is the only one who encounters this proprotein convertase. Although CG is not involved
in amyloid formation [145], the loss of G2 stability negatively affects its actin binding and severing
capacity. The same holds true for the fraction of mutant PG that is secreted intact. In patients,
impairment of these actin-related functions results in an altered platelet shape [146]. Furthermore,
the observation that neuronal cells, transfected with mutant CG, display a reduced plasticity [147]
may suggest altered, gelsolin related, intraneuronal processes in AGel patients. At the moment,
little is known regarding the gelsolin-3 variant nor the effects of AGel mutations on its function.
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3.1.5 Diagnosis and treatment
The clinical diagnosis of AGel most commonly starts with the detection of corneal lattice dystrophy
(Figure 3.1) [118]. Together with cutis laxis and bilateral facial pareses (Figure 3.2), it forms a
triad of consistent features differentiating AGel from other amyloid disorders3. The diagnosis can
be easily confirmed using molecular genetics. In older or homozygous patients renal amyloidosis
resulting in proteinuria can also be a first clue [121].
No specific treatment is currently available. Only symptomatic treatments are being offered to
improve the overall quality of life. Most important is good ophthalmological care ranging from
eye drops to corneal transplantation. Next to that, aesthetic surgery is often needed to ameliorate
the patients’ overall confidence as the facial pareses and cutis laxis burden the patients with a
constant droopy facial expression [135].
Although therapeutic strategies involving the inhibition of protease activity have been suggested,
unwanted side-effects are to be expected given the major physiological roles of furin and MT1-
MMP [143, 144]. Tackling the problem the other way round by directly shielding PG* from
degradation, proved to be a more valuable route, as will be discussed later in this manuscript.
3.1.6 Mouse model
To further study the molecular aspects of AGel and to test different therapeutic avenues, two
animal models were set up. In a first attempt, the gene coding for the 8 kDa amyloidogenic
fragment was successfully transferred into the genome of Drosophila melanogaster. Unfortunately
AGel amyloid deposition could not be detected [121].
As of 2009, a mouse model is available that faithfully recapitulates the entire proteolytic cascade
of human PG* [148]. Following electroporation of the human plasma GSN cDNA (carrying
the G654A mutation) into mouse ES cells, a transgene animal was obtained where gelsolin is
expressed under control of a muscle creatine kinase (MCK) promoter. PG*, C68 and the 8
and 5 kDa amyloidogenic fragments were detected in the heart, skeletal muscle, diaphragm and
skin. Plasma samples contain both full length PG* and C68. With age, increasing amounts
of gelsolin-positive amyloid deposits can be seen in the endomysium. Eventually the phenotype
of old homozygous AGel mice starts to resemble sporadic inclusion body myositis (sIBM)4 with
accompanied muscle weakness [148].
3As G167R and N184K patients only present nephrosis, their diagnosis is more challenging. The few
reported patients were correctly diagnosed after laser microdissection of an amyloid deposit followed by mass
spectrometry. DNA sequencing was performed to confirm gelsolin involvement. As no more than a handful
of such patients is known, this subsection focuses on the D187N/Y patients.
4Sporadic inclusion body myositis is an acquired muscle disorder characterized by progressive weakness
and degeneration of the muscles.
4
Introduction to nanobodies
4.1 Antibodies and their fragments
In general, when people get sick, their physician will prescribe a certain medicine which they can
get at the pharmacy in the form of a suspension or tablets. These readily available therapeutics
consist of relatively simple organic molecules and are known as small compounds. Since, in the
majority of cases, these are easily absorbed in the intestinal tract, such medicines can be taken
orally. Despite the fact that small compounds able to inhibit furin or MT1-MMP like proteases
are frequently being used for research purposes, they have no clinical value. Since both furin and
MT1-MMP perform key cellular functions, tinkering with their activity would result in serious,
unwanted, side effects. This has been evinced in mouse trials where furin knockout mice proved to
be unviable [149] and MT1-MMP knockout mice, although viable, were burdened with dwarfism,
arthritis, osteopenia - low bone mineral density - and several connective tissue defects [150]. We
therefore redirected our attention away from these proteases. Instead we explored whether it was
possible to directly shield PG* without having to interfere with the normal function of both furin
and MT1-MMP. We chose to work with nanobodies, a derivative from a special kind of antibody,
discovered right here in Belgium.
4.1.1 Conventional antibodies
Despite the many physical barriers, from time to time, viruses, bacteria and other parasites
are able to invade our body. Through the course of evolution an ingenious system has been
developed which specifically targets and removes these pathogens. Macrophages form the first
line of defense. These cells are part of the innate immune system and are able to recognize,
engulf and digest - a process known as phagocytosis - a wide array of substances, cell debris and
pathogens. When this innate immunity proves insufficient, a second, specific line of defense comes
into play; the adaptive immune system. Two types of adaptive immunity can be distinguished.
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(i) The cell mediated immune response is carried out by T-lymphocytes. When activated, T-cells
start to proliferate and generate cytotoxic T-cells and T-helper cells. (ii) The humoral immune
response, executed by B-lymphocytes. Upon activation, these cells produce vast amounts of
antibodies and keep record of the antigens they encounter, thereby ensuring a faster reaction in
the case of a recurrent infection.
Antibodies or immunoglobulins are large, multichain, Y-shaped glycoproteins with the ability to
recognize and bind specific molecular patterns - called antigens - on pathogens. They do this
via their antigen-binding site - Fab variable regions - at the tips of their ‘Y-structure’. Such
interactions between antibodies and antigens can neutralize pathogens, activate the complement
system and agglutinate and/or precipitate antigens1.
Since the introduction of hybridoma technology in 1975, monoclonal antibodies (mAb) have
become an indispensable tool in fundamental research and all sorts of clinical applications [152].
Fusing mice B-cells with myeloma cells - immortal B-cell cancer cells - produces a hybrid cell
line - hence the name hybridoma - which continuously secretes antibodies. This ability to mass
produce antibodies against a plethora of proteins, carbohydrates, nucleic acids and haptens gave
rise to molecular diagnostic tests such as ELISA, Western blotting, immunohistochemistry and
immunofluorescence. Antibodies in the clinic are used in diagnostic applications by linkage to
radioactive or fluorescent moieties. Furthermore they are also being applied therapeutically, be it
directly or as a means for drug delivery. As the applications became more and more sophisticated
and diversified, the potential pitfalls of this technology also surfaced. First, the production of vast
amounts of monoclonal antibodies (mAbs) is very expensive. Second, the mAb format is hard to
manipulate to obtain site specific linkage to other molecules such as fluorophores and radioactive
nuclids. Last but not least, mAbs hold the potential of evoking an immune response rendering
the therapy ineffective. This last hurdle has been addressed with the production of so called
humanized antibodies. These second generation antibodies contain a humanized antigen-binding
fragment (Fab). Third generation antibodies go one step further and also include an engineered Fc
domain to improve the therapeutic activity in patients. Particularly in subpopulations expressing
low affinity variants of the Fc receptor [153].
Conventional antibodies (Figure 4.1) are comprised of 2 heavy and 2 light chains. This multichain
nature is one of the major hurdles when trying to manipulate mAb. Attempts have been made
to bypass this by producing mAb fragments such as antigen-binding fragments and single chain
variable fragments (scFv). The first, Fab, is composed of the variable and first constant domain
of a heavy chain, combined with the variable and constant domain of a light chain. The second,
scFv, only contains the variable parts of the heavy and light chain but these are interconnected
via a linker. Although these smaller formats ameliorated some of the problems posed by classical
mAbs, their production still proved to be troublesome and the functionality of the original mAb
1As a complete description of the fascinating immune system would fill this entire manuscript, I would
like to refer those readers who desire a more in to depth exposition about the immune response to the book
Immunobiology from Murphy, 2011 [151].
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was (partly) lost in some cases.
Figure 4.1: Schematic representation of a conventional and a heavy-chain antibody. A
conventional antibody (left) consists of two heavy chains (CH3, CH2, CH1 and VH) and two light
chains (CL and VL). Fragment antigen-binding (Fab) and single-chain variable fragment (scFV) are
built from a subset of these domains but retain their binding characteristics when recombinantly
expressed. Heavy-chain antibodies (right) only consist of two heavy chains (CH3, CH2 and VHH).
A nanobody corresponds with the variable part of the heavy chain of a heavy-chain antibody (VHH)
and is the smallest, single-domain, natural, antigen binding fragment which remains fully functional
when recombinantly expressed [23].
4.1.2 Discovery of nanobodies
By a stroke of luck in 1993, a new type of antibody was discovered in the blood of Camelus
dromedaries (Figure 4.1) [154]. These antibodies consist solely of two heavy chains, hence they
were named heavy chain antibodies (HCAbs). Their paratope - the region which interacts with
the antigen - is no longer formed by a combination of a heavy and light chain variable fragment
but consists exclusively of the variable fragment of a heavy chain. The single domain nature of
this paratope offered the natural solution which researchers had been looking for. It has since
been named variable domain of the heavy chain of heavy chain antibodies, VHH in short or
Nanobody® (www.ablynx.com). Since their discovery these HCAbs have been detected in the
blood of all Camelidae family members, nurse sharks, wobbegongs and ratfish [155, 156].
4.1.3 Structure and characteristics of nanobodies
The most important novelty about nanobodies was, and still is, the fact that they are the smallest
- 2.5 by 4 nm - single domain, natural, antigen-binding fragments available. Their basic structure
consist of two β-sheets - one with four and one with five β-strands - who take on the same im-
munoglobulin fold like the variable domains of conventional antibodies (Figure 4.2). Nanobodies
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contain four conserved regions - framework regions (FRs) - separated by three complementarity-
determining regions (CDRs) (Figure 4.3). In dromedary, the CDR3 sequences are on average
longer (16-18 AA) compared those of regular human antibodies (12 AA) [157]. Not only does
this compensate for the absence of a light chain, it also allows the CDR3 to form protruding
loops which are able to bind cryptic epitopes.
Figure 4.2: Schematic of the nanobody structure. The framework regions (grey) encompass
nine β-strands which form two β-sheets connected by the CDR loops (blue = CDR1, green = CDR2
and red = CDR3). Several amino acids are often replaced compared to conventional antibodies
in order to increase solubility (indicated with their respective three-letter codes). Figure adapted
from Muyldermans et al., 2013 [158]
.
In conventional antibodies a VH and VL fragment interact via their FR2 region to form the
paratope. As VHHs do not interact with a VL, their previously hydrophobic FR2 region contains
four hallmark mutations - V37F/Y, G44E/Q, L45R/C and W47G/S/L/P - rendering it more
hydrophilic, which greatly enhances the solubility of isolated VHH domains [159].
Figure 4.3: Schematic, linear representation of a nanobody. CDR regions (blue, green and
red) form the linker between the framework regions (grey). In a heavy-chain antibody, the VHH does
not associate with a VL. In order to maintain solubility, several amino acids have therefore been
substituted in the second framework region (purple diamonds). Figure adapted from Muyldermans
et al., 2009 [160]
.
The above described unique, single domain nature of nanobodies translates into valuable prop-
erties, absent in conventional antibodies and their derived antigen-binding fragments.
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Table 4.1: Biophysical, biochemical and functional characteristics of nanobodies
Property
Proteolytic resistance Nbs retain functional activity in gastric and jejuna fluid
and display resistance against degradation by pepsin,
trypsin and chymotrypsin [161].
Thermal stability Nanobodies display high Tm values (60 – 80°C) and
retain functionality after exposure to elevated tempera-
tures of up to 90°C [162, 163].
pH Nanobodies are resistant to extremes of pH [159]
Chemical denaturation Nbs are exceptionally resistant to chemical unfolding
with Cm values of 2.3 – 3.3 M and ≥ M in high salt
(GdmCl) and urea conditions [163].
Refolding capacity Thermal unfolding of several nanobodies was shown to
be fully reversible (in contrast to conventional antibody-
derived fragments) [164, 165].
Solubility Nanobodies were soluble at concentrations of >3 mM
without any signs of aggregation [157, 166, 167].
Cloning A single exon of 450 bp encodes for the VHHs, which en-
ables easy cloning, engineering, optimization, tailoring
and generation of Nbs [168].
Expression yield Recombinant Nbs can be obtained at levels up to 10
mg/L when expressed in E. coli and even higher when
expressed in S. cerevisiae or Picha pastoris (yeast) [169,
170].
Unique epitopes and targets Because of their small size, Nbs have access to a wider
range of conformational (cryptic) epitopes, including en-
zymes, small molecule toxins and other haptens, than
conventional antibodies [171–176].
Low immune-genicity Nbs share a high sequence homology to human VH do-
mains, and additional engineering can be performed for
further humanization [166, 177, 178].
Affinity and specificity Due to the in vivo affinity maturation of the HCAbs,
high specificity and high-affinity Nbs are generally ob-
tained (nano/picomolar range) [167, 179].
Tissue penetration Nb’s small size results in fast tissue penetration (benefi-
cial in solid tumor treatment and in vivo imaging) and
in rapid blood clearance (serum t1/2 of ± 2h) (treatment
of acute indications) [180–183].
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4.1.4 Nanobody production
Nanobody generation in camelids is a straightforward process. Weekly, for 5 weeks, the antigen
is subcutaneously injected. Following this immunization, the VHH genes are isolated from the
camelids lymphocytes and cloned into a phagemid vector. One or several rounds of phage display
and panning are then performed to isolate specific and hopefully high affinity binders. Positive
clones are withheld. After expression in bacteria or lower eukaryotes - with yields of up to 40-70
mg/l - the nanobodies can be further characterized using several molecular techniques such as
ELISA, isothermal titration calorimetry, co-immunoprecitation, . . . [184]. Furthermore, the fact
that nanobodies are encoded by single short gene fragments - 450 base pairs - allows easy and
straightforward protein engineering, thereby opening the doors for a whole array of research and
clinical application.
4.2 Applications of nanobodies
4.2.1 Research
4.2.1.1 Crystallography
As mentioned earlier, the unique shape of a nanobodies’s paratope allows it to bind recognise
cryptic epitopes often situated in crevices on the antigens surface. Such interactions may stabilize
flexible antigen regions, thereby locking them in a specific conformation. This has rendered
nanobodies as ideal chaperones for the crystallization of otherwise uncrystallizable proteins [185,
186]. In the case of amyloidogenic protein research this has been nicely demonstrated in human
lysozyme amyloidosis, a hereditary systemic disease associated with at least seven amyloidogenic
lysozyme variants [163, 187]. In one specific case β2-microglobulin-specific nanobodies have
been shown to serve as efficient crystallization chaperones for transient intermediate species
during fibrillation [188]. The structural data gained from such experiments may provide valuable
insights into the mechanisms behind amyloid fibril formation.
4.2.1.2 Intrabodies
The high stability of nanobodies (see Table 4.1) allows one to use them intracellularly as an in-
trabody. More specifically, nanobodies obtained in llama’s may be best suited for this application
as they are less likely to possess interloop disulfide bonds, thereby reducing the change of intra-
cellular, destabilizing disulfide reduction in the reducing cytoplasm. Intrabodies have been used
to produce functional protein knock-outs and inhibit enzymatic activity [189–194]. It is important
to note the difference compared to RNAi-based gene knock-outs were the entire protein is re-
moved; intrabodies make it possible to alter a specific function of a protein without disturbing its
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other potential interactions/functions. Linked to a signal peptide intrabodies have also been used
to lure their targets to a particular cellular compartment different from their normal subcellular
location. In this way this kind of intrabodies may indirectly inhibit their targets function [195].
Furthermore, chromobodies - intrabodies fused to a fluorophore - can and have been used to track
specific proteins in living cells [196, 197]. In conclusion, due to their high intracellular stability
nanobodies hold a clear advantage over other antibody fragments. But before intrabodies can
reach their full clinical potential, efficient transduction methods will have to be developed.
4.2.2 Diagnostics
4.2.2.1 Biosensors
An ideal Biosensor is a highly stable probe which binds its target with a high affinity and selec-
tivity and can be produced in a cost-efficient way on a large scale. Nanobodies definitely meet
these requirements (see Table 4.1). In fact nanobodies have already been used in HIV and Try-
panosoma detection [168, 198], quantification of caffeine levels [199] and differentation between
Brucella and Yersinia infections [200, 201].
4.2.2.2 In vivo imaging
Via molecular imaging one can visualize molecular biomarkers in a patient’s body in a non-invasive
way. Equipped with a radionuclide nanobodies can be applied as such an imaging tracer in a
single-photon emission computed tomography (SPECT) or positron emission tomography (PET)
based setup allowing in vivo visualization of tumors, artherosclerotic plaques and rheumatoid
arthritis-associated inflammation sites [183, 202, 203]. Indeed, nanobodies are well-suited for
imaging purposes. Firstly, their high stability and small size allows a rapid tissue penetration
followed by an equally swift clearance of unbound nanobody. Secondly, as their C-terminus is
situated on the opposite site of the nanobody paratope [178] it can be readily employed to site-
specifically label a nanobody. More specifically, incorporation of a C-terminal His6-tag or cysteine
allows a straightforward labeling with 99mTc or 111In respectively [204, 205]. Thirdly, a nanobody’s
low immunogenicity reduces the risk of inflammatory reactions in the case of repeated imaging.
Lastly, as highly specific, high affinity nanobodies are fairly inexpensive one may conclude that
nanobodies come close to being an ideal imaging format. However, some disadvantages are worth
mentioning. First and foremost, their rapid renal clearance results in high kidney and bladder
signals, thereby rendering the imaging of nearby targets impossible. Secondly, nanobody-based
imaging is limited to extracellular targets and antigens accessible at the cell surface. Intracellular
in vivo imaging is, at least for the moment, not possible. Lastly, although the production of
nanobodies is indeed cheap, they are still more expensive compared to peptide derived tracers.
4.2 APPLICATIONS OF NANOBODIES 52
4.2.3 Therapeutics
4.2.3.1 Multidomain nanobodies
Nanobodies, being small and stable, are ideal candidates for various therapeutic applications.
Their single-gene/single-domain nature allows one to easily modify, combine or tag a nanobody.
As such, bivalent nanobodies - a dimer of two identical nanobodies - to increase the avidity have
been created [206].
Bispecific nanobodies on the other hand are a dimers of two different nanobodies which either
target two different antigens or two epitopes on the same antigen. Such nanobodies have been
used to guide immune effector cells to cancer cells [207], create more potent anti-toxins [208, 209]
and extend the overall serum half-life of a nanobody [182, 210]. The latter is achieved via an
albumin binding nanobody. More specifically, when bound to albumin the bispecific nanobody-
albumin complex is larger than the renal cutoff. As a result, the half-life increases from several
hours to several days [100].
4.2.3.2 Cancer therapy
As mentioned several times before, nanobodies have some distinct advantages over conventional
antibodies; small size, high stability, long shelf-life and easy to produce. It is therefore not surpris-
ing that in recent years a lot of research has been done on nanobody-based cancer therapeutics.
However, just as conventional antibodies, nanobodies are unable to freely cross the plasma mem-
brane. As such the targeted cancer antigens still have to be transmembrane or extracellular,
cancer specific proteins.
Nanobody-based cancer therapeutics can be effective in three distinct ways. (i) Antagonistic
nanobodies which bind to receptors and alter the signaling cascade [211]. (ii) Allosteric nanobod-
ies which alter the enzymatic activity of their target [212]. (iii) Nanobodies can also be deployed
as simple carriers of an anticancer drug. This kind of magic bullet approach can either be achieved
by directly linking the nanobody to the therapeutic moiety [181] or attaching the nanobody to
nanoparticles which encapsulate the drug [213].
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This thesis is a continuation of previous work performed by Van Overbeke et al., concerning the
development, characterization and therapeutic exploration of both Nb11 and the FAF nanobodies
[18, 100]. Therefore it seemed appropriated to provide a concise overview of the rationale behind




2.1 Extracellular targeting of the AGel pathological pathway
Consecutive aberrant cleavage of PG* by furin and MT1-MMP-like proteases leads to the pro-
duction of amyloidogenic fragments which eventually polymerize into fibrils, causing gelsolin
amyloidosis pathology. But these two proteases are active in different compartments. Indeed,
whereas furin is active in the (intracellular) ER-Golgi compartments, MT1-MMP is inserted in
the plasma membrane and oriented to the extracellular environment. This has far reaching con-
sequences in terms of molecular therapeutic avenues that should be followed when gelsolin has to
be protected from cleavage by either of these proteases. As the second cleavage step occurs in the
extracellular matrix we reasoned that it might be possible to block this process by intraperitoneal
administration of C68 chaperone nanobodies [100].
A dromedary was simultaneously immunized with the G2 domain and the 8 kDa fragment of
PG*. Phage panning was also performed with both gelsolin fragments. This yielded three
different nanobodies, termed FAF Nb1-3. All three bind to PG, PG*, C68 and the 8 kDa peptide
when tested via immunoprecipitation on crude bacterial lysates, but they did not cross-react with
CapG, a protein that is structurally related to gelsolin. Unlike gelsolin, CapG is only capable of
capping actin filaments but does not sever. It is the member of the gelsolin superfamily most
closely resembling gelsolin. It possesses 49% identity with the N-terminal half of gelsolin.
The hypothesis was that if one of these FAF nanobodies bound to C68 in the vicinity of the MT1-
MMP cleavage site, or an important docking area, it would be able to (at least partly) inhibit
the production of the 8 kDa fragments. This was indeed confirmed by in vitro experiments.
C68 was pre-incubated with one of the three FAF Nbs after which MT1-MMP was added to the
mixture. Formation of the 8 kDa fragment could be followed by Western blotting and this showed
a 70-80% reduction in the presence of a FAF nanobody, attesting to their ability to indirectly
prevent MT1-MMP activity on gelsolin (Figure 2.1a and d). Nb13, a nanobody that binds to
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the linker between gelsolin domain 4 and 5 did not show the same effect. Furthermore, the FAF
Nbs had no effect on the proteolysis of collagen, another substrate of MT1-MMP. Therefore, it
was concluded that a nanobody can be used as a chaperone to prevent degradation of a structural
protein by an enzyme without directly inhibiting the activity of the enzyme. In doing so, potential
side effects may be prevented. Whether the observed effects are due to a direct inhibition of
MT1-MMP docking on C68, shielding of the cleavage site, or rather due to an indirect structural
affect caused by the binding of the Nb with C68, still remains to be clarified. A crystal structure
of MT1-MMP bound to C68 would bring clarity in this matter.
While these results were promising at first, a new caveat presented itself when considering that
nanobodies, because of their small size, are characterized by rapid blood clearance. This could
impede their use as a therapeutic in vivo. Indeed, although their small size is mostly advantageous,
when used as a therapeutic it is rather a burden. Thus it seemed necessary to increase their half
life in the circulation as this will improve their probability of binding C68 gelsolin. To achieve
this goal, FAF Nb1-3 were coupled to the mouse albumin binding nanobody MSA21 via a short
Gly-Ser linker. This linkage did not greatly affect the binding affinity between the Nb and C68
(FAF2 = Kd: 8.4x10-7 ± 4.7x10-8 M, FAF2-MSA21 = Kd: 5.4x10-7 ± 0.6x10-7 M, determined
by Isothermal Titration Calorimetry (ITC) ). The bispecific FAF2-MSA21 Nb binds albumin in
the bloodstream and the formation of this larger complex should extend the half-life, resulting in
a higher efficiency of the FAF Nb1-3 therapeutic intervention. Serum analysis of injected mice
confirmed this assumption. While the monovalent FAF Nb1-3 were no longer detectable after
4h, the bispecific format could still be clearly visualized up until one week post injection (Figure
2.1d). Additionally the linkage between FAFNb1-3 and MSA21 did not offset the MT1-MMP
inhibiting potential in vitro. Hence all requirements were fulfilled to test their effect in vivo.
The in vitro results were validated using the available AGel mouse model. Over a period of 12
weeks, on a weekly basis, mice were injected with 100 µg of either FAF Nb1, FAF Nb2-MSA21
or phosphate buffered saline (PBS). The trial started at the age of 4 weeks, the nanobodies used
were the ones which performed best during the in vitro set-up. End stage analysis consisted
of immunohistochemistry (IHC) and ex vivo muscle contractility measurements. IHC revealed
a decrease in amyloidogenic gelsolin staining for FAF Nb1 of 15% and FAF Nb2-MSA21 of
30%. Both results were statistically significant. The difference between both nanobody formats
shows that a longer half-life is definitely desirable in a therapeutic approach such as this. The
reduction seen with IHC in the FAF Nb2-MSA21 treated mice translated into improved muscle
contractility and relaxation speed function in the extensor digitorum longus (EDL). Therefore
these nanobodies are endowed with a therapeutic quality. It should be noted that the FAF Nbs
display an intermediate affinity for their target. Although clear data in support of this contention
are wanting, it seems likely that stronger binders might even have stronger effects in vivo. Further
exploration of the FAF Nb2-MSA21 potential in human gelsolin amyloidosis patients requires two
important modification to be made. Firstly the MSA21 nanobody would have to be replaced by a
human serum albumin binder. The longer serum half-life of human versus mouse albumin (19 days
versus 35 hours) may further lower the administration frequency. Secondly, although nanobodies
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are known for their low immunogenicity, humanizing their framework regions can further decrease
the risk of an undesirable immune response during therapeutic intervention. More specifically,
a universal humanized nanobody scaffold has already been proposed onto which all the CDR
antigen-binding loops could be grafted [178].
2.2 Intracellular targeting of the AGel pathological pathway
Thanks to their excellent stability, nanobodies are also valuable compounds to be used as intrabod-
ies. The reducing environment of the cytoplasm seems to have little effect on their functionality
[215, 216]. As mentioned above, the FAF Nb approach significantly reduced AGel amyloid buildup
in vivo, but it did not completely halt the 8 kDa peptide production. AGel pathogenesis is a two
step process; a furin cleavage of mutant PG produces C68, which is then on its turn cleaved by
MT1-MMP, thereby releasing 8 kDa amyloidogenic peptides. This opens the opportunity for a
double hit approach.
For that reason we tested whether a different set of gelsolin nanobodies could be applied as a
chaperone for gelsolin to divert furin activity in the same manner as we had implemented the
FAF Nb1-3 towards C68 [18].
The nanobodies used in this study were not specifically designed for this purpose. Instead, they
had been raised against wild type CG and characterized some time ago. Through in vitro epitope
mapping experiments, Nb11 was shown to interact with the G2-G3 domains (N-terminal half)
whereas Nb13 interacts with G4-G5 (C-terminal half). Furthermore, both nanobodies interact
with different populations of gelsolin in cells. Indeed, Nb11 binds human gelsolin with high affinity
(Kd = 3.65x10-9 ± 0.54x10-9 M, determined by ITC), irrespective of whether Ca2+ is present or
not, whereas Nb13 strongly interacts with gelsolin (Kd = 9.26x10-9 ± 1.61x10-9 M, determined
by ITC) only when the latter is activated by Ca2+. Both nanobodies were further shown to
act as reliable tracers of gelsolin in MCF-7 cells when expressed as intrabodies. Both gelsolin
and nanobody are abundantly present in the cytoplasm of unstimulated MCF-7 cells, preventing
straightforward assessment of their co-localization. However, when the cells were stimulated
with epidermal growth factor (EGF), both endogenous gelsolin and the nanobodies extensively
decorated membrane ruffles [191]. In view of the binding region of Nb11 in gelsolin, it was
surmised that it could interfere with furin-mediated degradation. In analogy with the MT1-MMP
study, these gelsolin nanobodies were incubated with PG* and Western blotting showed that only
Nb11 reduced furin cleavage of PG* by 34% when added in concentrations equimolar to PG*
(Figure 2.1a and b).
This finding however does not guarantee that the same result will be obtained in mammalian cells.
PG will naturally travel through the secretory pathway but simple expression of the nanobody
will result in its cytoplasmic and nuclear localization in cells. Hence, the nanobody will not be
able to protect gelsolin. For this reason, the nanobody was equipped with an ER-signal peptide
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Figure 2.1: Overview of different diagnostic and therapeutic nanobody-based strate-
gies developped in transgenic mice. a: schematic representation of the steps leading from
mutant PG to the 8 and 5 kDa amyloidogenic fragments. b upper panel: Gelsolin Nb11 reduces
C68 formation in vitro: lane 1: PG incubated with furin, lane 2: PG* incubated with furin, line
3: PG* incubated with furin and Nb11. b second panel: Nb11 co-localizes with mutant gelsolin
in the secretory pathway of HEK293T cells. b third panel: Nb 11 decreases C68 formation in
HEK293T cells: lane 1: medium from cells transfected with PG, lane 2: medium from cells trans-
fected with PG*, lane 3: medium from cells transfected with PG* and Nb11. This led to designing
the Nb11 expressing mouse model. c: Representative images obtained with 99mTc-labeled FAF
Nb1 in 9 months old AGel mice. The heart and front and hind leg muscles show a clear signal
(blue). Kidneys and bladder signal represents unbound nanobody which is cleared via the urinary
system (green and red). FAF Nb1 can also be used as a primary antibody to stain amyloidogenic
gelsolin buildup in AGel mice tissue (lower panel). d upper panel: FAF Nb1-3 partly inhibits
C68 proteolysis in vitro. For each nanobody, from left till right, after incubation with MT1-MMP:
PG, PG*, PG* + 0.5, 1.0 and 2.0 X FAF Nb. Numbers indicate the Nb/PG* molar ratios. d
middle panel: Linkage with the albumin binding MSA21 nanobody increases serum half-life from
4 h to more than one week. d lower panel: In vivo analysis was performed via intraperitoneal
injection in AGel mice [23].
to ensure its secretion via the Golgi apparatus. Furin naturally resides in the Golgi apparatus and
the first step in the AGel pathology takes place in this compartment. By quantifying the amount
of C68 that is secreted in the extracellular environment it could be confirmed that Nb11 exerts a
protective effect. The cell media from HEK cells transfected with PG* and Nb11 contained 80%
less C68 compared to HEK cells solely transfected with PG* (Figure 2.1b).
Although nanobodies can, and are, currently being applied in research involving intracellular
perturbation of protein-protein interactions, at the moment there is no efficient, fail proof method
to introduce them into cells in a recombinant format. Therefore, to test whether the observed
effect of Nb11 in vitro could be reproduced in vivo, a Nb11 expressing mouse model had to
be created. To our knowledge this is the first transgenic mammal that contains a therapeutic
nanobody in its genome. The ER-directed Nb11 cDNA was cloned in the pROSA-DV2 vector
which targets the ROSA26 locus. This locus was identified in 1991 using gene-trap mutagenesis
screening on embryonic stem cells. Thanks to its ubiquitous expression in both embryonic and
adult tissues, over 130 knock-in mouse lines have been created using this cloning site. G4
ES cells were electroporated and positive colonies were selected via Southern blotting. Next,
cells were aggregated with Swiss inner cell mass cells. These blastocysts were transferred into
pseudopregnant mice uteri and the resulting chimeric offspring was backcrossed with wild-type
C57BL/6 to check for germline transmission. Finally these mice could then be crossed with a
non-tissue specific Cre/lox-deleter mouse strain. This resulted in CAGG promoter driven Nb11
expression, resulting in the first Nb11 expressing mice. Nb11 could be visualized and quantified
in the serum through co-immunoprecipitation and Western blotting.
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The newly developed Nb11 mouse model was crossed with AGel mice. Double positive offspring
was evaluated at three distinct time points; 3, 6 and 9 months. Gastrocnemius muscle tissue
was stained for AGel buildup. A costaining for laminin was used as an internal control and to
discern any potential artefacts. The AGel staining was homogenous in every age group, allowing
quantification. Compared to AGel mice or littermates not expressing Nb11, a reduction in AGel
staining of 27% and 28% respectively could be detected at 3 and 9 months of age. For the
group of 6 months, no significant reduction could be found. The reason for this is unclear. The
group of 9 months old mice was also subjected to a muscle performance evaluation. The extensor
digitorum longus (EDL) muscle showed a strong attenuation of the typical decrease in contraction
speed during the fatiguing protocol. This therapeutic effect was not mimicked by Nb13 that binds
to another region in gelsolin (G4-G5 linker) and that had no effect on gelsolin degradation by
furin. Neither Nb11 nor Nb13 showed any cross-reactivity with endogenous mouse gelsolin. Thus
Nb11 attenuates amyloid buildup by (partly) protecting gelsolin against degradation by furin.
One might wonder why the reduction in AGel staining was not as high as expected, given that
Nb11 is a strong binder (Kd ± 5 nM). One possibility involves the relative expression levels of
gelsolin and Nb11. Western blotting with internal gelsolin and nanobody standards indicated
that both are present at roughly equimolar levels. In the AGel mouse model however, gelsolin
is secreted from muscle whereas nanobody expression is thought to be secreted from multiple
organs, tissues and cells, because no tissue specific promoter was used to drive expression of the
nanobody. Therefore, the nanobody that was detected in the serum of these animals has multiple
origins suggesting that its secretion from muscle is significantly lower as compared to gelsolin
secretion. This contention however needs to be examined experimentally.
3
Scope of the thesis
Amyloidosis is a group of diseases characterized by the deposition of protein fibrils which exhibit
green, yellow or orange Congo red birefringence under polarized light. At the moment, 35 of such
proteins are known. In each disease the causative protein will adopt a cross-β-sheet structure
while forming oligomers and fibrils. Their mode of deposition: systemic or localized greatly
influences the type and severity of symptoms in patients. Despite the enormous effort of the
global amyloid research community, at the moment no treatments are available1.
In this thesis the focus is on gelsolin amyloidosis. Gelsolin amyloidosis is an autosomal dominantly
inherited disease caused by a point mutation in the gelsolin gene; G640A and G640T are most
common, G580A and C633A were more recently discovered [113, 116, 117]. At the protein
level these mutations result in the amino acid substitutions D187N, D187Y, G167R and N184K
in gelsolin domain 2. Consequently a Ca2+ binding site, crucial for the correct folding and
function, is lost. As a result, mutant PG adopts an intermediate state between active and inactive,
thereby negatively influencing the overall structural stability of the protein and exposing a cryptic,
otherwise buried, furin cleavage site [22]. In the trans-Golgi network this intermediate form of
mutant PG is susceptible to furin cleavage, giving rise to a 68 kDa C-terminal fragment [20].
On its turn, C68 is cleaved by MT1-MMP-like proteases during secretion into the extracellular
matrix. This MMP activity results in the formation of 8 and 5 kDa amyloidogenic peptides
which polymerize into mature amyloid fibrils [220]. Patients are generally heterozygous for the
mutations and experience a triad of neurological, ophthalmological and dermatological symptoms
starting from their thirties [121]. Given the importance of furin and MT1-MMP-like proteases
in cell homeostasis, a classical small compound therapy targeting these proteases is unlikely to
be successful. Moreover, the gain-of-toxicity nature of this disease rules out replacement gene
therapy. In gelsolin amyloidosis, the mutant gelsolin gene still undergoes normal expression.
1Clinical trials on AL patients using a combination bone marrow transplantation, the drug (R)-1-[6-[(R)-
2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC) and anti serum amyloid P
IgG appears to be successful and may represent the first ever amyloid therapy [217–219].
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Curing gelsolin amyloidosis via replacement gene therapy would therefore require the deletion of
the mutant gene from every single cell. This is (at the moment) not possible with the available
gene therapy technology. Shielding the mutant gelsolin from furin and MT1-MMP-like proteases
on the other hand, proved to be a worthwhile approach to tackle this disease.
As described above, two routes to address AGel have already been explored. In a first approach,
nanobodies, which partly protect C68 against MT1-MMP, were intraperitoneally injected in AGel
mice [100]. In a second approach a mouse model expressing Nb11 was developed [18]. Nb11 binds
to mutant PG and shields it from furin degradation. The mouse model secretes this nanobody
in its bloodstream. These mice were crossed with AGel mice. Consequently, during the secretion
pathway Nb11 encounters PG* in the trans-Golgi network. Both techniques resulted in a reduced
deposition of amyloidogenic gelsolin.
We continued this research in two directions. (i) The nanobodies capable of shielding C68 were
generated against the 8 kDa amyloidogenic gelsolin fragment. This characteristic was further
explored to develop a 99mTc based imaging agent (Figure 2.1c). Using the AGel model we
selected FAF Nb1 as the most promising candidate based on its superior signal-to-noise ratio
and signal specificity. Furthermore, using immunohistochemistry we demonstrated a positive
correlation between the generated SPECT signal and in vivo amyloid buildup. Indeed using the
99mTc-FAF Nb1 we are now able to assess the effect of novel therapeutics under development in
a non-invasive manner. (ii) The two therapeutic strategies mentioned above have been merged
into a single format; a bispecific Nb11-FAF nanobody capable of (partly) inhibiting both furin and
MT1-MMP. Using AAV9 gene therapy we were able to significantly reduce the amyloid burden
in the AGel mouse model. Furthermore, here, for the first time, we successfully implemented the
99mTc-FAF Nb1 imaging tracer.
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Non-invasive imaging of amyloid deposits in
a mouse model of AGel using
99mTc-modified nanobodies and SPECT/CT
1.1 Abstract
Purpose: Gelsolin amyloidosis (AGel), also known as familial amyloidosis, Finnish type (FAF), is
an autosomal, dominant, incurable disease caused by a point mutation (G654A/T) in the gelsolin
(GSN) gene. The mutation results in loss of a Ca2+-binding site in the second gelsolin domain.
Subsequent incorrect folding exposes a cryptic furin cleavage site, leading to the formation of
a 68-kDa C-terminal cleavage product (C68) in the trans-Golgi network. This C68 fragment
is cleaved by membrane type 1- matrix metalloproteinase (MT1-MMP) during secretion into
the extracellular environment, releasing 8- and 5-kDa amyloidogenic peptides. These peptides
aggregate and cause disease-associated symptoms. We set out to investigate whether AGel-
specific nanobodies could be used to monitor amyloidogenic gelsolin buildup.
Procedures: Three nanobodies (FAF Nb1-3) raised against the 8-kDa fragment were screened
as AGel amyloid imaging agents in WT and AGel mice using 99mTc-based single-photon emis-
sion computed tomography (SPECT)/X-ray tomography (CT), biodistribution analysis, and im-
munofluorescence (IF). The quantitative characteristics were analyzed in a follow-up study with
a Nb11-expressing mouse model.
Results: All three nanobodies possess the characteristics desired for a 99mTc-based SPECT/CT
imaging agent, high specificity and a low background signal. FAF Nb1 was identified as the most
potent, based on its superior signal-to-noise ratio and signal specificity. As a proof of concept,
we implemented 99mTc-FAF Nb1 in a follow-up study of the Nb11-expressing AGel mouse model.
Using biodistribution analysis and immunofluorescence, we demonstrated the validity of the data
acquired via 99mTc-FAF Nb1 SPECT/CT.
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Conclusion: These findings demonstrate the potential of this nanobody as a non-invasive tool to
image amyloidogenic gelsolin deposition and assess the therapeutic capacity of AGel therapeutics
currently under development. We propose that this approach can be extended to other amyloid
diseases, thereby contributing to the development of specific therapies.
1.2 Introduction
Amyloidosis comprises 35 diseases characterized by the deposition of protein fibrils with a cross-
beta sheet structure [101, 221]. Each disease differs from the other in terms of cause,amyloid
deposition sites, and clinical features. Gelsolin amyloidosis (AGel) is an orphan disease with
worldwide only about 1000 gene carriers of which the majority lives in Finland [121]. As a
component of the actin-scavenging system, plasma gelsolin (PG) prevents a drastic increase in
blood viscosity after tissue damage [222]. In AGel patients, a point mutation (G654A being most
common, D187N) in the gelsolin (GSN) gene results in loss of the Ca2+-binding site in the second
domain, thereby exposing a furin cleavage site [20]. Mutant PG (PG*) is cleaved by furin in the
trans-Golgi network leading to the production of a 68-kDa C-terminal cleavage product (C68).
This C68 fragment is subsequently degraded by membrane type 1-matrix metalloproteinase (MT1-
MMP) during secretion, resulting in the release of 8- and 5-kDa amyloidogenic peptides [220].
Patients experience a triad of ophthalmological, dermatological, and neurological symptoms.
During disease progression, renal and cardiac complications may also occur [121].
Two routes to address AGel have already been explored in our lab [18, 100]. In the first approach,
transgenic gelsolin Nb11- expressing mice were crossed with AGel mice [191]. Nb11 is a gelsolin-
binding nanobody that is capable of shielding PG* furin degradation both in vitro and in vivo. In
the second approach, AGel mice were injected with C68 binding nanobodies (familial amyloidosis,
Finnish type (FAF) Nbs) that partly protect against MT1-MMP proteolysis [18, 100]. These
findings represent an important step toward a clinically applicable therapeutic. In both approaches
however, responses had to be evaluated by immunofluorescence (IF), an end-stage screening
method.
In the clinic, 123I-labelled serum amyloid P (SAP) scintigraphy is implemented to assess the
visceral amyloid burden. The non-fibrillar glycoprotein SAP is a member of the pentraxin family
and is present in all types of amyloid deposits. Radiolabeled SAP will distribute rapidly and
specifically to amyloid, making it a useful imaging tracer. However, it is not capable of visualizing
amyloid in neurological tissue and skin, which are two major AGel deposition sites in patients [223].
Other limitations are the relatively high cost of 123I and the availability of SAP. Furthermore, in
AGel patients, the rate of disease progression and the severity of symptoms vary significantly. An
individual therapeutic approach and regular assessment of the amyloid burden is thus desirable.
Nanobodies correspond with the variable part of heavy chain antibodies [154]. These fragments
are the smallest (15 kDa), intact antigen-binding fragments currently available. Their small size
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combined with excellent stability makes them the ideal tool for a plethora of biotechnological
applications [224, 225]. Here, we show that nanobodies raised against the 8-kDa amyloidogenic
gelsolin peptide can be labeled with 99mTc and used as amyloidogenic gelsolin imaging agents
in vivo. In addition, we provide evidence that this can be done with a low background signal
and high specificity. This and other nanobody-based imaging agents may prove useful in drug-
screening research and clinical application, especially in those situations where the current imaging
platforms expose their limits.
1.3 Materials & Methods
1.3.1 Antibodies and reagents
Penta-His6 horseradish peroxidase antibody (1:1000 Western blot) from Qiagen (Venlo, the
Netherlands), polyclonal anti-V5 antibody (1:100 IF) from Sigma-Aldrich (Diegem, Belgium),
Alexa Fluor 488 goat anti-rat IgG (H + L) and 594 goat anti-rabbit IgG (H + L) from Life
Technologies (Merelbeke, Belgium; 1:500 IF), and monoclonal anti-laminin antibody (1:500 IF)
from Abcam (Cambridge, UK) were included.
1.3.2 Generation of FAF gelsolin-specific nanobodies
Gelsolin-specific nanobodies were obtained in collaboration with the VIB Nanobody Service Fa-
cility as described [100]. Briefly, a single dromedary was immunized with synthetic biotinylated
human gelsolin 8-kDa AGel peptide and recombinant GST-tagged human mutant (D187N) gel-
solin domain 2 (G132-S286). After lymphocyte preparation, a VHH complementary DNA (cDNA)
library was subjected to phage panning using the gelsolin 8-kDa peptide or mutant G2 domain
as antigen. Three distinct nanobodies could be identified and are referred to as FAF Nb1-3.
1.3.3 cDNA cloning
Cloning of the FAF nanobodies in the pHEN6 vector was performed using the Cold Fusion Kit (Sys-
tem Biosciences, Mountain View, CA). The following primers were used: 5’ CCAGGTGCAGCT-
GCAGGAGTCTGGGGGAGGCTC 3’ (forward) and 5’ GACGGCCAGTGAATTCTCAATGGTGATG-
GTGATGATG 3’ (reverse). This reverse primer incorporated a His6 tag at the C-terminus of the
nanobodies necessary for labeling with 99mTc.
1.3.4 Purification of the nanobodies
FAF-His6 nanobodies were produced as previously described [191]. The samples were treated with
Pierce® High-Capacity Endotoxin Removal Resin according to the manufacturer’s instructions
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(Thermo Scientific, Erembodegem, Belgium).
1.3.5 Serum stability assay
Mouse plasma was obtained by collecting 180 µl blood of WT C57BL/6 mice and mixed with 20
µl of 18 mg/ml EDTA. Serum was collected after 4-min centrifugation at 1700×g and cleared
from albumin with ProMax Albumin Removal Kit following the manufacturer’s protocol (Thermo
Scientific, Erembodegem, Belgium). Subsequently, 0.5 µg of FAF Nb1-3 was added to 50 µl
albumin-cleared plasma and incubated at 37°C. At different time points, 10 µl was withdrawn.
The reaction was terminated by addition of 5 µl Laemmli sample buffer and analyzed by 15%
SDS-PAGE followed by western blotting using anti-His6-HRP antibody.
1.3.6 Radiolabeling with 99mTc
Nanobodies were radiolabeled with 99mTc using the tricarbonyl method as previously described
[226]. Briefly, (99mTc(H2O)3(CO)3)+ was synthesized using the Isolink Kit (Mallinckrodt Medical
BV). After neutralization with 125 µl of 1 M HCl, 50 µl of 1 mg/ml FAF Nb1-3 and 50 µl of
carbonate buffer, pH 8, were added. This mixture was incubated at 60°C for 90 min. Assessment
of the final radiochemical purity was done with instant thin layer chromatography (ITLC) in
acetone as a mobile phase and analyzed with a radiometric chromatogram scanner (VCS-201;
Veenstra).
1.3.7 Single-photon emission computed tomography/X-ray tomography ima-
ging experiments
Animal models: Animal experiments were approved by the Animal Experimental Ethics Commit-
tee of Ghent University Hospital (ECD 10/32) and the ethical committee for animal research of
Vrije Universiteit Brussel, Faculty of Medicine and Pharmacy (project 13-272-12). Animals were
housed in individually ventilated cages with food and water ad libitum. Environmental conditions
were controlled at 20-23°C, 50 % relative humidity, and 12h light/dark cycles. AGel mice were
obtained from the Scripps Research Institute (La Jolla, CA, USA). Wild-type C57BL/ 6 mice
were obtained from Charles River (L’arbresle Cedex, France).
Biodistribution analysis: Mice were intravenously injected with 50-75 MBq of 99mTc-labeled FAF
Nb1-3. One hour postinjection, mice were anesthetized using 18.75 mg/kg ketamine hydrochlo-
ride (Ketamine 1000, CEVA) and 0.5 mg/kg medetomidin hydrochloride (Domitor, Pfizer). Ani-
mals were positioned in a solid holder with two plastic disks containing three 57Co (3.7 MBq)
sources. Image acquisition was done using a micro-X-ray tomography (CT) scan for 2 min (60
keV, 615 mA, 360°; Skyscan 1178, Kontich, Belgium) and a dual-headed single-photon emission
computed tomography (SPECT) camera (e.cam 180, Siemens, USA) equipped with triple pinhole
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collimators (1-mm apertures, focal length of 265.5 mm, and a radius of rotation of 20 mm) for 30
s per projection step and a total scan time of about 40 min. Afterward, the mice were euthanized
and dissected. 99mTc activity in the individual organs was measured using a Cobra Inspector 5003
gamma-counter (Canberra-Packard, Downers Grove, IL, USA). Measurements were expressed as
percentage injected activity per gram of tissue (% IA/g).
Image quantification: After image acquisition, SPECT images were reconstructed using an itera-
tive reconstruction algorithm adapted for the pinhole geometry and reoriented for fusion with CT
based on the two plastic disks containing the 57Co sources. Images were quantified using AMIDE
(a Medical Image Data Examiner) software [227]. Ellipsoid regions of interest (ROIs) were drawn
around the heart, hind leg muscle, and liver. The same ROIheart, ROImuscle, and ROIliver were used
for each individual animal. SPECT signals, obtained/acquired from the ROIs, were calculated
and expressed as % IA/cc.
AGel progression in Nb11-expressing mice using SPECT/CT : AGel mice expressing therapeutic
gelsolin Nb11 (AGel-Nb11) were subjected to SPECT/CT at 2, 5, 7, 9, and 11 months of age
[18]. At 9 and 11 months of age, one group was submitted to a biodistribution study. Muscle
and heart tissues were analyzed by immunofluorescence as described below. In all the imaging
experiments, nanobody BcII10 was chosen as a negative control. The BcII10 (β-lactamase of
Bacillus cereus) antigen is not present in healthy mice [228].
1.3.8 Immunofluorescence
Hind leg muscles and heart were dissected and snap frozen in liquid nitrogen. Cryosections were
made and thawed for 15 min followed by 10-min incubation in acetone at -20°C. After 10 min
incubation in PBS, the sections were incubated in 50 mM NH4Cl followed by PBS for another
10 min followed by an additional PBS washing step. The endogenous peroxidase activity was
blocked after 20 min incubation in 0.3 % H2O2 and then washed in PBS. Sections were incubated
with 1 % BSA/PBS for 20 min and with the laminin antibody (1:500) at 4°C overnight, followed
by another PBS washing step for 10 min. FAF Nb1-V5 (5 µg/ml) was incubated for 1 h at
room temperature followed by 10 min incubation in PBS. Polyclonal anti-V5 (1:800) was used
as secondary antibody. Alexa Fluor antibodies (488 anti-rat and 594 anti-rabbit, both 1:500)
were incubated for 1 h at room temperature. Finally, sections were rinsed with PBS, stained
with DAPI (1:500) for 2 min, and mounted with VectaShield. Imaging was performed at room
temperature with a Leica DM6000 B microscope. Three sections were made per tissue, and
within each section, two images from separate regions were taken for quantification with ImageJ
software. This resulted in six technical repeats per tissue, per animal, from which the average
was used for further statistical calculations.
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1.3.9 Statistical analysis
Statistical analysis was performed by SPSS software (SPSS Statistics 22, Chicago, IL, USA)
using one-way analysis of variance (ANOVA). Reported values are expressed as mean ± SEM
(*p<0.05).
1.4 Results
1.4.1 Nanobody stability and labeling
In vivo imaging agents are required to remain stable at 37°C in complex environments such as
the blood and extracellular matrix. For this reason, a stability assay was performed. FAF Nb1-3
were incubated in albumin-cleared C57BL/6 mouse serum at 37°C, and samples were taken at
different time points. FAF Nb1-3 showed no sign of degradation, even after 24-h incubation
(Figure 1.1). Next, a test labeling was performed with 99mTc. The radiochemical purities of
99mTc-FAF Nb1-3 were 99.7 ± 1.3 %, 99.7 ± 0.9 %, and 98.3 ± 1.0 %, respectively.
Figure 1.1: FAF Nb1-3 does not show any deterioration in albumin-cleared mouse
plasma. Western blot analyses shows, from left to right; serum without nanobody (Blanc), FAF
Nb1-3 in albumin-cleared mouse plasma after 0, 1, 2, 4 and 24 h incubation at 37°C. The band at
26 kDa is the light chain of mouse Ig. The band at 17 kDa is the nanobody.
99mTc-FAF Nb1-3 show no aspecific background signal in WT C57BL/6 mice
To screen for aspecific background signals, 9-month-old WT C57BL/6 mice (three per nanobody)
were injected with 99mTc-FAF Nb1, 2 or 3. As a negative control, data from previous experiments
with the irrelevant control 99mTc-Nb-BcII10 nanobody were used [229]. The SPECT/CT and
dissection data show that FAF Nb1- 3 behave similar to the negative control BcII10 regarding a
very low background signal (Figure 1.2 and 1.6, left panels). The kidneys and bladder illustrate
the typical high uptake of renal-filtered small hydrophilic proteins (Figure 1.2 and 1.6). The
variability can be attributed to differences in nanobody amino acid sequence [230].
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Figure 1.2: Biodistribution in 9 month old WT C57BL/6 and 3 and 9 month old
C57BL/6 AGel mice after SPECT/CT with 99mTc-FAF Nb1. Analysis with 99mTc-BcII10
as a control was performed in 9 month old C57BL/6 AGel mice. The kidneys illustrate the typical
high uptake of nanobody based imaging agents. The heart, limb muscle and diaphragm show a
higher %IA/g tissue for FAF Nb1 compared to BcII10. Data represented as mean ± SEM.
99mTc-FAF Nb1-3 specifically recognize amyloidogenic gelsolin buildup in the AGel mouse
model
A SPECT/CT and dissection analysis was performed on 12 homozygous, 9-month-old AGel
mice (3 per nanobody; Figure 1.6 right panels). At this age, the animals show significant
amyloidogenic gelsolin buildup in muscle tissue [148]. The dissection data showed a specific
uptake (p<0.05) in skeletal muscle, heart, and diaphragm for FAF Nb1 and 2. FAF Nb3 did not
give a significant signal in the heart nor diaphragm (Figure 1.3a, c). BcII10 (negative control)
showed statistically significant uptake in the heart (Figure 1.3a). The difference is larger in
muscle but not statistically significant (Figure 1.3b). Also, compared to the WT controls, a
significant uptake in the bones (p<0.05) of AGel mice was detected (Figure 1.3d).
1.4 RESULTS 75
Figure 1.3: Comparison of biodistribution data between WT and AGel C57BL/6 mice.
FAF Nb1-3 were tested against BcII10 in a biodistribution analysis after 99mTc-based SPECT/CT.
In the heart (a), skeletal muscle (b), and diaphragm (c), at least two FAF nanobodies showed
significant buildup. Bones (d) showed a significant increase for all nanobodies. BcII10 showed
a statistical significant difference in the heart (a). The difference in the skeletal muscle (b) was
not statistically relevant and significantly smaller than the signal differences acquired with FAF
nanobodies. Data were represented as mean ± SEM (*p<0.05).
99mTc-FAF Nb1 produces the best signal-to-noise ratio and signal specificity in AGel mice
Previous research showed that FAF Nb1 has a slightly higher affinity for the 8- kDa peptide (FAF
Nb1 Kd 3.8 × 10-7 ± 1.2 × 10-8 M, FAF Nb2 Kd 8.4 × 10-7 ± 4.7 × 10-8 M, and FAF Nb3 Kd
6.6 × 10 -7 ± 1.7 × 10-7 M [100]). Based on these results, it was hypothesized that FAF Nb1
would deliver the best SPECT/ CT result.
The results from C57Bl/6 WT mice and the AGel mice were combined and showed that FAF Nb1
indeed performed best. Using AMIDE software, a ROI around the heart, hind leg muscle, and
liver was defined to determine the signal coming from these tissues. FAF Nb1-3 performance was
assessed by defining the signal-to-noise ratio as the signals gained with the FAF Nb1-3 in AGel
mouse heart or muscle over the signal obtained in AGel mouse liver. Next, signal specificity was
defined as the signal obtained with FAF Nb1-3 in AGel mice over the signal obtained with BcII10
in AGel mice. FAF Nb1 has a significantly better (p<0.05; Figures 1.4 and 1.5) signal-to-noise
ratio and signal specificity score in muscle tissue (Figures 1.4 and 1.5). Therefore, FAF Nb1
was designated as the best candidate for a 99mTc-based amyloid imaging agent.
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Figure 1.4: Signal-to-noise ratios and signal specificities for the FAF nanobodies.
Signal-to-noise ratio: signal in AGel mice heart or muscle with FAF Nb1-3/signal in AGel mice
liver with FAF Nb1-3 (a, c). Signal specificity: signal in AGel mice with FAF Nb1-3/ signal in
AGel mice with BcII10 Nb (b, d). FAF Nb1 significantly outperformed the other two nanobodies in
skeletal muscle tissue (c, d). All raw data were gained from 9-month-old mice and are represented
in Figure 1.5. Data were represented as mean ± SEM (*p<0.05).
Figure 1.5: Heart (a,b) and skeletal muscle (c,d) image quantification data via AMIDE
software in C57BL/6 WT and AGel mice. Raw data were used to define the signal-to-
noise ratio and the signal specificity as depicted in Figure 1.4. FAF Nb1 outperformed all other
nanobodies in the muscle tissue (c, d). All data were obtained from 9 month old mice. Data
represented as mean ± SEM.
99mTc-FAF Nb1 shows quantitative features
The AGel mice show progressive amyloidogenic gelsolin buildup over time [148]. A high signal was
noted in 9-month-old homozygous AGel mice (Figure 1.6, right panels). Now, 3-month-old
homozygous AGel mice were evaluated (Figure 1.6, middle panels). As positive controls, we
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Figure 1.6: SPECT/CT images obtained with 99mTc-FAF Nb1. In WT mice (left), no
significant background signal can be detected. In AGel mice from 3 months onward (middle and
right), the major muscle groups clearly light up. The heart however seems unaffected at 3 months
(middle) but gives a high signal at 9 months (right). White arrows indicate the heart (upper two
panels) and major muscle groups of the hind legs (lower panel). Color scale: NIH (0.5-3%) + white.
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used biodistribution data from both the 3- and 9-month-old imaged mice as well as immunoflu-
orescence data from previous experiments [100]. FAF Nb1 showed good quantitative properties
as a 99mTc-based imaging agent in AGel mice. When comparing data from the heart obtained
with IF analysis, biodistribution analysis, and SPECT/CT image analysis, the same pattern of
signal increase was found (Figure 1.7a). In the muscle, SPECT/ CT image analysis shows
some deviation from IF and biodistribution controls (Figure 1.7b). The first shows the highest
signal difference between 3- and 9-month-old AGel mice, whereas the latter two show the highest
difference between WT and 3-month-old AGel mice (Figures 1.6, 1.7 and 1.8).
Figure 1.7: Quantitative characteristics of 99mTc-FAF Nb1 in SPECT/CT image and
biodistribution analysis. Heart (a) and hind leg muscle (b) signals were quantified on SPECT-
/CT images and via dissection after injection with 99mTc-FAF Nb1. IF image quantification was
used as control. All data were normalized to the maximum signal obtained in 9-month-old C57BL/6
AGel mice per technique. Raw data are presented in Figure 1.8. In the heart (a), all three quan-
tification methods show the same pattern of signal increase. In the muscle (b), biodistribution
follows the pattern of IF. SPECT/CT image analysis however shows different slopes between the
three data points.
Figure 1.8: Absolute signal strength in the heart and muscle. SPECT/CT image
quantification. (a), biodistribution (b) and IF(c) before normalization. Raw data were
used to determine quantitative features and are depicted in Figure 1.7. We analyzed amyloid
burden in 9 month old C57BL/6 WT, 3 and 9 month old C57BL/6 AGel mice using SPECT/CT
image quantification (ROI) (a),biodistribution analysis (b) and IHC image quantification (c) in
both heart and skeletal muscle tissue. Data represented as mean ± SEM.
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1.4.2 Follow-up study of GSN Nb11-expressing AGel mice with 99mTc-FAF Nb1
SPECT/CT image analysis
In a previous study, we presented a transgenic AGel mouse model that not only expresses mutant
PG but also GSN Nb11. GSN Nb11 reduces amyloidogenic gelsolin buildup in vitro and in vivo
due to its ability to interact with the second domain of gelsolin and hence counteract mutant
gelsolin proteolysis by furin [18]. Now, as a proof of concept, the study was repeated and the
newly developed 99mTc-FAF Nb1 amyloidogenic gelsolin imaging agent was used as a means to
follow disease progression in a non-invasive manner.
Starting from the age of 3 months, one group of AGel/ GSN Nb11 mice (AGel+/- GSN Nb11+/-)
underwent a SPECT/CT scan every 2 months until the age of 9 or 11 months. Littermates
(AGel+/- GSN Nb-/-) were used as the control group. At the age of 9 and 11 months, a set of
animals was euthanized followed by biodistribution analysis (Figure 1.9b, d) and IF (Figure
1.11).
Figure 1.9: Absolute signal after SPECT/CT image quantification and biodistribution
analysis. After SPECT/CT, using identical ROIs, the absolute signals in the heart (a) and skeletal
muscle (c) tissues were determined in 3-, 5-, 7-, 9-, and 11-month-old AGel and Nb11-expressing
AGel mice. At 9 and 11 months, a group was euthanized and biodistribution analysis was performed
on the heart (b) and skeletal muscle (d). No statistical differences were detected in the heart (a,
b). At 7 and 9 months, a statistical difference was detected in the muscle tissue (c, d). Data
are expressed as % IA/cc tissue (a, c) or % IA/g tissue (b, d) and represented as mean ± SEM
(*p<0.05).
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The SPECT-CT follow-up revealed no statistical differences in heart amyloidogenic gelsolin
buildup during the entire course of the study (Figure 1.9a). In muscle tissue, a statistical
significant difference (p<0.05) was detected at the age of 7 and 9 months but not at 11 months
(Figure 1.9c). The same pattern appeared in the biodistribution analysis at 9 and 11 months
(Figure1.9b, d).
To validate the results, IF was performed on heart and hind leg muscle tissues from animals in
the 9- and 11-month groups. At the age of 9 months, the heart shows diffuse AGel-positive
spots, both in the AGel and AGel/Nb11 groups. At 11 months, the staining pattern becomes
more evenly distributed (Figure 1.11a). In muscles, overall staining can be seen both at 9 and
11 months. Albeit difficult, some differences in staining intensity can be discerned at the age of 9
and 11 months (Figure 1.11a). After quantification, the results depict the same pattern as we
obtained with the 99mTc-FAF Nb1, no statistical difference in the heart, whereas in the muscle,
there is a significant difference (p<0.05) at the age of 9 months but no longer at 11 months
(Figure 1.11b and c).
1.4.3 Correlation between SPECT/CT signal and in vivo binding site levels
To demonstrate specific binding, we investigated the relationship between in vivo radioligand
uptake (by SPECT/CT) and binding site expression levels (by IF). To this end, a group of 3-
, 5-, and 7-month-old AGel/Nb11 mice underwent SPECT/CT analysis with 99mTc-FAF Nb1
after which they were sacrificed. Skeletal muscle tissue was examined by immunofluorescence.
Combined with the 9- and 11-month-old AGel/Nb11 mouse data from the follow-up study, a
correlation plot between the specific muscle uptake (SPECT/CT signal) and in vivo binding site
levels was generated (Figure 1.10). The trend line (R2 = 0.8447) indicates a positive correlation
suggesting that the radioligand binds specifically to its target.
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Figure 1.10: Correlation plot between the SPECT/CT signal (X-axis) and the amount
of antigen present (Y-axis, as determined by IHC quantification). The data points from
every age group are color coded. The trend line (R2 = 0.8447) shows a positive correlation between
specific muscle uptake (SPECT/CT signal) and in vivo expression levels (in proxy determined by
IHC).
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Figure 1.11: Immunofluorescent analysis and quantification in heart and skeletal mus-
cle in AGel and AGel/Nb11 mice at the age of 9 and 11 months. Heart and hind leg
muscles were dissected from Nb11-expressing AGel mice and their negative littermates as control.
IF was done for gelsolin (red) and laminin as a constant control (green). Scale bar = 100 µm (a).
The staining pattern was quantified (b, c). At 9 months, a statistical difference was detected in
the muscle tissue. Results are expressed as mean ± SEM (*p<0.05).
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1.5 Discussion
In a previous study, three nanobodies, FAF Nb1-3, against the amyloidogenic 8-kDa gelsolin
fragment were characterized as part of an intervention study to counteract amyloidogenic gelsolin
deposition [100]. Several groups of mice had to be sacrificed at different time points to assess
the efficacy of FAF nanobody therapy. In an attempt to circumvent this necessity, we set out
to ascertain whether we could implement these same FAF nanobodies as a radionuclide-based
amyloid imaging agent.
We showed that the FAF nanobodies possess the characteristics desired for a 99mTc-based SPECT-
/CT imaging agent. We demonstrated their stability in a complex environment for at least 24 h
(Figure 1.1) and detected no significant background signal when administered in WT C57BL/6
mice (Figure 1.6, left panels). In addition, specific uptake was evinced in skeletal muscle,
heart, and diaphragm (Figure 1.3a, b and c), accompanied by a low circulatory blood signal
when administered in AGel mice (Figure 1.2). Furthermore, when comparing the nanobodies,
FAF Nb1 was identified as the most potent nanobody given its higher signal-to-noise ratio and
signal specificity in muscle tissue (Figure 1.4c and d). Additionally, we also illustrated the quan-
titative qualities of 99mTc-FAF Nb1 by comparing quantified signals obtained with SPECT/CT,
biodistribution analysis, and IF. Similar patterns in signal increase were detected (Figure 1.7).
Finally, a correlation plot showed a positive relationship between the 99mTc-FAF Nb1 uptake and
in vivo binding site levels (Figure 1.10).
Unexpectedly, BcII10, the negative control nanobody, showed statistically significant uptake in
the heart (Figure 1.3a). Given the small absolute difference, 0.25 % IA/g in WT versus 0.36 %
IA/g in AGel mice, this could represent a biologically irrelevant statistical coincidence. Further
research on a larger set of mice might provide a more conclusive answer.
A second unexpected result is the significant uptake in the bones of AGel mice compared to the
WT controls. As this was the case for both the FAF Nbs and the BcII10 control nanobody, it seems
logical that this phenomenon is somehow caused by the AGel amyloidogenic buildup. Although in
AGel patients, abnormalities have been observed in the bones, gastro-intestinal tract, and thyroid
gland [137, 139], there is no evidence at this moment that AGel mice deposit amyloidogenic
gelsolin in periostea or bone marrow. The connection between these findings and AGel is unclear.
More specific research, on a larger scale, will be needed to discern whether these findings are just
a statistical coincidence or whether there actually is amyloidogenic gelsolin buildup in the bone
tissue.
Based on the results discussed above and as a proof of concept, 99mTc-FAF Nb1 was implemented
in a follow-up study of the Nb11-expressing AGel mouse model. Identical conclusions could be
drawn when comparing data obtained with SPECT/CT, biodistribution, and IF analyses (Figure
1.9 and Figure 1.11). No significant difference could be discerned in the heart between the
AGel and AGel/Nb11 mice (Figure 1.9a). It might be contended that FAF Nb1 does not bind
amyloidogenic gelsolin in the heart, but this is not the case since 99mTc-FAF Nb1 generates no
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signal in the heart of 9-month-old WT mice, proving that Nb1 does not bind aspecifically to a
ligand in the heart. Furthermore, Nb11 expression is not driven in a tissue-specific manner, and we
therefore expect secretion from different tissues. It is possible that the Nb11 expression cassette
is not or less active in the heart. In an attempt to clear this issue, immunofluorescent staining
against V5-tagged Nb11 was performed on several tissues. Unfortunately, no clear images could
be obtained (data not shown). Most likely, this is due to the overall low expression of Nb11, shown
earlier [18]. In muscle tissue, a second intriguing phenomenon was detected; the AGel/Nb11 mice
showed significantly less amyloidogenic gelsolin buildup at 7 and 9 months but no longer at 11
months. We know that the amount of Nb11 in the serum diminishes over time [18]. It is possible
that the decrease of detectable Nb11 is mainly due to a drop in expression in the muscle tissue,
given that, due to the aberrant cleavage of mutant PG, this tissue experiences considerable
proteasome stress. Consequently, the therapeutic effect would be lost.
The positive correlation between the specific muscle uptake and in vivo amyloidogenic gelsolin
expression levels (Figure 1.10) hints at a potential use of this nanobody as a noninvasive tool
to assess the therapeutic capacity of AGel therapeutics currently under development [231].
Congo red staining is considered the gold standard dye in amyloid research when screening patient
biopsies [232]. When amyloid is detected, an evaluation of the global amyloid burden is needed to
identify the involved organs, select treatment, and monitor progression of the patient. Currently,
123I-SAP scintigraphy is the only tool implemented in clinics to assess visceral amyloid burden.
Besides the cost of 123I , there is the unfortunate inability to visualize small, hollow, or diffuse
structures like the GI tract, skin, and nervous system [223]. Together with the cornea, these last
two form the triad of clinically most affected tissues in AGel amyloidosis [119]. Evidently, there
is a need for an alternative. The results described above might be a step in this direction.
The heart, skeletal muscle, and diaphragm (Figure 1.3) represent three of the four main tissues
in which the AGel mouse model shows amyloidogenic gelsolin buildup [148]. We were unable to
identify the fourth tissue, skin, as an organ showing significant uptake (data not shown). In the
AGel mouse model however, at least at the age of 18 months, amyloidogenic gelsolin is present
in this tissue [148]. Since the skin can be targeted using the 99mTc-nanobody technology [233],
we hypothesize that the skin only becomes burdened with amyloidogenic gelsolin somewhere
between the age of 9 and 18 months. Future research should test this theory. It is plausible that
the significantly smaller size of Nbs compared to SAP (15 versus 127 kDa) helps to probe this
tissue and thereby overcomes one of the limitations of 123I-SAP scintigraphy.
Furthermore, nanobodies have already been applied to the nervous system and showed good
biodistribution without causing any significant inflammatory reaction [234]. This makes us confi-
dent that when applied in the clinic, the FAF Nbs would also be able to target amyloidogenic gel-
solin surrounding the affected facial nerve branches (cranial nerve VII) in AGel patients, thereby
surmounting a second tissue barrier of 123I-SAP scintigraphy. Unfortunately, the AGel mouse
model does not allow testing amyloidogenic gelsolin buildup in nervous tissue, although this does
occur in human patients.
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Finally, nanobodies have already proven to be ideal instruments for imaging carcinomas, artheroscle-
rotic plaques, and tumor-associated macrophages in mouse models [235–237]. Some studies even
suggest that nanobodies, able to cross the blood-brain barrier, can be selected [238–240]. These
findings do however require confirmation by other researchers. We showed here that the nanobody
approach can also be employed in AGel amyloid. This, together with the fact that nanobodies
have been raised against several other amyloidogenic proteins, hints at the potential clinical use
of these antibody fragments to monitor global amyloid burden in patients with Alzheimer’s or
Huntington’s disease [187].
In this study, we have used the 99mTc and multi-pinhole SPECT technology because of its high
resolution when scanning small lab animals [241]. With the clinical application and human
patients in mind, we will have to migrate toward a PET-based setup. This should not pose a
problem as nanobodies can also be linked with gallium-68 or fluorine-18 to be compatible with
PET scanners [237, 242].
Using these 99mTc-based nanobody tracers, values of 1.1 ± 0.06 % IA/g tissue in the muscle
and 3.9 ± 0.68 % IA/g tissue in the heart were obtained (Figure 1.3a). We believe that at
least the preclinical values obtained in the heart are high enough to proceed toward clinical PET
imaging. Firstly because, similar research with an anti-HER2 nanobody which showed values of
4.19 ± 0.47 % IA/g tissue [183] was recently successfully translated to the clinic in a phase I
clinical trial [243]. Secondly image quality is also dependent on good focal uptake, which can be
achieved with the 99mTc-FAF Nb1 (Figure 1.6), and the difference in %IA/g between WT and
AGel mice (0.2 % IA/g versus 3.9 % IA/g in the heart and 0.09 % IA/g versus 1.1 % IA in the
muscle; Figure 1.3a and b).
The AGel mouse model only shows good Congo red birefringence at 18 months of age [148].
The FAF nanobodies are able to bind monomeric and polymeric amyloidogenic 8- kDa gelsolin
fragments [100]. It is therefore likely that 99mTc-FAF Nb1 predominantly visualizes non-mature
amyloidogenic gelsolin deposits instead of fully polymerized, cross-beta sheet AGel amyloid. In
recent years, it was evidenced that oligomers may be the major causative agent of cytotoxicity
[244, 245]. Therefore, it may prove valuable to visualize the toxic oligomeric intermediates and
not just the mature cross-beta fibrils. Future developments will have to reveal which approach is
most beneficial or whether a combined strategy is necessary.
1.6 Conclusion
Nanobodies against the AGel 8-kDa fragment were tested as non-invasive imaging agents. FAF
Nb1 proved to be the most potent candidate. Application in a Nb11 mouse model provided
evidence for its qualitative and quantitative characteristics.
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1
AAV9 delivered bispecific nanobody
attenuates amyloid burden in the gelsolin
amyloidosis mouse model.
1.1 Abstract
Gelsolin amyloidosis is a dominantly inherited, incurable type of amyloidosis. A single point
mutation in the gelsolin gene (G654A is most common) results in loss of a Ca2+ binding site in
the second gelsolin domain. Consequently this domain partly unfolds and exposes an otherwise
buried furin cleavage site at the surface. During secretion of mutant plasma gelsolin consecutive
cleavage by furin and MT1-MMP results in the production of 8 and 5 kDa amyloidogenic peptides.
Nanobodies that are able to (partly) inhibit furin or MT1-MMP proteolysis have previously been
reported. In this study the nanobodies have been combined into a single bispecific format able
to simultaneously shield mutant plasma gelsolin from intracellular furin and extracellular MT1-
MMP activity. We report the successful in vivo expression of this bispecific nanobody following
adeno-associated virus serotype 9 gene therapy in gelsolin amyloidosis mice. Using SPECT/CT
and immunohistochemistry, a reduction in gelsolin amyloid burden was detected which translated
into improved muscle contractile properties. We conclude that a nanobody-based gene therapy
using adeno-associated viruses shows great potential as a novel strategy in gelsolin amyloidosis
and potentially other amyloid diseases.
1.2 Introduction
Gelsolin amyloidosis (AGel) is an autosomal dominantly inherited disease caused by a point
mutation in the gelsolin (GSN) gene (G654A being the most common, D187N) [110, 246]. The
resulting destabilization of the second gelsolin domain (gelsolin consist of 6 domains, G1-G6)
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results in an aberrant proteolytic cascade, specifically affecting the plasma variant [14, 22, 145,
247]. During its transport through the intracellular secretion pathway, mutant plasma gelsolin
(PG*), is first cleaved by furin in the trans-Golgi network leading to the formation of a 68 kDa
C-terminal fragment [20]. When this C68 fragment is secreted, a second proteolytic cleavage
by MT1-MMP like proteases results in the release of 8 and 5 kDa amyloidogenic fragments
[144]. Over time, particularly the 8 kDa peptide will start to aggregate, forming cross-beta-
sheet amyloid fibrils and plaques. Patients experience a triad of neurological, ophthalmological
and dermatological symptoms [121, 135]. At the moment, no specific treatments for AGel are
available. Instead, patients undergo several symptomatic and aesthetic treatments to improve
their quality of life.
Our previous studies have shown that chaperoning nanobodies are able to (partly) inhibit the
pathological furin and MT1-MMP cleavages in vitro and in vivo, resulting in physiological im-
provements in transgenic mice that recapitulate the proteolytic AGel cascade [18, 100]. In view
of the central roles that furin and MT1-MMP undertake in neuropeptide maturation and con-
nective tissue organization/activation of other metalloproteases, respectively, we argue that these
proteases should not be considered as therapeutic targets, particularly since familial amyloidosis
is a chronic disease. For this reason we used camelid nanobodies that interact specifically with
(mutant) gelsolin and shield the protein either from furin [18] or MT1-MMP degradation [100],
thus acting as molecular chaperones.
In the present study we combined the two nanobodies into a single bispecific format with the aim
of providing simultaneous protection against both proteases simultaneously. The nanobodies were
separated by a MT1-MMP-sensitive peptide sequence which was used as an MT1-MMP protease
decoy. We investigated if this approach affected the binding characteristics of the individual
nanobodies and if this format was able to significantly increase the chaperoning capacity in vitro.
Because furin is an intracellular protease, our approach required intracellular delivery of the pro-
tective bispecific nanobody. We opted for adeno-associated virus serotype 9 (AAV9) gene therapy
considering that AAVs are able to infect both dividing and quiescent cells [248]. Moreover, as only
a small fraction of the virus integrates in the genome, the likelihood of insertional mutagenesis
is lower compared integrating gene therapy vectors [249, 250].
Using a recently developed nanobody based imaging agent [251] and immunohistochemistry, we
provide evidence of a significant decrease in gelsolin amyloid buildup in both the skeletal muscle
and heart of AGel mice injected with AAV9-Nb11-FAF1 vector during the neonatal period. These
results are further supported by improved muscle contractile properties following treatment.
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1.3 Materials & Methods
1.3.1 Antibodies and reagents
Anti-mouse/rabbit IgG HRP conjugate was purchased from VWR (Leuven, Belgium). Polyclonal
anti-V5 antibody (1:100 in IHC) was purchased from Sigma-Aldrich (Diegem, Belgium). Alexa
fluor 488 goat anti-rat IgG (H+L) and 594 goat anti-rabbit IgG (H+L) were purchased from
Life Technologies (Merelbeke, Belgium) (both 1:500 in IHC). Monoclonal anti-laminin antibody
(1:500 in IHC) was obtained from Abcam (Cambridge, UK).
1.3.2 Generation of gelsolin-specific nanobodies
Both the anti-gelsolin nanobodies (Nb11 and Nb13) and the anti-8 kDa nanobodies (FAF Nb1-
3) were obtained in collaboration with the VIB Nanobody Service Facility as described earlier
[100]. In short, dromedaries were injected with either CG or biotinylated human gelsolin 8 kDa
AGel peptide and recombinant GST-tagged human D187N gelsolin domain 2. Lymphocytes were
collected from the blood, total RNA was extracted and a cDNA library constructed. Phage
panning for the anti-gelsolin nanobodies was performed with CG and resulted in two functional
nanobodies; Nb11 and Nb13 [191]. Phage panning for the anti-gelsolin nanobodies was performed
with the 8 kDa peptide and the mutant G2 domain. Three nanobodies could be identified; FAF
Nb1-3.
1.3.3 cDNA cloning
All monovalent nanobodies were available in the pHEN6 vector with a C-terminal V5-His6 tag.
The bispecific nanobodies were constructed as followed: the pHEN6 vector containing the FAF
Nb1-3-V5-His6 constructs was cleaved with NcoI, opening the vector between the pelB signal
and nanobody N-terminus. The Nb11 sequence was amplified with a double set of primers to
introduce a 5’ HA-tag and a 3’ linker sequence (Figure 1.1a). This sequence encodes a MT1-
MMP sensitive peptide (SLAPLGLQRR) flanked by two GS linkers. The Cold Fusion Kit (System
Biosciences, Mountain View, CA) was used to ligate the PCR fragment in the opened pHEN6
vector.
Primers used in the first PCR cycle: 5’ GGT GGT GGT GGT TCT GGT CAG GTG CAG CTG
CAG GAG TCT GG 3’ (forward) and 5’ GAC GCT GCA GAC CCA GCG GCG CCA GAG AAC
CAG AAC CAC CAC CAC CGC TGG AGA CGG TGA CCT GGG TCC C 3’ (reverse).
Primers used in the second PCR cycle, using the product of the first cycle as template: 5’ CGC
GGC CCA GCC GGC CAT GGC CTA CCC ATA CGA TGT TCC AGA TTA CGC TGG TGG TGG
TGG TTC TGG TCA GGT G 3’ (forward) and 5’ CCT CCT CCA GAC TCC TGC AGC TGC
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ACC TGA CCA GAA CCA CCA CCA CCA CGA CGC TGC AGA CCC AGC GGC GCC AG 3’
(reverse).
1.3.4 Purification of recombinant PG*, C68 and nanobodies
Performed as previously described [100].
1.3.5 ELISA
Enzyme-linked immunosorbent assays (ELISA) were performed in Nunc Maxisorp 96-well plates
(Roskilde, Denmark). Target protein was coated in coating buffer (100 mM bicarbonate/car-
bonate, pH 9.6) at 0.2 µg of protein per well. PBS + 1% BSA was used as a blocking buffer,
PBS + 0.5% Tween was used as a washing buffer. Nanobodies were added in a ten-fold dilution
series ranging from 1 µg to 10-5 µg/well. Anti-V5 antibody followed by anti-mouse HRP +TMB
substrate kit (3,3’,5,5’ tetramethylbenzidine, Thermo Scientific, Erembodegem, Belgium) was
used for detection.
1.3.6 WB with bispecific Nb11-FAF nanobodies as primary antibody
Bacterial pellets containing PG, PG*, C68, 8 kDa peptide or CapG were resuspended in lysisbuffer
+ 0.5% NP40. Lysis was performed with 0.2 mg/ml lysozyme for 30 min at room temperature
followed by sonication (Vibracell, Sonics and Materials, Newtown, CT). The lysates were col-
lected after 30 minutes of centrifugation at 29.000 x g, 4°C. 5 µg bacterial protein extract were
fractionated by SDS-PAGE. Western blot analysis was performed with V5-tagged Nb11-FAF1, 2
and 3 as primary antibody. Monoclonal anti-gelsolin antibody was used as a positive control.
1.3.7 In vitro MT1-MMP sensitive linker assay
In vitro MT1-MMP proteolysis of the Nb11-GAF constructs was performed in a total reaction
volume of 75 µl. 2.5 µg bispecific Nb11-FAF Nb1-3 was incubated with 100 ng of the catalytic
domain of MT1-MMP for 1 hour at 37°C in reaction buffer (50 mM Tris pH 7.5, 5 mM CaCl2,
200 mM NaCl, 20 µM ZnSO4 and 0.05% Brij-35). At 0, 15, 30, 45 and 60 minutes, samples
were taken and the reaction was terminated by adding 5 µl Laemmli sample buffer. Samples were
boiled for 5 minutes, fractionated on a 15% SDS-PAGE gel and stained with Coomassie.
1.3.8 In vitro Furin/MT1-MMP assay
The in vitro proteolytic furin and MT1-MMP reaction was performed in a total end volume of
20 µl. 3 µM purified recombinant PG* was incubated with an equimolar amount of Nb in furin
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reaction buffer (250 mM Tris, 20 mM CaCl2, 1 mM β-mercapthoethanol, pH 7.0) for 1 hour
at 4°C. Furin was added (0.5 units) and the mixture was incubated for 1 hour at 37°C. Furin
Inhibitor I (Merck Millipore, Brussels, Belgium) was added at a final concentration of 100 µM
together with 50 ng of the catalytic domain of MT1-MMP. The buffer was supplemented with
200 mM NaCl, 0.05% Brij-35 and 20 µM ZnSO4. After 30 minutes at 37°C the reaction was
stopped by adding 5 µl of Laemmli sample buffer. The sample was boiled for 5 minutes and
separated on an tricine SDS-PAGE gel. Detection of both the C68 and 8 kDa fragment was
done via Western blotting with a polyclonal antiserum raised against the 8 kDa AGel fragment.
Quantification was done with the Image J software.
1.3.9 HEK293T cell culture, transfection and microsopy
Cell culture and transfection
HEK293T cells were grown in DMEM medium (Gibco Life Technologies, Grand Island, NY,
USA) supplemented with 10% fetal bovine serum (Thermo Scientific, Erembodegem, Belgium),
10 µg/ml streptomycin and 10 IU/ml of penicillin, at 37°C in a humidified 10% CO2 incuba-
tor. Transient expression of both PG and the nanobodies was achieved with Jetprime (Polyplus
Transfection Inc., New York, NY).
Microscopy
Cells were fixed with 3% PFA (paraformaldehyde) and permeabilized with 0.1% Triton. Coverslips
were blocked with 1% BSA (bovine serum albumin) and incubated with primary antibodies (1
hour at 37°C). The appropriate Alexa Fluor-conjugated secondary antibodies were incubated at
room temperature for 30 minutes. Nuclei were stained with DAPI (0.4 µg/ml) (Sigma, St. Louis,
MO, USA). Cells were mounted with VectaShield (Vector Laborotories, Burlingame, CA, USA)
and imaged with a Carl Zeiss Axiovert 200 M Apotome epifluorescence microscope equipped with
a cooled CCD Axiocam camera (Zeiss X63 1.4-NA Oil Plan-Apochromat objective; Carl Zeiss,
Oberkochen Germany) and Axiovision 4.5 software (Zeiss).
1.3.10 HEK293T medium analysis
HEK293T cells were cultured and transiently transfected as described above. 24 hours prior to
analysis the cell medium was replaced with a minimum amount of serum free medium. Medium
was collected and centrifuged (29.000 x g) for 5 min at 4°C. The cells were washed 2 times with
PBS and disrupted in Tris lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% triton-100,
1 mM PMSF and 200 µg/ml protease inhibitor cocktail) followed by 10 seconds of sonication.
Samples were centrifuged (29.000 x g) for 10 min at 4°C, the supernatant was collected. 20 µg
of the medium was separated on a 10% SDS-PAGE gel followed by Western blot analysis.
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1.3.11 AAV9 gene therapy intervention study
The gene encoding the V5-tagged bispecific Nb11-FAF1 nanobody was cloned downstream of a
ubiquitously expressed cytomegalovirus (CMV) promoter. This expression cassette was cloned
into a self-complementary (sc) AAV backbone (33) to generate the AAV9-Nb11-FAF1 vector
Figure 1.1b. As before AAV9-Luc2 vector was chosen as viral control [252]. AAV serotype
9 (AAV9) was chosen based on its efficient transduction efficiency in skeletal muscle and heart
[252–254]. To produce the AAV9-Nb11-FAF1 vector particles, AAV-293 cells were co-transfected
by Ca2+ phosphate (Invitrogen Corp, Carlsbad, CA, USA) with the AAV9-Nb11-FAF1 vector
along with a chimeric AAV Rep2 Cap9 packaging construct and an adenoviral helper plasmid, as
described previously [255]. All plasmids were prepared using Qiagen Maxi kits. Two days after
transfection, the cells were harvested and lysed by freeze/thaw cycles and sonication, followed by
benzonase (Novagen, Madison, WI, USA) and deoxycholic acid (Sigma-Aldrich, St Louis, MO,
USA) treatments. The cognate AAV vector particles were then purified by cesium chloride (In-
vitrogen Corp, Carlsbad, CA, USA) density gradient ultracentrifugation. Fractions containing the
AAV vector particles were collected in phosphate buffered saline (PBS) (Gibco, BRL) containing 1
mM MgCl2. The vector titer was determined using quantitative real-time PCR with SYBR Green
and primers specific for the CMV promoter. The forward primer sequence was 5’ CAT GGT GAT
GCG GTT TTG G 3’. The reverse primer sequence was 5’ TGG AAA TCC CCG TGA GTC A
3’. To generate standard curves, known copy numbers of the corresponding vector plasmid was
used.
The intervention study was performed on 2 groups of mice: WT C57BL/6 and AGel mice. Each
group consisted of 3 subgroups (6-12 mice): AAV9-Nb11-FAF1 injected (treatment), AAV9-Luc2
injected (viral control) and PBS injected (negative control). Neonatal mice (2-3 days) were
injected with 4.7x1010 vg/mouse (viral genomes/mouse) or PBS in the retro-orbital plexus. Over
the course of 3 months blood samples were taken from the tail vein at 4, 8 and 12 weeks. After
4 minutes of centrifugation at 1700 x g, plasma was collected. 1 mg of plasma was incubated
with V5-agarose and HA-agarose. Bound protein was separated on an SDS-PAGE gel. HA- and
V5-tagged nanobody was visualized via Western blotting.
Animal experiments were approved by the Animal Experimental Ethics Committee of Ghent
University Hospital (ECD 14/62). Animals were housed in individually ventilated cages with
food and water ad libitum. Environmental conditions were controlled at 20-23°C, 50% relative
humidity and 12 h light/dark cycles. AGel mice were obtained from the Scripps Research Institute
(La Jolla, California, USA). Wild type C57BL/6 mice were obtained from Charles River (L’arbresle
Cedex, France).
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1.3.12 SPECT/CT imaging
Amyloid burden was visualized using 99mTc-FAF Nb1 SPECT-CT imaging (14). Mice were
intravenously injected with 51 - 100 MBq of 99mTc labeled FAF Nb1. One hour post injection,
mice were anaesthetized using 18.75 mg/kg ketamine hydrochloride (Ketamine 1000, CEVA) and
10 mg/kg xylazine hydrochloride (Rompun, Bayer). Animals were positioned in a solid holder
with two plastic discs containing three 57Co (3.7 MBq) sources. Image acquisition was done
using a micro-CT scan for 2 min (60 keV, 615 mA, 360°; Skyscan 1178, Kontich, Belgium) and a
dual-headed SPECT camera (e.cam 180, Siemens, USA) equipped with triple pinhole collimators
(1.5 mm apertures, focal length of 265.5 mm and a radius of rotation of 20 mm) for 10 s per
projection step, 64 projections, and a total scan time of about 10 min. Images were quantified
using AMIDE (a Medical Image Data Examiner) software [227]. Ellipsoid regions of interest
were drawn (ROIs) around the heart and hind leg muscle. The same ROIheart and ROImuscle was
used for each individual animal. SPECT signals, acquired from the ROIs, were calculated and
expressed as % IA/cc.
1.3.13 Muscle contractile properties
Muscle contractile properties were determined as described before [256]. In short, mice were
anaesthetized with 80% Ketalar/20% Rompun (3.6 µl/g body weight). The soleus and EDL mus-
cles were dissected, wires were attached to the tendons and the muscles were vertically mounted
in an Krebs-Heinseleit medium incubation bath with one tendon attached to a force transducer
(PowerLab, ADInstruments, Spechback, Germany) and stimulated with capacitor discharges be-
tween platinum electrodes. The Krebs-Henseleit incubation medium (10 ml) was continuously
gassed (95% O2, 5% CO2) and maintained at 30°C. After a 15 minutes stabilization period,
optimal muscle length was determined by titanic contractions. Next, the force-frequency relation
was determined by stimulating at 10, 20, 35, 50, 75, 100, and 125 Hz with 1 minute rest interval
for soleus and stimulating at 25, 40 and 55 with 1 minute rest followed by 70, 100, 125 and 150
Hz with 2 minutes rest interval, unless stated otherwise, for EDL. Furthermore, fatigability was
evaluated as the percentage decrease in tetanic force, contraction speed (maximum slope) and
relaxation rate (minimum slope) values during 8 minutes of repeated tetanic contractions (train
duration, 350 microseconds; soleus, 50 Hz every 5 seconds; EDL, 100 Hz every 10 seconds). At
the end, mice were euthanized via cervical dislocation.
1.3.14 Immunofluorescence
Musculus gastrocnemius and the heart were dissected and snap frozen in liquid nitrogen. Cryosec-
tions were made and thawed for 15 min followed by 10 min incubation in acetone at -20°C. After
10 min incubation in PBS, the sections were incubated in 50 mM NH4Cl/PBS for another 10 min
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followed by an additional PBS washing step. The endogenous peroxidase activity was blocked
after 20 min incubation in 0.3% H2O2 and then washed in PBS. Sections were incubated with 1%
BSA/PBS for 20 min and with the laminin antibody (1:500) at 4°C overnight, followed by another
PBS washing step for 10 min. FAF Nb1-V5 (5 µg/ml) was incubated for 1 h at room temper-
ature followed by 10 min incubation in PBS. Polyclonal anti-V5 (1:800) was used as secondary
antibody. Alexa Fluor antibodies (488 anti-rat and 594 anti-rabbit, both 1:500) were incubated
for 1 h at room temperature. Finally, sections were rinsed with PBS, stained with DAPI (1:500)
for 2 min and mounted with VectaShield. Imaging was performed at room temperature with a
Leica DM6000 B microscope. Two sections were made per tissue and within each section, 3
images from spate regions were taken for quantification with Image J software. From these 6
technical repeats per animal, per tissue, the average was used for further statistical calculations.
1.4 Results
1.4.1 Production of the bispecific nanobody
In a previous study we have identified a gelsolin nanobody, Nb11, capable of partly inhibiting the
production of C68 by furin [18]. Nb11 binds (mutant) PG irrespective of Ca2+, and acts as a
molecular chaperone when targeted to the trans-Golgi network where it binds to and protects gel-
solin. Further downstream, reduced C68 formation results in a decrease of AGel amyloid buildup.
In another study, we followed a different approach and identified three closely related nanobodies,
FAF Nb1, 2 and 3, (FAF1-3) capable of binding both C68 and the 8 kDa amyloidogenic gelsolin
fragment, thwarting MT1-MMP activity, not furin. In vivo, upon binding of C68, these nanobod-
ies once again acted as a chaperone and partly prevented production of the pathological 8 kDa
AGel fragment [100]. Here our aim was to combine the two in a clinically applicable way.
Nb11 cDNA was amplified through PCR, introducing a HA-tag at the 5’ end and the sequence
encoding the MT1-MMP sensitive peptide SLAPLGLQRR [257], sandwiched between two Gly-Ser
linkers (GS) at the 3’ end. This fragment was linked to the 5’ end of FAF Nb1-3 cDNA, already
present in the pHEN6-V5-His6 vector, resulting in a final construct where both nanobodies occur
in tandem configuration, separated by the MT1-MMP sensitive peptide sequence and GS linker
(Figure 1.1a).
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Figure 1.1: Schematic representation of the bispecific Nb11-FAF format and AAV9-
Nb11-FAF1 vector. The two nanobodies, Nb11 and FAF Nb1-3, are linked via the MT1-MMP
sensitive sequence SLAPGLQRR, flanked between two GS linkers. An N-terminal HA and C-
terminal V5-His6 tag is present (a). The expression cassette was cloned in a self-complementary
(sc) adeno-associated virus backbone that was packaged using AAV serotype 9 capsids (AAV9).
Expression of Nb11-FAF1 is driven by the CMV promoter. The 5’ and 3’ inverted terminal repeats
(ITR) and SV40 polyadenylation site (pA) are indicated (b).
1.4.2 Bispecific gelsolin nanobodies merge the binding characteristics of their
monovalent constituents in vitro
The binding characteristics of the bispecific nanobodies were compared to their monovalent
counterparts using ELISA. As antigen, PG, PG*, C68 and the 8 kDa AGel fragment were coated.
CapG was chosen as a negative control. This protein belongs to the same family as gelsolin
and displays 49% similarity [113]. Nb11 recognized, in decreasing order of magnitude, PG, PG*,
C68 and 8 kDa. The FAF Nbs displayed the opposite binding pattern, as previously described
[18, 100]. The bispecific Nb11-FAF combinations exhibited a merge of the Nb11 and FAF1-
3 binding characteristics (Figure 1.2). No significant binding with the negative control was
observed. Furthermore, as previously described [100], FAF Nb1-3 can be used in Western blotting
as primary antibodies against PG, PG*, C68 and the 8 kDa AGel fragment. Linked to Nb11, this
ability remained unaffected (Figure 1.3).
1.4.3 The MT1-MMP peptide linker is functional in an in vitro setup
As mentioned earlier, the linker between Nb11 and FAF Nb1-3 contains the MT1-MMP sensitive
peptide SLAPLGLQRR (proteolysis of the GL scissile bond). The purpose of this setup was that,
in vivo, during secretion, proteolysis of this sequence would release the FAF Nb, enabling it to
perform its function without any interference of Nb11. At the same time this mechanism may
act as a decoy, luring MT1-MMP away from the (lower amount of) C68 being secreted. This was
tested in vitro using the recombinant catalytic domain of MT1-MMP. The MT1-MMP sensitive
peptide proved to be very efficient in all three bivalent Nb11-FAF constructs and they were readily
cleaved upon incubation with MT1-MMP (Figure 1.4).
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Figure 1.2: Comparison of the ELISA profiles of monovalent and bispecific nanobodies.
The interaction of monovalent Nb11 and FAF Nb1 with PG, PG*, C68 and the 8 kDa peptide, in an
ELISA setup, are merged in the Nb11-FAF1 construct (a). Each time a tenfold nanobody dilution
series was used, starting from 1 µg up to 10 pg. Signals are represented relative to the highest
value, normalized to 1. FAF Nb2 (b) and FAF Nb3 (c) displayed the same merge of characteristics
as FAF Nb1 when merged with Nb11.
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Figure 1.3: Bivalent constructs can be used as primary antibody for Western blotting.
5µg bacterial lysate containing PG, PG*, C68, 8 kDa peptide or CapG was fractionated by SDS-
PAGE. Nb11-FAF1-3 can be used as the primary antibody in Western blot analysis (a,b) [100].
Polyclonal anti-AGel antibody was used as a positive control. Both the monomeric and oligomeric
forms of the 8 kDa peptide are visualized by the nanobodies (b). Additional bands under the
PG/PG* signal (95 kDa marker) and C68 signal (72 kDa marker) represent degradation products
(a).
1.4.4 Bivalent Nb11-FAF Nb protects D187N plasma gelsolin against combined
furin/MT1-MMP proteolysis
Since Nb11 can inhibit furin proteolysis of PG* whereas FAF1-3 counteract MT1-MMP proteolysis
of C68 by shielding the substrate, we hypothesized that bivalent Nb11-FAF formats might be able
to combine both traits, leading to a synergetic inhibitory effect on 8 kDa amyloidogenic peptide
production. An in vitro assay was set up wherein the nanobodies were incubated with PG*,
followed consecutively, by furin and MT1-MMP proteolysis. Formation of both C68 and the 8
kDa fragment was assessed by Western blotting (Figure 1.5a). Only Nb11-FAF1 could match
the inhibitory capacity of Nb11 when looking at C68 formation, the intermediate AGel species
formed by furin (Figure 1.5b). Quantification of the amyloidogenic 8 kDa fragment showed
that all three Nb11-FAF constructs were able to inhibit formation of the 8 kDa AGel peptide
more efficiently than their monovalent counterparts (Figure 1.5c). Hence, the bivalent format
is endowed with a double protective activity, and formation of the 8 kDa fragment in particular
is strongly reduced in comparison to monospecific Nb11 or FAF nanobodies.
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Figure 1.4: The MT1-MMP linker sequence is cleaved in vitro. The bispecific Nb11-FAF
constructs were incubated in vitro with MT1-MMP for 1 hour at 37°C. At distinct time points
(0, 15, 30, 45 and 60 minutes) samples were taken and the reaction was stopped with Laemmli
sample buffer. Samples were boiled for 5 minutes. Visualization was done via Coomassie staining
after SDS-PAGE fractionation. MT1-MMP was able to recognize and cleave the SLAPGLQRR
sequence, thereby releasing the two individual nanobodies.
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Figure 1.5: The bispecific Nb11-FAF nanobodies outperform their monovalent coun-
terparts in vitro in protecting PG* against proteolytic degradation. The AGel degrada-
tion was recapitulated in vitro through consecutive incubation of PG* with furin and MT1-MMP.
Lane 1: negative control, no furin nor MT1-MMP. Lane 2: positive control, furin and MT1-MMP
but no nanobody. Lane 3-9: Furin, MT1-MMP and an equimolar amount of different nanobodies.
C68 and the 8 kDa peptide were detected with polyclonal anti-AGel antibody (a) and quantified
(b-c). Based on the amount of C68 formed, only Nb11-FAF1 could match Nb11 (b). Quantification
of the 8 kDa peptide (c), the end stage of AGel degradation, showed that all three Nb11-FAF con-
structs performed significantly better than their monovalent counterparts. Data shown are mean
of quadruplicates ± SE, normalized to the + ctrl sample. ∗p < 0.05 in a two sided unpaired t-test.
1.4.5 Furrin assay in HEK293T cells - Bivalent Nb11-FAF Nbs inhibit furin proteolysis
In the in vitro setup Nb11-FAF1-3 were able to bind their antigen targets and showed a signif-
icant protective chaperone activity towards PG* and C68. As we wanted to confirm this in a
more complex environment, PG, PG* and the Nb11-FAF constructs were transiently expressed
in HEK293T cells. Since the first step in AGel pathogenesis, furin cleavage, takes place in the
trans-Golgi network, all constructs were equipped with an N-terminal ER-targeting sequence.
Co-staining of the constructs followed by epifluorescence microscopy confirmed their colocalisa-
tion along the secretory pathway (Figure 1.7). After 24 hours, we analyzed the cell medium
via Western blotting (Figure 1.6a). Quantification of the C68 signal revealed a similar pattern
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as in the in vitro setup; the bispecific Nb11-FAF nanobodies show an inhibitory effect towards
furin proteolysis, however none can outperform monovalent Nb11 in this cell based setup (Figure
1.6b). We were unable to assess the effect on MT1-MMP proteolysis as no 8 kDa peptide could
be detected within the observed timeframe.
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Figure 1.6: Nb11-FAF nanobodies shield PG* from furin degradation in HEK293T
cells. PG, PG*, Nb11 and Nb11-FAF constructs were expressed in HEK293T cells and directed to
the secretory pathway using an N-terminal ER signal peptide 1.7. (a) Cell medium of transfected
HEK293T cells was collected and analyzed via Western blotting. PG, PG*, C68, Nb11 and Nb11-
FAF nanobodies could all be detected. (b) C68 levels in the cell culture supernatans was quantified
using ImageJ. Scale bar = 50 µm. Data shown are mean of triplicates ± SE, normalized to the
PG* sample. ∗p < 0.05 in a two sided unpaired t-test.
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Figure 1.7: Colocalisation between Nb11-FAF2/3 and PG/PG*. Nb11-FAF2, Nb11-
FAF3, PG and PG* were expressed in HEK293T cells and directed to the secretory pathway using
an N-terminal ER signal peptide. Via immunohistochemistry the nanobodies (green, first column),
PG/PG* (red, second column) and nucleus (blue, third column) were visualized. Merged images
(right column) show colocalisation between the nanobodies and PG/PG* in the secretory pathway.
Scale bar = 50 µm.
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1.4.6 Bispecific Nb11-FAF1 gene therapy in AGel mice via AAV9
Since the bispecific nanobodies effectively combined the binding and therapeutic characteristics
of its monovalent counterparts, an AGel mouse model intervention study was set up. This mouse
model recapitulates the pathological AGel pathway in its muscle tissue, leading to extensive, age
related, extracellular amyloidogenic gelsolin buildup [148]. Nb11-FAF1 was chosen based on its
superior characteristics in vitro. Homozygote neonates (2-3 days old) were injected with 4.7 x
1010 vg/mouse of AAV9-Nb11-FAF1, AAV9-Luc2 (viral control) [252, 258] or PBS (negative
control) via the retro-orbital plexus. No adverse effects on the development or behavior of
the mice were apparent. Nanobody expression was confirmed at 1, 2 and 3 months of age in
the plasma of both WT and AGel mice (Fig.1.8). The presence of a band at 34 kDa and
two at 17 kDa indicates that the MT1-MMP sensitive linker is functional in vivo (Fig.1.8).
At the age of 3 months Nb11-FAF1 gene therapeutic efficacy was determined via SPECT-CT,
immunofluorescence and ex vivo muscle performance.
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Figure 1.8: Nb11-FAF1 is expressed in AGel mice after AVV9 gene therapy. At 1 month
of age (a), 1 mg of plasma protein was incubated with anti V5-agarose and anti HA-agarose. Bound
protein was visualized via Western blotting after SDS-PAGE. Nb11-FAF1 is visible at the 34 kDa
marker. The double band at the 17 kDa marker represents the Nb11 and FAF1 fragments, released
after in vivo MT1-MMP cleavage. No differences in expression could be detected between WT (lane
1-4, 4 littermates) and AGel mice (lane 5-8, 4 littermates) mice. Nanobody expression remained
detectable at 2 (b) and 3 (c) months. At each time point, corresponding lanes represent plasma
taken from the same mouse.
1.4.7 AAV9-Nb11-FAF1 displays therapeutic properties in AGel mice
SPECT-CT imaging
3 months post treatment, AGel amyloid burden in skeletal muscle and myocardium was determined
using SPECT/CT and a recently developed 99mTc-FAF Nb1 AGel tracer [251]. In the WT control
groups, AAV treatment did not significantly alter the background control signal (Figure 1.9a
and b). In the AGel group however, expression of Nb11-FAF1 resulted in a significantly lower
signal (t-test, p< 0.05) in the skeletal muscle (25% vs. PBS and 28% vs. AAV9-ctrl) (Figure
1.9a) and a significantly lower signal (t-test, p< 0.05) in the heart (30% vs. PBS and 36%
vs. AAV9-ctrl) (Figure 1.9b). This is consistent with a reduction of the characteristic amyloid
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burden in the AAV9-Nb11-FAF1-treated AGel mice.
Figure 1.9: Quantified SPECT-CT data in skeletal muscle and heart. At 3 months of
age all mice underwent a SPECT-CT scan with the 99mTc-FAF Nb1 AGel tracer [251]. Identical
regions of interest were drawn around hind leg muscles and heart. Signal quantification showed
that Nb expression had no effect on WT background signal, neither in skeletal muscle (a) nor in
heart (b). In AGel mice, Nb11-FAF1 expression resulted in a significantly lower signal in skeletal
muscle (a) and the heart (b) compared to PBS and AAV9-control groups. Data shown as mean ±
SE. ∗p < 0.05 in a two sided unpaired t-test.
Immunofluorescence
The mice were sacrificed three months post AAV injection. AGel amyloidogenic buildup in skeletal
muscle and heart tissue was stained and quantified. Laminin was used as an internal control.
Nb11-FAF1 expression resulted in a significant reduction (t-test, p< 0.05) of AGel amyloidogenic
buildup in skeletal muscle (39% vs. PBS and 36% vs. AAV9-ctrl) (Figure 1.10c) and in the
heart (43% vs. PBS and 55% vs AAV9-ctrl) (Figure 1.10d) in AGel mice. In contrast, WT
control groups expressing Nb11-FAF1 showed no significantly different staining compared to the
WT-PBS or WT-AAV9-Ctrl groups (Figure 1.10a).
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Figure 1.10: Nb11-FAF1 expressing AGel mice show a decreased immunohistochem-
istry staining pattern in skeletal muscle and heart tissue. Mice were sacrificed three months
post AAV injection. Skeletal muscle and heart tissue was stained for AGel amyloidogenic buildup
(a-b, red, scale bar = 50 µm) and laminin (a and b, green, control, scale bar = 50 µm). The
staining pattern was reduced in Nb11-FAF1 expressing AGel mice both in skeletal muscle (c) and
heart tissue (d) compared to PBS and AAV9-control groups.
Ex-vivo muscle performance is improved in AAV9-NB11-FAF1 treated mice
At the end of the trial, mice were anaesthetized, the extensor digitorum longus (EDL) and soleus
were dissected and their contractile properties were measured. The expression of Nb11-FAF1
in AGel mice resulted in a specific twitch force indistinguishable from the WT control groups
(t-test, p > 0.05) and significantly different compared to the untreated (PBS or AAV9-ctrl) AGel
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groups in EDL muscle (t-test, *p < 0.05) but not in the soleus (Figure 1.11a and b). The
amount of force that could be produced for a given frequency (force-frequency) was not affected
by the amyloid burden nor by the treatment. Interestingly, fatigue progression was, both in EDL
and soleus, significantly more pronounced in the WT versus the (un)treated FAF mice (data not
shown). However, the speed of muscle contraction during fatigue in EDL muscle in the Nb11-
FAF1 expressing AGel mice showed, as expected, a similar decline as the WT controls in contrast
to the untreated (PBS or AAV9-ctrl) AGel mice (Figure 1.11d). The soleus seemed unaffected
(Figure1.11c).
Figure 1.11: Ex-vivo muscle contractile properties improve after AAV9-Nb11-FAF1
gene therapy. Soleus and EDL muscles were dissected and their ex-vivo contractile properties
measured. Expression of Nb11-FAF1 in AGel mice resulted in a specific twitch force significantly
different from AGel control mice (both PBS and AAV9-control) and indistinguishable from the
WT-control groups in EDL but not soleus (a and b, upper panels, data shown as mean ± SE.
∗p < 0.05 in a two sided unpaired t-test). EDL maximum slope (d), during the fatigue protocol,
in Nb11-FAF1 expressing AGel mice, displayed the same delay as the WT controls. In contrast,
AGel PBS and AAV9-control treated mice displayed a significantly faster fatigue onset. The soleus
maximum slope during fatigue protocol (c) seemed unaffected. ∗p < 0.05 in a two sided unpaired
t-test (a and b), one way ANOVA (c and d).
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1.5 Discussion
As is the case in the majority of amyloid diseases, AGel is characterized by a systemic deposition
of amyloid fibrils. The amyloidogenic 8 kDa fragment is produced in a two step process; the first
intracellular cleavage of PG* by furin is followed by an extracellular cleavage of C68 by MT1-
MMP like proteases. Both in the present and previous studies, intra- and extracellularly active
chaperoning nanobodies have been investigated regarding their potential to inhibit the formation
of the amyloidogenic 8 kDa gelsolin fragment. The in vivo success of such chaperone based
therapeutics strongly depends on the degree in which they distribute throughout the body. In the
case of the extracellularly active FAF Nb1, systemic distribution was achieved by intraperitoneal
injection [100]. For the intracellularly active Nb11 study, a transgenic mouse model, constitutively
expressing Nb11, had to be developed [18]. Here our aim was to combine the FAF Nbs and Nb11
into a single format administered in a clinically applicable way; AAV9 based gene therapy.
Three bispecific nanobodies, Nb11-FAF1, Nb11-FAF2 and Nb11-FAF3 (Figure 1.1a), were cre-
ated. ELISA and Western blot analysis (Figure 1.2 and 1.3) showed that, when linked together,
the binding characteristics of the constituent nanobodies remained intact. The peptide used to
link the two nanobodies was chosen for its susceptibility towards MT1-MMP proteolysis. We
envisaged that this approach would result in proteolysis of the amino acid stretch in vivo upon
secretion of C68, thereby releasing the FAF Nbs, after which they can exert their C68 chaperoning
capacity in an unhindered manner. In vitro, this peptide sequence performed perfectly; incubation
of the bispecific nanobodies with MT1-MMP resulted in the intact release of both constituent
nanobodies (Figure 1.4).
The chaperone activities of Nb11-FAF constructs were tested in vitro in a combined furin/MT1-
MMP assay. Quantification of C68 and the 8 kDa peptide revealed that Nb11-FAF1 can rival
with Nb11’s PG* chaperoning activity. At the level of the 8 kDa peptide, all Nb11-FAF constructs
outperformed their monovalent counterparts (Figure 1.5).
To address the in vivo problem of amyloid buildup in the AGel mouse model we used a therapeutic
approach involving on AAV vector-mediated delivery of the cDNA encoding the Nb11-FAF1
nanobody. AAV is a promising vector for gene therapy yielding long-term expression of therapeutic
proteins in clinical trials. The vector tropism is determined by the type of AAV capsid used. We
and others had previously demonstrated that AAV serotype 9 is well suited for cardiac and skeletal
muscle gene delivery [252–254, 259, 260]. Moreover, the first systemic AAV9 clinical therapy was
initiated in 2014, in children up to nine months old, suffering from spinal muscular atrophy type
1 [261], resulting in an apparent sustained therapeutic effect. Since the AGel mouse model
recapitulates AGel pathology in skeletal muscle and heart, we therefore also opted for AAV9. In
vivo transduction with AAV9 vectors encoding the Nb11-FAF1 nanobody resulted in long-term
expression of Nb11-FAF1, at least for 3 months post vector-injection, the endpoint of the study
(Figure 1.8). This is consistent with previous studies showing prolonged expression in the muscle
after AAV gene therapy with many different serotypes, including AAV9 [252–254, 259, 260].
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Analysis by SPECT/CT and immunohistochemistry revealed a significant decrease in AGel amy-
loid buildup in both muscle and heart tissue (Figure 1.10 and 1.11), consistent with Nb11-FAF1
nanobody expression. The pathological AGel amyloid accumulation could be readily detected us-
ing anti-8 kDa antiserum or nanobodies in AGel mice, whereas it was absent in wild-type mice.
Most importantly, the observed decrease in AGel buildup translated into improved muscle con-
tractile properties. The EDL showed a specific twitch force indistinguishable from the WT control
groups but significantly different from the untreated AGel mice. However, the fact that untreated
AGel mice show the highest specific twitch force, and that Nb11-FAF1 treatment reduces this
back to the WT base level, is quite counter-intuitive. One would expect that the presence of AGel
amyloid between the muscle fibers would negatively influence overall muscle performance. At the
moment the molecular mechanisms behind this observation is are still obscure. One possibility
would be that in AGel affected muscle tissue, the fraction of unaffected muscle fibers somehow
overcompensate the functional loss of the more affected fibers. EDL from Nb11-FAF1 treated
mice also displayed improved relaxation speeds at the onset of fatigue (Figure 1.11). The decline
in the speed of muscle contraction during fatigue was identical to the one observed in the wild
type mice. In contrast, in the untreated AGel control mice, the presence of AGel amyloid around
the muscle fibers most likely hinders an efficient exchange of nutrients and metabolites, adversely
impacting the relaxation rate. A reduction in AGel deposition, due to Nb11-FAF1 gene therapy,
seems to ameliorate this pathological feature. Our results are consistent with our previous studies,
showing that intraperitoneal administration of purified monovalent FAF Nbs or transgenic mice
expressing Nb11 following insertion in the ROSA26 locus, also resulted in a significant reduction
of the AGel amyloid burden. Head to head studies in the same AGel mouse model are required to
compare the relative efficiencies of this Nb11-FAF1 nanobody-based gene therapy approach versus
injections of purified nanobodies. Nevertheless, the main advantage of the current nanobody-
based AAV9-dependent gene therapy approach is that it enabled sustained in vivo nanobody
expression that is targeted for secretion following passage through the ER and Golgi apparatus
where it binds PG*. Consequently, the current gene therapy approach is well suited to treat a
monogenic disorder like AGel that requires life-long treatment. In contrast, treatment of AGel
patients with purified nanobodies, would require life-long, fairly frequent nanobody injections, due
to their relatively rapid clearance rates from the circulation. It is particularly encouraging that a
long-term therapeutic effect was observed after AAV9-Nb11-FAF1 gene therapy in homozygous
AGel mice, which have a more severe phenotype than their heterozygous counterparts (which
were used in our earlier studies [18, 100]). In particular, homozygosity of the D187N mutant PG
gene results in an earlier onset and higher degree of AGel amyloid deposition leading to a more
significant muscle impairment, as opposed to heterozygous AGel mice [148].
Despite the advantages of AAV, some challenges would still need to be addressed to enable
its widespread use in patients afflicted by monogenic disorders like AGel. First, there is a high
prevalence of pre-existing immunity in the human population (40-80%) against the known AAV
serotypes [262]. In time this may be overcome by the discovery of new serotypes against which
there is almost no pre-existing immunity or by mutating the antigen epitopes on the AAV capsid.
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Using directed evolution, the latter has already proven to be at least partly successful [263, 264].
Secondly, off-target transduction can severely abate the AAV therapeutic efficiency. Any vector
taken up by the off-target tissue is essentially lost as it can no longer exert its effect in the
desired target tissue. Consequently, this requires higher viral doses, thereby increasing the risk of
an immune response. Moreover, since AAV9 also transduces the liver, any nanobody produced
in this organ would no longer be able to perform its PG* chaperone activity. Looking forward
to applications in patients, such off-target transductions will have to be minimized. Once again
mutagenesis of specific capsid proteins can redirect AAVs more specifically to the tissue of interest
[265–267]. In the case of AGel, and more generally in the case of amyloidosis, this may prove
useful as the amyloid precursors are quite often formed in a specific cell type, tissue or organ.
Preventing the formation of amyloid precursors, as was attempted here with nanobodies, would
be a major step forward in amyloid research. Currently, administration of (R)-1-[6-[(R)-2-carboxy-
pyrrolidin-1-yl]-6-oxo-hexanoyl] pyrrolidine-2-carboxylic acid (CPHPC) followed by anti-SAP an-
tibody is the most promising amyloid removing strategy, as has been proven in patients with
AL amyloidosis [268]. Obviously, such interventions are only meaningful if, as is the case in AL
amyloidosis, one is also able to stop the production of new amyloid precursors. The development
of this bispecific, chaperoning, anti-AGel nanobody, may prove to be a fundamental step towards
this goal.
1.6 Conclusion
Two types of anti-AGel nanobodies were combined into a single bispecific format; Nb11 which
inhibits furin proteolysis and the FAF Nbs which inhibit MT1-MMP proteolysis. In vitro studies
showed that the Nb11-FAF1 format was most potent. Using AAV serotype 9 gene therapy its
therapeutic potential was explored in the AGel mouse model. Expression of Nb11-FAF1 resulted
in a reduced amyloid burden and improved muscle contractile properties.
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Where are we now
Gelsolin amyloidosis, originally discovered in 1969, can sadly still be categorized under ’incurable
diseases’. But significant progress has been made in the past several decades. First off all, the
underlying molecular mechanism and causative mutations - at the moment four are known - have
been thoroughly characterized. Secondly, the phenomenon of amyloidosis has been unraveled.
We now know that all amyloid diseases converge towards cross β-sheet amyloid fibrils regardless
of the causative protein or protein fragment. Lastly, the creation of the gelsolin mouse model
in 2009 [148] allowed us to test potential therapeutic strategies in vivo, a milestone in the AGel
story.
So why are patients still only receiving symptomatic treatments? What are we missing? Which
hurdles still need to be overcome before a groundbreaking therapeutic can be developed?
The fragments responsible for the AGel symptoms are generated from a mutated form of gelsolin.
During the secretory pathway of (mutant) gelsolin, it encounters furin in the trans-Golgi network.
The AGel mutations result in a partly unfolded variant which reveals an otherwise buried furin
cleavage site. Proteolysis generates a 68 kDa C-terminal fragment which, upon secretion, is
cleaved by MT1-MMP-like proteases. The latter gives rise to 8 and 5 kDa amyloidogenic frag-
ments able to polymerize into cross β-sheet amyloid fibrils causing the triad of ophthalmological,
neurological and dermatological symptoms discussed in Chapter 3, Introduction to gelsolin amy-
loidosis. At first glance, a direct inhibition of furin and/or MT1-MMP with small compounds
may seem to be the best therapeutic option. However, these proteases perform key functions in
a whole array of crucial biological processes.
Furin is a membrane bound member of the proproteine convertase family, active in the endosomal
and lysosomal pathway. While shuttling between the trans-Golgi network and the cell surface
it activates a wide range of serum proteins, hormones and receptors [140–142]. Systemic furin
knockout mice proved unviable with embryos dying between days 10.5 and 11.5 [269]. An impaired
processing of transforming growth factor β (TGFβ) superfamily members has been suggested as
the cause [269]. In sharp contrast with its necessity during embryonic development, furin’s
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functions seem partially redundant in adult mice. Inducible furin knockout mice did not develop
severe phenotypes; lipoprotein receptor-related protein, albumin, αV integrin, α1-microglobulin,
and vitronectin processing was reduced. TGFβ and PC subtilisin/kexin type 9 processing however
seemed entirely dependent on furin [270–273].
MT1-MMP is a membrane bound member of the matrix-metalloprotease family [148] which plays
a pivotal role in protein degradation processes during embryonic development and tissue remod-
eling. MT1-MMP deficient mice suffer from craniofacial dysmorphism, osteopenia, dwarfism,
arthritis and fibrosis of soft tissues. The overall cause is the loss of collagenolytic activity essen-
tial for the remodeling of skeletal and connective tissue during embryogenesis, growth and tissue
maintenance and repair [150].
Taking into account these knockout experiments, in the context of AGel one may expect signifi-
cant unwanted side effects with a therapy based on furin and/or MT1-MMP inhibition. Especially
considering patients would have to take the inhibitors lifelong. At our lab we therefore focused
on the development of molecular chaperones with the ability to shield PG* and/or C68 from furin
and MT1-MMP respectively. One nanobody, Nb11, originally developed against CG proved to be
able to bind PG* and shield it from furin degradation [18]. To tackle the MT1-MMP proteolysis,
a new set of nanobodies was raised against the amyloidogenic 8 kDa peptide. Three nanobodies,
FAF Nb1-3, were selected and all were able to bind and shield C68 from MT1-MMP degradation
[100]. In the first article presented in this manuscript the potential of these FAF nanobodies as
molecular imaging tools was explored. In the second article Nb11 was combined with the FAF
nanobodies, forming a bispecific, therapeutic nanobody applicable via AAV gene therapy.
2
SPECT/CT imaging of amyloid deposits in the
AGel mouse model
As stated above, the development of the AGel mouse model in 2009 [148] can be considered a
milestone in the AGel research. It expresses D187N human PG under the control of a muscle
creatine kinase promoter. From then onwards, new potential therapeutics could, and have been
tested in vivo. Their efficacy could be evaluated via immunohistochemistry on muscle tissue and
analysis of ex vivo muscle contractile properties [18, 100]. Nonetheless, the end-stage nature of
these experiments leaves many questions unanswered as, over the course of the experiment, the
therapeutic mode of actions remains a black box. For example, treatment with FAF Nb1, FAF
Nb2-MSA21 - FAF Nb 2 coupled to the albumin binding MSA21 nanobody to enhance the overall
half-life - and Nb11 all resulted in a decreased amyloidogenic gelsolin buildup in the AGel mice
as determined by immunohistochemistry [18, 100]. From the in vitro data we know that this is
the result of their chaperoning activity towards C68 and PG*, respectively, but we have no clue
how the resulting lower production of the 8 kDa amyloidogenic fragment influences the amyloid
formation process (Figure 2.1). Does it delay the nucleation or elongation process? Or does the
lower amount simply limit the amount of amyloid which can be formed?
As a first step towards answering these questions we investigated the potential of the FAF
nanobodies as an imaging tool. Binding specificity and overall thermal stability are two basic
characteristics desired in an imaging agent. The first had already been thoroughly confirmed
[100]. The second, thermal stability, was determined via incubation of the nanobodies in mouse
serum at 37°C. None of the FAF Nbs showed any degradation up until 24 h of incubation. More-
over, all three nanobodies could be labeled via their hexahistidine tag with 99mTc - a process
which involves an incubation step at 60°C - with yields over 98%. Technetium was chosen be-
cause of its convenient nuclear decay and ideal coordination chemistry for site specific labeling of
nanobodies with 99mTc(CO)3. Furthermore, compared to PET isotopes 99mTc is relatively cheap
and conveniently availably from 99Mo/99mTc generators [275].
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Figure 2.1: Amyloid formation happens in two stages: (i) a nucleation phase in which un- or
misfolded monomers associate into oligomers and (ii) an elongation phase characterized by a rapid
growth of the original oligomers into large fibrils. The nucleation phase is the limiting step due to
its unfavorable thermodynamics [274].
A first in vivo screening was performed in WT C57BL/6 mice, the WT background of the AGel
mouse line. As no aspecific background signals could be detected we began screening the signal-
to-noise ratio and signal specificity of the three FAF Nbs. For this 9 month old AGel mice were
used and the attained results were compared with the data collected from the WT mice. Given
that the AGel mice only produce the D187N gelsolin mutant in their muscle tissue, we specifically
focused on the skeletal and cardiac muscle. The liver was chosen as an aspecific control organ.
Overall, FAF Nb1 proved superior in both signal-to-noise ratio as signal specificity compared to
FAF Nb 2 and 3.
Having selected FAF Nb1 as the best candidate we were interested to see whether or not the
SPECT signals generated with 99mTc-FAF Nb1 held any quantitative information. After all, the
objective was the development of an imaging tool via which we could, non-invasively, access the
efficacy of potential FAF therapeutics. In order to do this, the generated SPECT signals would
have to correlate with the actual amount of amyloidogenic gelsolin buildup. Therefore a group of 3
month old AGel mice underwent 99mTc-FAF Nb1 SPECT/CT analysis. Next, as was also the case
for the 9 months old group, the animals were sacrificed and dissected. Tissue specific 99mTc-FAF
Nb1 retention was determined - biodistribution analysis - and immunohistochemistry - the golden
standard in amyloid research - was performed on both skeletal and cardiac muscle. Quantification
and comparison of the three techniques revealed a similar pattern of signal increase, thereby
confirming that 99mTc-FAF Nb1 based SPECT imaging holds quantitative value and correlates
with the actual amyloidogenic gelsolin buildup in the tissue.
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As a proof of concept an earlier study involving Nb11 expressing mice [18] was repeated. These
mice, express and secrete Nb11. In the trans-Golgi network this nanobody encounters PG* and
(partly) shields it from furin degradation, resulting in decreased amyloidogenic gelsolin deposition
[18]. Originally, three separate groups were euthanized and analyzed at 3, 6 and 9 months of
age. Now, two groups of mice were monitored via SPECT/CT every 2 months up until 9 and
11 months respectively. Next they were euthanized, dissected and analyzed via biodistribution
analysis and immunohistochemistry. At these time points the results obtained with all three
techniques were identical; Nb11 expressing AGel mice showed significantly less amyloidogenic
gelsolin buildup compared to their AGel littermate controls at 9 months, but no longer at 11
months.
To further strengthen our claim that 99mTc-FAF Nb1 SPECT imaging can be used for non-invasive
assessment of the amyloidogenic gelsolin buildup a set of 5 and 7 month old AGel mice underwent
SPECT/CT and immunohistochemistry analysis. Using the already generated data from 3, 9 and
11 month old AGel mice a correlation plot was made between SPECT signal strength and in vivo
binding site levels, the latter determined in proxy via immunohistochemistry quantification. The
trend line (R2 = 0.8447 ) clearly revealed a positive correlation, thereby supporting our claim.
In conclusion, the study described above has shown that (i) labeling the FAF Nbs with technetium
is possible, (ii) none of them recognizes any aspecific target when injected in mice, (iii) that FAF
Nb1 is superior in terms of signal-to-noise-ratio and signal specificity and that (iv) with 99mTc-
FAF Nb1 it is possible to non-invasively assess the amyloid burden in AGel mice. At this point I
feel it is important to notice that this study also highlights the pluripotent nature of nanobodies.
Indeed, FAF Nb1, originally developed against the 8 kDa amyloidogenic gelsolin fragment can be
used both as a molecular chaperone [100] and as a SPECT imaging agent [251].
3
AAV9 gene therapy with bispecific
Nb11-FAF1 nanobody in AGel mice
Two types of therapeutic studies had already been performed at our lab. (i) The extracellularly
active FAF Nb1 - half-life of one day - and FAF Nb2-MSA21 - half-life of one week - were both
intraperitoneally administered for 12 weeks. After diffusion into the tissue these nanobodies could
(partly) protect C68 from MT1-MMP degradation [100]. (ii) A Nb11 expressing mouse line has
been developed and crossed with AGel mice. As Nb11 works intracellularly the Nb11 gene was
accommodated with a N-terminal ER signal ensuring its processing via the Golgi apparatus where
it could (partly) protect PG* from furin [18]. Both approaches led to a reduction of amyloidogenic
gelsolin buildup in AGel mice. In theory the easy mode of administration - injection - of FAF
Nb2-MSA21 can easily be translated to the clinic. The Nb11 study on the other hand not so
much. At the moment, the only truly viable technique is gene therapy, an experimental technique
gaining more and more momentum 1 and one which we wanted to explore. If one goes through
all the trouble of developing a nanobody gene therapy, would it not be a waste to only deploy
half of the available therapeutic potential? More specifically, although the FAF Nb formats are
active in the extracellular matrix, and thus can simply be injected, would their efficacy change
if we administered them via gene therapy just like Nb11? We thought not. Moreover, we saw
a potential extra advantage in combining Nb11 and the FAF nanobodies into a single bispecific
format; using a peptide linker sensitive to MT1-MMP proteolysis might lure MT1-MMP away
from ( the already lower amount of) C68. Thereby this newly envisioned ’two hit strategy’ (Figure
3.1) might gain even more therapeutic value. In short, the idea behind the second paper was
to combine the therapeutic potential of Nb11 and the FAF Nbs using a mode of administration
easily translatable to the clinic.
1In 2015, Glybera, the first gene therapy that has been approved by the European Commission, has
become commercially available.
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Figure 3.1: Envisioned molecular mechanism of the therapeutic bispecific Nb11-FAF1.
The left-hand side depicts the pathological PG* processing with the formation of C68 in the trans-
Golgi network and the 8 and 5 kDa amyloidogenic fragments in the extracellular matrix. On the
right-hand side, the intervention with bispecific Nb11-FAF1 is shown. In the trans-Golgi network,
the nanobody uses its Nb11 moiety to bind PG* and (partly) protect it from furin degradation.
In the extracellular matrix, the MT1-MMP–sensitive linker between Nb11 and FAF1 serves as a
decoy. At the same time, FAF Nb1 is released and is able to perform its C68 chaperoning effect,
thereby further decreasing the overall formation of the 8 and 5 kDa amyloidogenic fragments. [23].
We started out by linking Nb11 head-to-tail with each one of the FAF Nbs via the MT1-MMP
sensitive peptide SLAPLGLQRR [257]. The latter was sandwiched between two Gly-Ser linkers
as a means to limit the constraint of movement each nanobody might inflict on the other. We
confirmed via ELISA and Western blot that the bispecific constructs perfectly combine the binding
characteristics of their monovalent constituent, hence this strategy seemed effective. Furthermore
the incorporated MT1-MMP sensitive peptide proved to remain available and effectively cleavable
although interposed between two nanobodies.
A combination of the furin and MT1-MMP in vitro assays, presented in earlier publications
[18, 100], revealed some interesting insights. (i) Only Nb11-FAF1 could match Nb11’s capacity
to shield PG* form furin. (ii) However, based on the amount of 8 kDa amyloidogenic peptide -
the main causative agent of the AGel pathology - all three Nb11-FAF constructs outperformed
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their monovalent counterparts. This confirms that, at least in vitro, a combination of these two
types of chaperones is effective. This experiment was repeated in HEK293T cells. Surprisingly
Nb11-FAF1 could no longer compete with the inhibitory effect of monovalent Nb11. Perhaps
the more complex environment magnifies the (minimized amount of) constraint the two linked
nanobodies exert on one another.
Having confirmed that the bispecific nanobody combines the desired characteristics of its monova-
lent constituents, a gene therapy study in AGel mice was set up. We opted for adeno-associated
viruses for their ability to infect both dividing and quiescent cells, their episomal nature after
infection and non-pathogenic nature. However some caution regarding the episomal nature is
necessary. A small fraction of infecting wild-type AAV genomes integrates in the host genome
which can result in insertional mutagenesis. In fact, increased tumorigenesis has been observed in
mucopolysaccharidosis VII animal trials [276]. Furthermore, AAV integration has been identified
in the testicular tissue of two individuals [277].
AAV9 was our serotype of choice considering its tropism from muscle cells, the afflicted tissue
in AGel mice. Three treatments were given, each one to an AGel and WT control group; (i)
AAV9-Nb11-FAF1, treatment group, (ii) AAV9-Luc2, viral control group and (iii) PBS, negative
control group. The mice were observed for three months, a timeframe during which the expression
of Nb11-FAF remained detectable in the serum. At the end of this period the mice were sacri-
ficed and analyzed via SPECT/CT, immunohistochemistry and ex vivo muscle performance. The
significant reduction in amyloidogenic gelsolin deposition detected with SPECT/CT and immuno-
histochemistry could be coupled to improved muscle functions. Indeed, the specific twitch force
of treated AGel mice was significantly different from the other AGel groups but indistinguishable
from the WT control groups. Furthermore, the muscle contractile speed, during fatigue in EDL
muscles, showed a similar decline in Nb11-FAF1 treated mice as in WT mice. This correlation
hints that the observed reduction in amyloid deposition might be significant enough to alleviate
some of the symptoms.
4
General conclusion and future prospects
Considering all of the above, what progress has been made and what are the next steps? First of,
the development of the gelsolin amyloid imaging agent - 99mTc-FAF Nb1 - is a step forward on two
levels. On the one hand, this new tool can significantly boost the overall development of an AGel
therapeutic. As we are now able to monitor the amyloidogenic gelsolin buildup non invasively, a
significantly lower amount of mice is needed per trial. Moreover, a longitudinal follow-up study
might reveal the mode of action of therapeutics under development. For example, SPECT/CT
analysis with 99mTc-FAF Nb1 in Nb11 expressing AGel mice revealed that deposits are already
present at the age of 5 weeks (Figure 4.1). We therefore hypothesize that the observed effect
of Nb11 expression is mainly due to a deceleration of the elongation phase rather than a delay
of the nucleation phase (Figure 2.1). This kind of knowledge might prove valuable during the
development process. Especially since the majority of cases is only diagnosed in a later stage
when significant symptoms start to arise and the nucleation phase is already long past. On the
other hand this imaging tracer might also find its way directly into the clinic. A few modifications
would have to be made. First, a transition will have to be made from 99mTc/SPECT towards a
PET-based setup with, for example, Gallium-68 or Fluor-18. Just as 99mTc, both can be easily
and site specifically linked to nanobodies [237, 242]. Secondly, it would be favorable to humanize
the FAF Nb [178]. Given the chronic nature of AGel, patients would most probably be imaged
multiple times throughout their life. Despite the low immunogenic nature of nanobodies such
repeated exposure could eventually trigger the immune system rendering further use of the FAF
Nb1 imaging agent impossible. Experiments regarding the humanization of nanobodies led to the
discovery of a universal humanized nanobody; h-NbBCII10FGLA. The antigen-binding loops of the
FAF Nb1 could be grafted into this humanized nanobody scaffold [178]. Lastly, it is important
to acknowledge that in the AGel mouse model deposition occurs in muscle tissue whereas in
patients it occurs (mostly) in cranial nerves and the cornea. Whereas the latter can be examined
directly by a physician, the cranial nerves however are the tissues to be targeted with Nb/PET
imaging. These are comparatively smaller than the skeletal muscles and heart on which we have
tested FAF Nb1. Despite the greater sensitivity and resolution which can be achieved with PET
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compared to SPECT, visualization of individual nerves is not possible. However, we are hopeful
that due the the associated angiopathy in nerve arterioles, amyloid surrounding the facial nerves
may be visualized. Indeed, the vascular smooth muscle cells surrounding the facial nerves are
heavily loaded with AGel amyloid.
Regarding the Nb11-FAF1 gene therapy approach, the progress is more direct. Both Nb11, FAF
Nb2-MSA21 and Nb11-FAF1 have proven to be effective in vivo in the AGel mouse model. For
FAF Nb2-MSA21 the implementation into the clinic would require a (i) humanization step (as
discussed above) and (ii) a replacement of the mouse albumin binding MSA21 nanobody by a
variant which binds human albumin. Therapy with Nb11-FAF1 necessitates gene therapy. The
here presented AAV-based setup can, and has been implemented in the clinic in various clinical
trials [278–288]. Interestingly neural cell lines can be targeted with a wide variety of serotypes;
AAV1, 2, 5, 6, 8 and 9. The degree in which they do differs not only in the subset of cell types
which they transduce, but also in the efficiency by which they express their incorporated transgene
[289]. For example, in rat sensory neurons AAV5 is most effective [290] whereas for spinal motor
neurons, AAV2, 6 and 9 proved to be the serotypes of choice [291–295]. At the moment it
is hard to say which serotype is the most suitable for treatment of AGel. We know that AGel
patients display amyloid deposition in the perineurial sheaths [296] but it is unclear whether the
nerve cells, the epithelioid myofibroblasts cells of the perineurium or perhaps both produce the
8 kDa amyloidogenic gelsolin fragment. The answer to this question will determine the desired
AAV serotype. Due to pre-existing immunity against AAVs amongst the human population the
ultimately selected serotype may be ineffective in a subset of patients. Attempts to avoid this
problem via induced mutation of AAV capsid proteins have been (partly) successful [263, 264].
Lastly it will also be desirable to limit off-target transduction as this process increases the required
viral doses, which in its turn increases the risk of an immune response. Once again, both the
correct serotype selection and induced mutation of capsid proteins are essential to address this
issue.
Given the more complex nature of a Nb11-FAF1 gene therapy approach one may wonder whether
it is really worth all the trouble. After all, injections with FAF2-MSA21 were effective in vivo
[100] and this format is more easily translated to the clinic. Although true, we believe that gene
therapy with Nb11-FAF1 has several advantages tilting the scale back in its favor. First of all,
injections with the FAF Nb would have to be (at least) on a weekly basis [100] whereas in the
case of AAV gene therapy adequate gene expression has been observed up until 12 weeks after
gene transfer [297]. The latter entails a significant decrease in patient discomfort. Secondly,
injected FAF Nb will circulate throughout the body before (eventually, partly) binding its target
whereas in the case of gene therapy the bispecific nanobody would only be produced in a subset
of cells and secreted directly in the vicinity of the amyloid deposits. Indeed, in the case of gene
therapy a much lower dose of nanobody may be needed, thereby decreasing the risk of an immune
reaction. Lastly, neither the monovalent FAF Nb approach nor the Nb11 approach [18, 100] could
completely stop the formation and progression of gelsolin amyloidosis. Admittedly, neither could
the bispecific Nb11-FAF1 Nb. But it could however decrease it to a larger degree compared to
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Figure 4.1: Using 99mFAF Nb1 and SPECT/CT, amyloidogenic gelsolin buildup can already be
detected in 5 week old mice. CT signal is represented in greyscale. SPECT color scale: NIH
(0.1-1%) + white.
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its monovalent constituents. Considering the chronic nature and severe symptoms of AGel we
therefore believe it to be imperative that each and every effective compound is utilized to its full
extent.
Despite all the positive results and prospects mentioned above, the Nb11-FAF1 gene therapy
intervention leaves a significant question unanswered; do all three components - Nb11, FAF
Nb1, MT1-MMP sensitive linker - contribute to the therapeutic effect? And if so, to what
degree? The used setup - PBS controls, vector control, treatment group - does not provide any
information regarding these individual components. Neither can we compare with the previously
reported studies with monovalent FAF Nb1, FAF Nb2-MSA21 and Nb11 as these were performed
in heterozygous AGel mice whereas the AAV-Nb11-FAF1 study was performed in homozygous
AGel mice - which show a significantly higher amyloid burden compared to heterozygous mice
[148]. As we were able to reduce the amyloid buildup with the bispecific Nb11-FAF1 to a higher
degree compared to the monovalent Nb studies it is more than likely that at least more than one
of its components was active in vivo. Nonetheless, an extensive study encompassing AAV-Nb1,
AAV-Nb11 and AAV-Nb11-FAF1 without the MT1-MMP sensitive linker, has to be performed
before one can try to answer this question.
The studies performed with the AGel mouse model have shown that nanobodies are useful, potent
therapeutics for both extra- and intracellular targets. They also highlighted that nanobodies can
be used as an imaging tool in AGel, thereby facilitating the screening of potentially new thera-
peutic compounds. While AGel is an orphan disease, it should be emphasized that this strategy
can be extrapolated to other amyloidogenic afflictions. The most infamous type of amyloido-
sis, Alzheimer’s disease, actually has a quite similar pathogenesis; the sequential proteolysis of
Alzheimer precursor protein by β-secretase and γ-secretase results in the release of Aβ amyloido-
genic peptides. Nanobodies against this β-secretase have already proven to be therapeutically
active in a transgenic AD mouse model [234]. However, we believe that in the long run it would
prove more beneficial to target the APP instead of the secretases. Inhibiting a protease will most
likely provoke unwanted side effects whereas chaperoning the target, as in the AGel research
discussed in this manuscript, is more unlikely to do so.
Raising nanobodies against full length APP, s-APP β or Aβ, may result in nanobodies that bind
near the β-secretase cleavage or docking site and that block the formation of s-APP β. A double
hit strategy as in the AGel case will most probably be more difficult to achieve. The γ-secretase is a
multi unit integral membrane protein. It cleaves transmembrane passes. At the moment there are
no reports of nanobodies being able to integrate into the plasma membrane and remain functional.
In addition, gamma secretase proteolysis also takes place in the non-pathogenic processing of APP.
As the transmembrane part of C-terminal fragment-α and C-terminal fragment-β are identical,
even a chaperone based intervention may provoke unwanted side effects.
Up untill now we have only discussed preventing the formation of amyloidogenic peptides. But
directly targeting the amyloidogenic peptides, after their formation, also holds great therapeutic
potential. The deposition of amyloid fibrils is the primary pathological feature of this group of
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afflictions. In recent years however, scientific insights in the initial processes leading to fibrillation
hint that the initial oligomeric aggregates may be the most toxic species in amyloid pathogenesis
and mature fibrils may be far less pathogenic than previously thought [244, 245]. These new
results hint to new therapeutic strategies. First, one could try to stimulate fibrillation, thus
attempting to lower the half-life of small oligomeric aggregates. Secondly, one could try to
remove the amyloidogenic peptides altogether as soon as they are formed. Most likely the latter
will prove to be the most rewarding in the long run. Because although evidence points at
intermediate oligomeric species as highly toxic, the accumulation of amyloidogenic plaques would
still impede normal homeostasis of the affected tissue from a certain point in time onwards.
FAF Nb1-3 could be tested for their ability to prevent 8 kDa AGel fibrillation. With transmission
electron microscopy (TEM) and/or atomic-force microscopy (AFM) the differences in fibrillation
could then be visualized in order to link reduced toxicity to a specific shift in amyloid oligomer-
ization or fibril species.
Once more Alzheimer researchers are also exploring this route. Studying the cytotoxic response of
SH-SY5Y cells via LDL release, they found that oligomeric Aβ provoked a higher cytotoxic reac-
tion compared to monomeric or fibrillar Aβ [298]. Next the cells were incubated with oligomeric
Aβ formed in the presence of anti-Aβ nanobodies. So far, two distinct nanobodies have been
discovered, each binding a specific oligomeric species. Both are able to lower the intrinsic toxicity
in SH-SY5Y cells. The first, Nb A4, does so by inhibiting further aggregation of its target. The
second, Nb E1, acts in a different manner by binding to smaller Aβ species than Nb A4, thereby
interfering earlier in the fibrillation process. Binding its target stabilizes the formation of small
non toxic low-n Aβ species.
It remains to be demonstrated if these approaches and beneficial effects can be translated in model
organisms or even in patients, but the current findings and results obtained with nanobodies in
several amyloid diseases indicate that they could represent an instrument of choice in the diagnosis
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Het dankwoord, wat we onszelf ook proberen wijsmaken tijdens het schrijven van een doctoraat,
het is en blijft het onderdeel dat finaal het snelst en meest frequent gelezen zal worden. Indien u
behoort tot de groep lezers die bij het bemachtigen van dit manuscript meteen naar dit onderdeel
doorbladerde, bedankt. Indien u echter eerst de tijd nam (of dit nog van plan bent) om ook
de wetenschappelijke hoofdbrok door te nemen, eveneens bedankt. Want, wat voor lezer u ook
bent, het feit dat u in het bezit bent gekomen van een kopie betekent hoogstwaarschijnlijk dat
u op de één of andere manier, zij het direct of indirect hebt bijgedragen aan de verwezenlijking
van mijn doctoraat. Hiervoor dan ook mijn oprechte dank.
Toch had ik ook graag enkele mensen persoonlijk bedankt omdat hun bijdrage er bovenuit springt
of omdat zonder hen dit doctoraat nooit mogelijk was geweest. Vooreerst wil ik mijn promotor,
Jan Gettemans bedanken. Jan, de voorbije jaren had ik steeds het gevoel dat je vertrouwen had
in mijn capaciteiten en je, indien nodig, telkens begripvol en rationeel bijstuurde. De vele uren
die je investeerde in het verbeteren van beursaanvragen, wetenschappelijke posters, publicaties
en finaal dit manuscript waren onontbeerlijk en niet vanzelfsprekend.
Vervolgens wil ik ook alle co-auteurs die hebben bijgedragen aan de wetenschappelijke publicaties
nog eens extra bedanken. Cindy Peleman, Nick Devoogdt en Tony Lahoutte van het ICMI
labo van de VUB, om mij in te leiden in de wereld van moleculaire beeldvorming. Rebecca De
Smet, Lynn Supply en Jo Van Dorpe van het departement pathologie UZ Gent voor de vele
uren geïnvesteerd in het maken van de prachtige weefselcoupes. Nisha Nair, Marinee Chuah en
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voor het creëren en implementeren van het AAV9-Nb virus. Inge Everaert en Wim Derave van het
departement beweging- en sportwetenschappen UGent voor de vele dissectieuren en spieranalyses
die uitgevoerd werden op de AGel muizen. Co-auteurs, zonder jullie bereidheid om jullie kennis met
mij te delen en tijd te willen investeren om mijn wensen om te zetten naar doenbare experimenten
was er van dit doctoraat geen sprake geweest. Bedankt!
Als laatste groep binnen de pure academische setting had ik graag mijn juryleden bedankt. Bruno
Verhasselt, Elke Decrock, Els Van Damme, Sophie Hernot, Lennart Zabeau en Patrick Santens,
jullie kozen er allemaal vrijwillig voor om tijd en moeite te steken in dit doctoraat. Hiervoor
mijn oprechte dank. De verschillende opmerkingen hebben dit manuscript naar een hoger niveau
getild! Alsook deed het deugd om tijdens de verdediging nog eens te kunnen discussiëren over
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omkadering doorheen de afgelopen 4 jaar zorgde er telkens voor dat de mindere momenten konden
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het is nu éénmaal een dog eat dog world en science is a bitch! Als je moe bent is ’het schaap de
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moment heb ik mij verveeld met jullie aan het eiland.
Wouter, van alle collega’s ben jij toch wel diegene die een individuele merci verdient. Als the-
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Buiten de muren van het Rommelaere complex stonden er eveneens een hele hoop mensen voor
mij klaar de voorbije jaren. Eerst en vooral mijn ouders en familie. Bedankt ma, pa en Sander
voor het steeds aanwezige luisterende oor gedurende dit grootse UGent avontuur. Steeds was
geen enkele moeite jullie teveel om tijdens de moeilijkere (examen)periodes in de bres te springen
en alles net dat tikkeltje dragelijker te maken. Ik zeg het nog steeds te weinig, maar jullie hulp
werd en wordt steeds geapprecieerd. Evenzeer een dankuwel richting mijn meme, tantes, nonkels,
neven en nichten die op elke familiegelegenheid polsten of alles nog steeds vlot verliep aan de
UGent.
Bio-ir vriendjes! Eva, Kaat, Bieke, Laurens en Steffie, jullie snapten als geen ander waarom
sommige zaken zo frustrerend kunnen zijn en wat er nodig was om die door tekomen. Exact;
eten, drank en eens goed kunnen zagen over hoe verschrikkelijk irritant de gemiddelde medemens
wel niet kan zijn. Het doet mij deugd dat we deze traditie tot op de dag van vandaag nog steeds
in ere houden.
Mede Izegemnaren, woorden schieten tekort om jullie significantie te beschrijven! Sinds onze
eerste dag in deze studentenstad zijn we door lief en leed extra naar elkaar toegegroeid. We
hebben dit avontuur samen beleefd. Een ervaring die niemand ons ooit nog kan afnemen en waar
we de komende decennia nog vrij frequent op zullen terugblikken met de nodige nostalgie. Maar
het doet mij evenzeer deugd dat we, eenmaal afgestudeerd, gewoon verder bleven en blijven gaan
met het maken van prachtige herinneringen! ’Gang’, de onverwoestbare vriendschap die ik onder
ons voel is voor mij van onschatbare waarde.
Ondanks de trots die ik voel betreffende deze academische verwezenlijking weegt ze niet op
tegen de spreekwoordelijke kers op de taart van dit UGent avontuur; Sandra Steyaert, mijn beste
vriendin, vrouw en soulmate! Maar eerst een kleine omweg langsheen alle mensen die dankzij
haar in mijn leven zijn gekomen.
Betsy, Eric en Nicola, als schoonfamilie aanvaardden jullie mij meteen als een ’echt’ lid van de
familie. Steeds konden we bij jullie terecht wanneer onze werkdagen iets te lang waren uitgelopen
en we de rit naar De Panne of Izegem niet zagen zitten. Telkens mochten we zonder probleem
mee aanschuiven aan tafel en vaak ook nog eens mee de menu bepalen. Jullie gastvrijheid heeft
ervoor gezorgd dat ik in een mum van tijd een tweede Oost-Vlaamse thuis had. Ook de rest van
de Steyaert familie wordt gekenmerkt door deze onvoorwaardelijke gastvrijheid. Op geen enkel
moment hebben jullie mij als een buitenstaander aanzien. Bedankt hiervoor!
Hetzelfde kan gezegd worden van de extra vriendengroep(en) die ik erbij kreeg via Sandra. On-
danks de obligatoire West-Vlaamse boerenmopjes en taalgrapjes hebben jullie mij stuk voor stuk
aanvaard zoals ik ben. Nooit had ik gedacht om in één slag zo’n verscheidenheid aan individuen
als vriend te kunnen bestempelen. Ik vind het fascinerend hoe jullie geen enkele gelegenheid voor-
bij laten gaan om af te spreken en hoe, zelfs nu we in het “verre Izegem” wonen, de uitnodigingen
ook nog steeds onze kant opkomen.
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Sandra, babe, bolleke, dat jij als laatste aan bod zou komen in dit dankwoord stond reeds
lang vast. Het is tenslotte het slotstuk van een wetenschappelijk avontuur en zoals gewoonlijk
is in wetenschappelijke literatuur worden de belangrijkste personen laatst vermeld. Sandra, ons
avontuur ontsproot in de Vooruit vanuit een gemeenschappelijke interesse in de boeken van Brian
Greene. (Djeezes wat zijn wij nerds!) De voorbije 6 jaar waren fenomenaal! Elke dag opnieuw
liet je mij zien dat de wereld niet steeds een zwart-wit film hoeft te zijn. Alhoewel in retrospect
niet al onze gemeenschappelijke beslissingen de beste waren zou ik geen enkele willen veranderen.
Ze hebben tenslotte geleid tot dit moment; getrouwd, beiden gedoctoreerd en samen een huis
gekocht! Ik hou ervan hoe je er nog steeds in slaagt om mij tot rust te brengen met een minimum
aan sussende woorden en hoe je mij zonder meer aanvaardt op mijn beste en slechtste momenten.
Babe, je was, bent en zal steeds de meest intrigerende, fascinerende persoon blijven die ik ken.
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